Atezolizumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 8, 2026

The clinical evidence base for Atezolizumab comprises 894 peer-reviewed publications across 15 journals, 99 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Carcinoma, Hepatocellular, and Urinary Bladder Neoplasms. Most recent publication: Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial., Future Oncol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
Spaas M, Sundahl N, Kruse V, et al. · JAMA Oncol · 2023
PubMed: PMID 37410476 · NCT03511391 (CHEERS) · Carcinoma, Non-Small-Cell Lung
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.
Sistigu A, Yamazaki T, Vacchelli E, et al. · Nat Med · 2015
PubMed: PMID 25344738 · NCT04186013 · Urinary Bladder Neoplasms
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.
Sharabi AB, Lim M, DeWeese TL, et al. · Lancet Oncol · 2016
PubMed: PMID 26433823 · NCT04186013 · Urinary Bladder Neoplasms
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.
Røssevold AH, Andresen NK, Bjerre CA, et al. · Nat Med · 2023
PubMed: PMID 36482103 · NCT03164993 (ALICE) · Neoplasms
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE, Hoffman-Censits J, Powles T, et al. · Lancet · 2016
PubMed: PMID 26952546 · NCT04186013 · Urinary Bladder Neoplasms
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.
Kim ST, Cristescu R, Bass AJ, et al. · Nat Med · 2019
PubMed: PMID 30013197 · NCT04059887 (BUDDY) · Carcinoma, Non-Small-Cell Lung
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
Gandara DR, Paul SM, Kowanetz M, et al. · Nat Med · 2019
PubMed: PMID 30082870 · NCT04059887 (BUDDY) · Carcinoma, Non-Small-Cell Lung
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L, Spira A, Ballinger M, et al. · Lancet · 2016
PubMed: PMID 26970723 · NCT04186013 · Urinary Bladder Neoplasms

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

Trial	Indication	Primary endpoint	Arm	Value
NCT02008227 OAK	—	OS: SP-ITT Baseline until death due to any cause (up to approximately 2.87 years)	Atezolizumab	13.3 Months
NCT02008227 OAK	—		Docetaxel	9.8 Months
NCT02008227 OAK	—	OS: TC1/2/3 or IC1/2/3 Subgroup of PP Baseline until death due to any cause (up to approximately 2.25 years)	Atezolizumab	15.7 Months
NCT02008227 OAK	—		Docetaxel	10.3 Months
NCT02008227 OAK	—	OS: TC1/2/3 Or IC1/2/3 Subgroup of SP Baseline until death from any cause (approximately 2.87 years)	Atezolizumab	14.3 Months
NCT02008227 OAK	—		Docetaxel	10.8 Months
NCT02008227 OAK	—	OS: TC2/3 or IC2/3 Subgroup of SP Baseline until death due to any cause (up to approximately 2.87 years)	Atezolizumab	16.6 Months
NCT02008227 OAK	—		Docetaxel	11.4 Months
NCT02008227 OAK	—	OS: TC3 or IC3 Subgroup of SP Baseline until death due to any cause (up to approximately 2.87 years)	Atezolizumab	20.5 Months
NCT02008227 OAK	—		Docetaxel	9.7 Months
NCT02008227 OAK	—	Overall Survival (OS): PP-ITT Baseline until death due to any cause (up to approximately 2.25 years)	Atezolizumab	13.8 Months
NCT02008227 OAK	—		Docetaxel	9.6 Months
NCT02008227 OAK	—	Percentage of Participants Who Died: PP-ITT Baseline until death due to any cause (up to approximately 2.25 years)	Atezolizumab	63.8 Percentage of Participants
NCT02008227 OAK	—		Docetaxel	70.1 Percentage of Participants
NCT02008227 OAK	—	Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP Baseline until death due to any cause (up to approximately 2.25 years)	Atezolizumab	62.7 Percentage of Participants
NCT02008227 OAK	—		Docetaxel	67.1 Percentage of Participants
NCT02302807	Urinary Bladder Neoplasms	Overall Survival (OS) Between randomization and death due to any cause, up to approximately 25 months after first participant enrolled	Atezolizumab	8.6 Months
			Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)	8.0 Months
			IC1/2/3 Atezolizumab	8.9 Months
			IC1/2/3 Chemotherapy	8.2 Months
			IC2/3 Atezolizumab	11.1 Months
			IC2/3 Chemotherapy	10.6 Months
NCT02366143 IMpower150	Carcinoma, Non-Small-Cell Lung	Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population Baseline until death (up approximately 53 months)	Arm A (Atezolizumab+Paclitaxel+Carboplatin)	19.0 Months
NCT02366143 IMpower150	Carcinoma, Non-Small-Cell Lung		Arm C (Bevacizumab+Paclitaxel+Carboplatin)	14.7 Months
NCT02366143 IMpower150	Carcinoma, Non-Small-Cell Lung	Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population Baseline until death until data cut-off on 22 January 2018 (up to approximately 34 months)	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)	19.2 Months
NCT02366143 IMpower150	Carcinoma, Non-Small-Cell Lung		Arm C (Bevacizumab+Paclitaxel+Carboplatin)	14.7 Months
NCT02366143 IMpower150	Carcinoma, Non-Small-Cell Lung	Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)	Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)	8.3 Months
			Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)	11.3 Months
			Arm C (Bevacizumab+Paclitaxel+Carboplatin)	6.8 Months
			Arm C (Bevacizumab+Paclitaxel+Carboplatin)	6.8 Months
NCT02367781 IMpower130	Carcinoma	Overall Survival (OS) in the ITT-WT Population Up to approximately 35 months after first patient enrolled	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	18.6 Months
NCT02367781 IMpower130	Carcinoma		Arm B (Nab-Paclitaxel+Carboplatin)	13.9 Months
NCT02367781 IMpower130	Carcinoma	Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population Up to approximately 35 months after first patient enrolled	Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)	7.0 Months
NCT02367781 IMpower130	Carcinoma		Arm B (Nab-Paclitaxel+Carboplatin)	5.5 Months
NCT02367794	—	Overall Survival (OS) in the ITT Population Up to approximately 39 months after first participant enrolled	Arm A: Atezolizumab + Paclitaxel + Carboplatin	12.6 Months
			Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	14.2 Months
			Arm C: Nab-Paclitaxel + Carboplatin	13.5 Months
NCT02367794	—	Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population Up to approximately 30 months after first participant enrolled	Arm A: Atezolizumab + Paclitaxel + Carboplatin	5.6 Months
			Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin	6.5 Months
			Arm C: Nab-Paclitaxel + Carboplatin	5.6 Months
NCT02409342	—	Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations From randomization to death from any cause until data cut-off on 4 February 2020 (up to approximately 54.5 months)	Atezolizumab	19.9 Months
			Atezolizumab	18.9 Months
			Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)	16.1 Months
			Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)	14.7 Months
NCT02409342	—	Overall Survival (OS) in the TC3 or IC3-WT Populations From randomization to death from any cause until data cut-off on 10 September 2018 (up to approximately 38 months)	Atezolizumab	20.2 Months
NCT02409342	—		Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)	13.1 Months
NCT02420821 IMmotion151	Carcinoma, Renal Cell	Overall Survival (OS) in ITT Population Baseline until death from any cause (until data cut-off date 14 February 2020, up to approximately 57 months)	Atezolizumab + Bevacizumab	36.1 months
NCT02420821 IMmotion151	Carcinoma, Renal Cell		Sunitinib	35.3 months
NCT02420821 IMmotion151	Carcinoma, Renal Cell	Percentage of Participants Who Died of Any Cause in ITT Population Baseline until death from any cause (until data cut-off date 14 February 2020, up to approximately 57 months)	Atezolizumab + Bevacizumab	54.8 percentage of participants
NCT02420821 IMmotion151	Carcinoma, Renal Cell		Sunitinib	55.3 percentage of participants
NCT02420821 IMmotion151	Carcinoma, Renal Cell	Percentage of Participants With Disease Progression as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death From Any Cause in Programmed Death-Ligand 1 (PD-L1)-Selected Population Baseline until documented PD or death, whichever occurred first (until data cut-off date 29 September 2017, up to approximately 24 months)	Atezolizumab + Bevacizumab	58.4 percentage of participants
NCT02420821 IMmotion151	Carcinoma, Renal Cell		Sunitinib	69.6 percentage of participants
NCT02420821 IMmotion151	Carcinoma, Renal Cell	Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 in PD-L1-Selected Population Baseline until documented PD or death, whichever occurred first (until data cut-off date 29 September 2017, up to approximately 24 months)	Atezolizumab + Bevacizumab	11.2 months
NCT02420821 IMmotion151	Carcinoma, Renal Cell		Sunitinib	7.5 months
NCT02425891	Triple Negative Breast Neoplasms	OS in Participants With Detectable PD-L1 Baseline until death due to any cause (up to approximately 58 months)	Atezolizumab Plus Nab-Paclitaxel	25.43 Months
NCT02425891	Triple Negative Breast Neoplasms		Placebo Plus Nab-Paclitaxel	17.91 Months
NCT02425891	Triple Negative Breast Neoplasms	Overall Survival (OS) in All Randomized Participants Baseline until death due to any cause (up to approximately 58 months)	Atezolizumab Plus Nab-Paclitaxel	21.03 Months
NCT02425891	Triple Negative Breast Neoplasms		Placebo Plus Nab-Paclitaxel	18.73 Months
NCT02425891	Triple Negative Breast Neoplasms	PFS According to RECIST v1.1 in Participants With Detectable Programmed Death-Ligand 1 (PD-L1) Baseline up to approximately 34 months	Atezolizumab Plus Nab-Paclitaxel	7.46 Months
NCT02425891	Triple Negative Breast Neoplasms		Placebo Plus Nab-Paclitaxel	4.96 Months
NCT02425891	Triple Negative Breast Neoplasms	Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants Baseline up to approximately 34 months	Atezolizumab Plus Nab-Paclitaxel	7.16 Months
NCT02425891	Triple Negative Breast Neoplasms		Placebo Plus Nab-Paclitaxel	5.49 Months
NCT02450331 IMvigor010	Carcinoma, Transitional Cell	Disease-Free Survival (DFS), as Assessed by Investigator Randomization up to first occurrence of DFS event (up to approximately 50 months)	Atezolizumab	19.4 Months
NCT02450331 IMvigor010	Carcinoma, Transitional Cell		Observation	16.6 Months
NCT02486718	Carcinoma, Non-Small-Cell Lung	DFS in All Randomized Stage II-IIIA Population Up to 95 months	Atezolizumab	57.4 months
NCT02486718	Carcinoma, Non-Small-Cell Lung		Best Supportive Care (BSC)	40.8 months
NCT02486718	Carcinoma, Non-Small-Cell Lung	DFS in the Programmed Death-ligand 1 (PD-L1) SP263 ≥ 1% Tumor Cell (TC) Subpopulation Within the Stage II-IIIA Population Up to 95 months	Atezolizumab	68.5 months
NCT02486718	Carcinoma, Non-Small-Cell Lung		Best Supportive Care (BSC)	37.3 months
NCT02486718	Carcinoma, Non-Small-Cell Lung	Disease-Free Survival (DFS) in Intent-to-treat (ITT) Population Up to 95 months	Atezolizumab	65.6 months
NCT02486718	Carcinoma, Non-Small-Cell Lung		Best Supportive Care (BSC)	47.8 months
NCT02657434	Carcinoma, Non-Small-Cell Lung	Overall Survival (OS) Randomization up to approximately 39 months	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	17.5 Months
NCT02657434	Carcinoma, Non-Small-Cell Lung		Arm B (Carboplatin or Cisplatin + Pemetrexed)	13.6 Months
NCT02657434	Carcinoma, Non-Small-Cell Lung	Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Randomization up to approximately 39 months	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed	7.7 Months
NCT02657434	Carcinoma, Non-Small-Cell Lung		Arm B (Carboplatin or Cisplatin + Pemetrexed)	5.2 Months
NCT02763579 IMpower133	Small Cell Lung Carcinoma	Duration of Overall Survival (OS) in the Global Population Baseline until death from any cause (up to approximately 23 months)	Atezolizumab + Carboplatin + Etoposide	12.3 Months (±10.8 95% Confidence Interval)
NCT02763579 IMpower133	Small Cell Lung Carcinoma		Placebo + Carboplatin + Etoposide	10.3 Months (±9.3 95% Confidence Interval)
NCT02763579 IMpower133	Small Cell Lung Carcinoma	Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1 in the Global Population Baseline until PD or death, whichever occurs first (up to approximately 23 months)	Atezolizumab + Carboplatin + Etoposide	5.2 Months (±4.4 95% Confidence Interval)
NCT02763579 IMpower133	Small Cell Lung Carcinoma		Placebo + Carboplatin + Etoposide	4.3 Months (±4.2 95% Confidence Interval)
NCT02788279	Colorectal Neoplasms	Overall Survival (OS) From randomization up to death due to any cause (up to approximately 20 months)	Atezolizumab	7.10 months
			Cobimetinib + Atezolizumab	8.87 months
			Regorafenib	8.51 months
NCT02807636 IMvigor130	Carcinoma, Transitional Cell	Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm Baseline up to first documented disease progression or death, whichever occurs first (up to approximately 35 months)	Atezolizumab+Gemcitabine+Carboplatin/Cisplatin	8.18 Months
NCT02807636 IMvigor130	Carcinoma, Transitional Cell		Placebo+Gemcitabine+Carboplatin/Cisplatin	6.34 Months
NCT02807636 IMvigor130	Carcinoma, Transitional Cell	Overall Survival (OS) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Baseline until death due to any cause (up to approximately 73 months)	Atezolizumab Monotherapy	15.21 Months
NCT02807636 IMvigor130	Carcinoma, Transitional Cell		Placebo+Gemcitabine+Carboplatin/Cisplatin	13.34 Months
NCT02807636 IMvigor130	Carcinoma, Transitional Cell	Overall Survival (OS) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Baseline until death due to any cause (up to approximately 73 months)	Atezolizumab+Gemcitabine+Carboplatin/Cisplatin	16.13 Months
NCT02807636 IMvigor130	Carcinoma, Transitional Cell		Placebo+Gemcitabine+Carboplatin/Cisplatin	13.44 Months
NCT02839707	Ovarian Neoplasms	Incidence of Dose Limiting Toxicities (DLT) of Experimental Regimens Up to 28 days	Arm I (PLD, Atezolizumab)	0 Participants
			Arm II (PLD, Bevacizumab, Atezolizumab)	0 Participants
			Arm III (PLD, Bevacizumab)	0 Participants
NCT02839707	Ovarian Neoplasms	Overall Survival (OS) (Phase III) From study enrollment to the date of death regardless of the cause, assessed up to 5 years	Arm I (PLD, Atezolizumab)	14.5 months
			Arm II (PLD, Bevacizumab, Atezolizumab)	14.9 months
			Arm III (PLD, Bevacizumab)	12.3 months
NCT02839707	Ovarian Neoplasms	PFS (Phase III) From study enrollment to the investigator determined date of progression or death due to any cause, whichever occurs first, assessed up to 5 years.	Arm I (PLD, Atezolizumab)	4.0 months
			Arm II (PLD, Bevacizumab, Atezolizumab)	7.4 months
			Arm III (PLD, Bevacizumab)	5.6 months
NCT02839707	Ovarian Neoplasms	Progression Free Survival (PFS) (Phase II) From study enrollment to the investigator determined date of progression or death due to any cause, whichever occurs first, assessed up to 5 years	Arm I (PLD, Atezolizumab)	4.2 months
			Arm II (PLD, Bevacizumab, Atezolizumab)	7.6 months
			Arm III (PLD, Bevacizumab)	5.5 months
NCT02908672	Melanoma	Progression-Free Survival (PFS), as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 33 months)	Arm A: Pbo + Cobi + Vem	10.6 months
NCT02908672	Melanoma		Arm B: Atezo + Cobi + Vem	15.1 months
NCT02912559	Colonic Neoplasms	Disease Free Survival (DFS) 3 years	Arm I (Combination Chemotherapy, Atezolizumab)	86.3 percentage of participants
NCT02912559	Colonic Neoplasms	Disease Free Survival (DFS) 3 years	Arm II (Combination Chemotherapy)	76.2 percentage of participants
NCT02928406	Urologic Neoplasms	Percentage of Participants With Adverse Events (AEs) Baseline up to end of study (up to approximately 6 years)	Atezolizumab	900 Participants
NCT03016312 IMbassador250	Prostatic Neoplasms, Castration-Resistant	Overall Survival (OS) Baseline until death from any cause (up to approximately 42 months)	Atezolizumab + Enzalutamide	15.2 Months
NCT03016312 IMbassador250	Prostatic Neoplasms, Castration-Resistant		Enzalutamide	16.6 Months
NCT03024996 IMmotion010	Carcinoma, Renal Cell	Investigator-assessed Disease-Free Survival (DFS) From baseline up to first occurence of event by investigator assessment (up to approximately 64 months)	Atezolizumab	57.2 Months
NCT03024996 IMmotion010	Carcinoma, Renal Cell		Placebo	49.5 Months
NCT03038100 IMagyn050	Ovarian Neoplasms	Overall Survival - ITT Population From randomization up to death from any cause (up to approximately 59 months)	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab	50.53 Months
NCT03038100 IMagyn050	Ovarian Neoplasms		Placebo With Paclitaxel, Carboplatin and Bevacizumab	46.59 Months
NCT03038100 IMagyn050	Ovarian Neoplasms	Overall Survival - PD-L1-Positive Subpopulation From randomization up to death from any cause (up to approximately 59 months)	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab	NA Months
NCT03038100 IMagyn050	Ovarian Neoplasms		Placebo With Paclitaxel, Carboplatin and Bevacizumab	49.15 Months
NCT03038100 IMagyn050	Ovarian Neoplasms	PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive Subpopulation From randomization until disease progression or death from any cause (up to approximately 55 months)	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab	20.83 Months
NCT03038100 IMagyn050	Ovarian Neoplasms		Placebo With Paclitaxel, Carboplatin and Bevacizumab	18.50 Months
NCT03038100 IMagyn050	Ovarian Neoplasms	Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population From randomization until disease progression or death from any cause (up to approximately 55 months)	Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab	19.48 Months
NCT03038100 IMagyn050	Ovarian Neoplasms		Placebo With Paclitaxel, Carboplatin and Bevacizumab	18.37 Months
NCT03125902 IMpassion131	Triple Negative Breast Neoplasms	Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population From Day 1 to disease progression (PD) or death from any cause, assessed up to primary completion date (approximately 26 months)	Atezolizumab and Paclitaxel	5.68 Months
NCT03125902 IMpassion131	Triple Negative Breast Neoplasms		Placebo and Paclitaxel	5.55 Months
NCT03125902 IMpassion131	Triple Negative Breast Neoplasms	Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status From Day 1 to disease progression (PD) or death from any cause, assessed up to primary completion date (approximately 26 months)	Atezolizumab and Paclitaxel	5.95 Months
NCT03125902 IMpassion131	Triple Negative Breast Neoplasms		Placebo and Paclitaxel	5.72 Months
NCT03191786 IPSOS	Carcinoma, Non-Small-Cell Lung	Overall Survival (OS) From randomization up to death from any cause (up to approximately 55 months)	Atezolizumab	10.3 Months
NCT03191786 IPSOS	Carcinoma, Non-Small-Cell Lung		Single Agent Chemotherapy (Vinorelbine or Gemcitabine)	9.2 Months
NCT03197935 IMpassion031	Triple Negative Breast Neoplasms	Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population After neoadjuvant study treatment and surgery, up to primary analysis data cut off on 03 ApriI 2020	Atezolizumab and Chemotherapy	95 Number of Participants
NCT03197935 IMpassion031	Triple Negative Breast Neoplasms		Placebo and Chemotherapy	69 Number of Participants
NCT03197935 IMpassion031	Triple Negative Breast Neoplasms	Number of Participants With pCR in Subpopulation With PD-L1-Positive Tumor Status (Tumor-infiltrating Immune Cell [IC] 1/2/3) Using AJCC Staging System After neoadjuvant study treatment and surgery, up to primary analysis data cut off on 03 ApriI 2020	Atezolizumab and Chemotherapy	53 Number of Participants
NCT03197935 IMpassion031	Triple Negative Breast Neoplasms		Placebo and Chemotherapy	37 Number of Participants
NCT03199885	Breast Neoplasms	Progression-Free Survival (PFS) At the definitive analysis 2.5 years	Arm I (Pertuzumab, Trastuzumab, Taxane Therapy, Placebo)	40.5 percentage of participants
NCT03199885	Breast Neoplasms		Arm II (Pertuzumab, Trastuzumab, Taxane Therapy, Atezolizumab)	52.3 percentage of participants
NCT03273153	—	Progression Free Survival (PFS) as Determined by the Independent Review Committee (IRC) Every 8 weeks (wks) from Day (D) 1 of Cycle (C) 1 through approximately 16 months	Cobimetinib and Atezolizumab	5.5 Months
NCT03273153	—		Pembrolizumab	5.7 Months
NCT03371017 IMpassion132	Triple Negative Breast Neoplasms	OS in Modified Intent-to-treat (mITT) Population Time from randomization to death (Up to 68 months)	Atezolizumab + Chemotherapy	10.35 months
NCT03371017 IMpassion132	Triple Negative Breast Neoplasms		Placebo + Chemotherapy	9.79 months
NCT03371017 IMpassion132	Triple Negative Breast Neoplasms	Overall Survival (OS) in PD-L1-positive Population Time from randomization to death (Up to 68 months)	Atezolizumab + Chemotherapy	12.09 months
NCT03371017 IMpassion132	Triple Negative Breast Neoplasms		Placebo + Chemotherapy	11.24 months
NCT03434379 IMbrave150	Carcinoma, Hepatocellular	Overall Survival (OS) in the China Population From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months)	Atezolizumab + Bevacizumab - China	24.05 months
			Atezolizumab + Bevacizumab - China	NA months
			Sorafenib - China	11.37 months
			Sorafenib - China	11.37 months
NCT03434379 IMbrave150	Carcinoma, Hepatocellular	Overall Survival (OS) in the Global Population From randomization to death from any cause up to the clinical cut off date (CCOD) of 29Aug2019 (up to approximately 18 months) and 31Aug2020 (up to approximately 30 months)	Atezolizumab + Bevacizumab - Global	NA months
			Atezolizumab + Bevacizumab - Global	19.22 months
			Sorafenib - Global	13.40 months
			Sorafenib - Global	13.24 months
NCT03434379 IMbrave150	Carcinoma, Hepatocellular	PFS-IRF Per RECIST v1.1 in the China Population Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)	Atezolizumab + Bevacizumab - China	5.72 months
NCT03434379 IMbrave150	Carcinoma, Hepatocellular		Sorafenib - China	3.19 months
NCT03434379 IMbrave150	Carcinoma, Hepatocellular	Progression Free Survival by Independent Review Facility-Assessment (PFS-IRF) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in the Global Population Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)	Atezolizumab + Bevacizumab - Global	6.83 months
NCT03434379 IMbrave150	Carcinoma, Hepatocellular		Sorafenib - Global	4.27 months
NCT03452137 IMvoke010	—	Investigator-Assessed Event-Free Survival (INV-assessed EFS) Randomization to the first documented disease recurrence, disease progression or death from any cause, whichever occurs first (up to 5 years)	Atezolizumab	59.47 months
NCT03452137 IMvoke010	—		Placebo	52.73 months
NCT03498716 IMpassion030	Triple Negative Breast Neoplasms	Invasive Disease-Free Survival (iDFS) From randomization until the occurrence of an iDFS event or death from any cause, whichever occurred earlier (up to 5 years)	Atezolizumab and Chemotherapy	NA months
NCT03498716 IMpassion030	Triple Negative Breast Neoplasms		Chemotherapy	NA months
NCT03726879 IMpassion050	Breast Neoplasms	pCR in the ITT Population From randomization to approximately 6 months	Atezolizumab +ddAC-PacHP	62.4 Percentage of Participants
NCT03726879 IMpassion050	Breast Neoplasms		Placebo + ddAC-PacHP	62.7 Percentage of Participants
NCT03726879 IMpassion050	Breast Neoplasms	Percentage of Participants With Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3) From randomization to approximately 6 months	Atezolizumab +ddAC-PacHP	64.2 Percentage of Participants
NCT03726879 IMpassion050	Breast Neoplasms		Placebo + ddAC-PacHP	72.5 Percentage of Participants
NCT03735121	Carcinoma, Non-Small-Cell Lung	Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1 Pre-dose on Day 1 of Cycle 2 (Cycle length=21 days for cohorts 1 and 3 and 14 days for cohort 2)	Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg	121 micrograms per milliliter (μg/mL) (±42.8 Geometric Coefficient of Variation)
			Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg	77.5 micrograms per milliliter (μg/mL) (±51.4 Geometric Coefficient of Variation)
			Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg	78.3 micrograms per milliliter (μg/mL) (±88.6 Geometric Coefficient of Variation)
NCT03735121	Carcinoma, Non-Small-Cell Lung	Part 2: Area Under the Concentration-Time Curve From Time Zero to 21 Days (AUC 0-21 d) at Cycle 1 From start of dosing up to Day 21 in Cycle 1 (Cycle length = 21 days)	Part 2: Atezolizumab IV 1200 mg	3327.9 micrograms day per mL (μg*day/mL) (±19.4 Geometric Coefficient of Variation)
NCT03735121	Carcinoma, Non-Small-Cell Lung		Part 2: Atezolizumab SC 1875 mg	2907.1 micrograms day per mL (μg*day/mL) (±35.9 Geometric Coefficient of Variation)
NCT03735121	Carcinoma, Non-Small-Cell Lung	Part 2: Observed Serum Ctrough of Atezolizumab at Cycle 1 Predose on Day 1 of Cycle 2 (Cycle length =21 days)	Part 2: Atezolizumab IV 1200 mg	85.4 μg/mL (±34.1 Geometric Coefficient of Variation)
NCT03735121	Carcinoma, Non-Small-Cell Lung		Part 2: Atezolizumab SC 1875 mg	89.4 μg/mL (±127.1 Geometric Coefficient of Variation)
NCT03755791 COSMIC-312	Carcinoma, Hepatocellular	Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population From the date of first participant randomization up to 36 months	Control Arm: Sorafenib	15.51 months
NCT03755791 COSMIC-312	Carcinoma, Hepatocellular		Experimental Arm: Cabozantinib + Atezolizumab	16.46 months
NCT03755791 COSMIC-312	Carcinoma, Hepatocellular	Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population From the date of first participant randomization up to 28 months	Control Arm: Sorafenib	4.21 months
NCT03755791 COSMIC-312	Carcinoma, Hepatocellular		Experimental Arm: Cabozantinib + Atezolizumab	6.80 months
NCT03811002	Lung Neoplasms	Overall Survival Randomization to date of death due or last follow-up. Median follow-up at the time of analysis was 23.8 months.	Arm I (Chemotherapy, Radiation Therapy)	36.1 months
NCT03811002	Lung Neoplasms		Arm II (Chemotherapy, Radiation Therapy, Atezolizumab)	31.1 months
NCT04102098 IMbrave050	Carcinoma, Hepatocellular	Recurrence-Free Survival (RFS), as Determined by IRF Baseline up to approximately 33 months	Arm A (Atezolizumab Plus Bevacizumab)	NA Months
NCT04102098 IMbrave050	Carcinoma, Hepatocellular		Arm B (Active Surveillance)	NA Months
NCT04148911 EL1SSAR	Triple Negative Breast Neoplasms	Percentage of Participants With Treatment-emergent Grade ≥2 Immune-mediated AEs (imAEs) Up to 60 months	Atezolizumab + Nab-paclitaxel	12.09 percentage of participants
NCT04148911 EL1SSAR	Triple Negative Breast Neoplasms	Percentage of Participants With Treatment-emergent Grade ≥3 Adverse Events (AEs) Up to 60 months	Atezolizumab + Nab-paclitaxel	46.70 percentage of participants
NCT04177108	Neoplasms	Overall Survival (OS) From randomization up to study completion or death (Up to 39 months)	Cohort 1 Arm A: Ipatasertib + Atezolizumab + Paclitaxel	15.7 months
			Cohort 1 Arm B: Ipatasertib + Atezolizumab Matching Placebo + Paclitaxel	15.3 months
			Cohort 1 Arm C: Ipatasertib Matching Placebo + Atezolizumab Matching Placebo + Paclitaxel	16.6 months
			Cohort 2 Arm A: Ipatasertib + Atezolizumab + Paclitaxel	NA months
			Cohort 2 Arm B: Ipatasertib Matching Placebo+ Atezolizumab + Paclitaxel	17.2 months
NCT04177108	Neoplasms	Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 From Randomization to disease progression, study completion, or death (up to 39 months)	Cohort 1 Arm A: Ipatasertib + Atezolizumab + Paclitaxel	7.1 months
			Cohort 1 Arm B: Ipatasertib + Atezolizumab Matching Placebo + Paclitaxel	5.6 months
			Cohort 1 Arm C: Ipatasertib Matching Placebo + Atezolizumab Matching Placebo + Paclitaxel	3.7 months
			Cohort 2 Arm A: Ipatasertib + Atezolizumab + Paclitaxel	5.6 months
			Cohort 2 Arm B: Ipatasertib Matching Placebo+ Atezolizumab + Paclitaxel	5.7 months
NCT04256421 SKYSCRAPER-02	Small Cell Lung Carcinoma	Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS) From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24 months)	Arm A: Placebo + Atezolizumab	5.55 months
NCT04256421 SKYSCRAPER-02	Small Cell Lung Carcinoma		Arm B: Tiragolumab + Atezolizumab	5.36 months
NCT04256421 SKYSCRAPER-02	Small Cell Lung Carcinoma	Overall Survival (OS) in the PAS From randomization to death from any cause (up to approximately 24 months)	Arm A: Placebo + Atezolizumab	13.14 months
NCT04256421 SKYSCRAPER-02	Small Cell Lung Carcinoma		Arm B: Tiragolumab + Atezolizumab	13.11 months
NCT04338269 CONTACT-03	Carcinoma, Renal Cell	Overall Survival (OS) From randomization to death due to any cause (up to 2 years 5 months).	Atezolizumab + Cabozantinib	25.72 months
NCT04338269 CONTACT-03	Carcinoma, Renal Cell		Cabozantinib (Control)	NA months
NCT04338269 CONTACT-03	Carcinoma, Renal Cell	Progression Free Survival (PFS) as Assessed by an Independent Review Facility (IRF) (IRF-PFS) According to RECIST v1.1 From randomization to the first occurrence of PD according to RECIST v1.1, or death from any cause, whichever occurred first (up to 2 years 5 months)	Atezolizumab + Cabozantinib	10.55 months
NCT04338269 CONTACT-03	Carcinoma, Renal Cell		Cabozantinib (Control)	10.81 months
NCT04446117 CONTACT-02	Prostatic Neoplasms	Duration of Overall Survival (OS) Up to a maximum of approximately 45 months (Median duration of follow-up was 24.05 months)	Control Arm: Second NHT	14.98 months
NCT04446117 CONTACT-02	Prostatic Neoplasms		Experimental Arm: Cabozantinib and Atezolizumab	14.78 months
NCT04446117 CONTACT-02	Prostatic Neoplasms	Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC) Up to a maximum of approximately 30 months (Median duration of follow-up was 14.31 months)	Control Arm: Second NHT	4.17 months
NCT04446117 CONTACT-02	Prostatic Neoplasms		Experimental Arm: Cabozantinib and Atezolizumab	6.34 months
NCT04471428 CONTACT-01	Carcinoma, Non-Small-Cell Lung	Overall Survival (OS) Up to approximately 24 months	Atezolizumab + Cabozantinib	10.7 months
NCT04471428 CONTACT-01	Carcinoma, Non-Small-Cell Lung	Overall Survival (OS) Up to approximately 24 months	Docetaxel Monotherapy	10.5 months
NCT04487067 AMETHISTA	Carcinoma, Hepatocellular	Number of Participants With Grade 3-5 National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE V5) Bleeding/Haemorrhage Up to approximately 47.6 months	Atezolizumab + Bevacizumab	17 Participants
			Atezolizumab + Bevacizumab	2 Participants
			Atezolizumab + Bevacizumab	3 Participants
NCT04540211 SKYSCRAPER-08	Esophageal Neoplasms	Independent Review Facility (IRF)-Assessed Progression-Free Survival (PFS) From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 19 months)	Atezolizumab + Tiragolumab + PC	6.18 months
NCT04540211 SKYSCRAPER-08	Esophageal Neoplasms		Placebo + PC	5.39 months
NCT04540211 SKYSCRAPER-08	Esophageal Neoplasms	Overall Survival (OS) From randomization to death from any cause (up to approximately 27 months)	Atezolizumab + Tiragolumab + PC	15.74 months
NCT04540211 SKYSCRAPER-08	Esophageal Neoplasms		Placebo + PC	11.10 months
NCT04637594 IMAGINE	Carcinoma, Transitional Cell	Overall Survival (OS) Rate at 12 Months 12 months	Arm A (Immune Checkpoint Inhibitor)	0 percentage of participants
NCT04637594 IMAGINE	Carcinoma, Transitional Cell	Overall Survival (OS) Rate at 12 Months 12 months	Arm B (Immune Checkpoint Inhibitor)	0 percentage of participants
NCT04665856 SKYSCRAPER-02C	Small Cell Lung Carcinoma	Investigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set (PAS) Up to 32.3 months	Placebo + Atezolizumab + Carboplatin + Etoposide	5.39 months
NCT04665856 SKYSCRAPER-02C	Small Cell Lung Carcinoma		Tiragolumab + Atezolizumab + Carboplatin + Etoposide	5.59 months
NCT04665856 SKYSCRAPER-02C	Small Cell Lung Carcinoma	Overall Survival (OS) in the PAS Up to 32.3 months	Placebo + Atezolizumab + Carboplatin + Etoposide	13.54 months
NCT04665856 SKYSCRAPER-02C	Small Cell Lung Carcinoma	Overall Survival (OS) in the PAS Up to 32.3 months	Tiragolumab + Atezolizumab + Carboplatin + Etoposide	18.69 months
NCT04732286	Carcinoma, Hepatocellular	Number of Participants Who Discontinued Atezolizumab and/or Bevacizumab Due to Adverse Events (AE) of Grade ≥ 3 From Cycle 1 Day 1 up to 30 days after the final dose of the study drug or until initiation of another anti-cancer therapy, whichever occurred first (up to approximately 32 months)	Atezolizumab + Bevacizumab	19 Participants
NCT04740918 KATE3	Breast Neoplasms	Overall Survival (OS) Up to 28 months	Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg	NA months
NCT04740918 KATE3	Breast Neoplasms	Overall Survival (OS) Up to 28 months	Trastuzumab Emtansine 3.6 mg + Placebo	NA months
NCT04740918 KATE3	Breast Neoplasms	Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Up to 28 months	Trastuzumab Emtansine 3.6 mg + Atezolizumab 1200 mg	8.61 months
NCT04740918 KATE3	Breast Neoplasms		Trastuzumab Emtansine 3.6 mg + Placebo	7.52 months
NCT05091567 IMforte	Small Cell Lung Carcinoma	Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS) Up to 26 months	Atezolizumab	2.14 months (±1.64 95% Confidence Interval)
NCT05091567 IMforte	Small Cell Lung Carcinoma		Atezolizumab+ Lurbinectedin	5.36 months (±4.24 95% Confidence Interval)
NCT05091567 IMforte	Small Cell Lung Carcinoma	Randomized Phase: Overall Survival (OS) Up to 26 months	Atezolizumab	10.64 months (±9.49 95% Confidence Interval)
NCT05091567 IMforte	Small Cell Lung Carcinoma	Randomized Phase: Overall Survival (OS) Up to 26 months	Atezolizumab+ Lurbinectedin	13.24 months (±11.89 95% Confidence Interval)
NCT05224141	Small Cell Lung Carcinoma	Overall Survival (OS) Up to approximately 25 months	Atezolizumab	12.9 Months
NCT05224141	Small Cell Lung Carcinoma	Overall Survival (OS) Up to approximately 25 months	Pembrolizumab/Vibostolimab	11.5 Months
NCT05694013 ORIGAMA	Neoplasms	Mean Difference in Change of Week 12 Value From Baseline of Participant-reported Total Symptom Interference Score From the MD Anderson Symptom Inventory (MDASI) Core Items Baseline, Week 12	Atezolizumab Regimen	3.00 Units on a scale
			Atezolizumab Regimen	3.33 Units on a scale
			Atezolizumab Regimen + DPM	3.08 Units on a scale
			Atezolizumab Regimen + DPM	2.33 Units on a scale

Publications by year

1976–2026: 894 publications.

1976

1980

1983

1985

1986

1990

1992

1995

1996

1997

1999

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

104

2023

2024

2025

2026

Publications by indication

Carcinoma, Non-Small-Cell Lung (117)

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.
JAMA Oncol · 2026 · PMID 42060297 · NCT04619797
IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer.
Cancer Sci · 2026 · PMID 41416818 · NCT02486718
The role of the molecular tumor board: learnings from the ROME trial.
NPJ Precis Oncol · 2026 · PMID 41963505 · NCT04591431
Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer.
Oncol Ther · 2026 · PMID 41296193 · NCT05171777
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.
Nat Med · 2025 · PMID 40379995 · NCT02366143

Neoplasm Metastasis (94)

Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors.
Cancer Chemother Pharmacol · 2024 · PMID 38451273 · NCT02794571
Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
BMC Cancer · 2024 · PMID 38724991 · NCT05525858
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
J Clin Pharmacol · 2024 · PMID 38105505 · NCT02794571
Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
Front Oncol · 2024 · PMID 32676455 · NCT06416436
The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond.
Front Oncol · 2024 · PMID 31428580 · NCT06416436

Carcinoma, Hepatocellular (84)

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.
J Hepatol · 2026 · PMID 41580093 · NCT04102098
Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis.
Oncologist · 2025 · PMID 40891895 · NCT03434379
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).
BMJ Open · 2025 · PMID 40930564 · NCT05690048
Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot study.
PLoS One · 2025 · PMID 40233040 · NCT05750030
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial.
ESMO Open · 2025 · PMID 39874903 · NCT04487067

Urinary Bladder Neoplasms (66)

Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19).
BMJ Open · 2023 · PMID 37286312 · NCT04630730
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol · 2023 · PMID 36803840 · NCT02792192
Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
Eur Urol · 2022 · PMID 33902955 · NCT02302807
Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI).
Clin Cancer Res · 2022 · PMID 35877091 · NCT02951767
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.
Eur Urol · 2022 · PMID 29273410 · NCT02108652

Neoplasms (62)

Prospective evaluation of genomics-guided off-label treatment.
Nature · 2026 · PMID 41986720 · NCT02925234
Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer.
Breast · 2026 · PMID 41581361 · NCT03164993
Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO Precis Oncol · 2026 · PMID 42018965 · NCT02693535
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO Precis Oncol · 2026 · PMID 42060861 · NCT02693535
Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO Precis Oncol · 2026 · PMID 41538762 · NCT02693535

Small Cell Lung Carcinoma (60)

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
Lancet · 2025 · PMID 40473449 · NCT05091567
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies.
Future Oncol · 2024 · PMID 39230120 · NCT05224141
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
J Clin Oncol · 2024 · PMID 37976444 · NCT04256421
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
Oncologist · 2024 · PMID 38377176 · NCT04028050
Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab.
Oncol Ther · 2024 · PMID 38280181 · NCT02763579

Publications by journal

J Clin Oncol77 papers
Lancet Oncol48 papers
Clin Cancer Res38 papers
N Engl J Med29 papers
Nat Med29 papers
Lancet29 papers
Ann Oncol23 papers
J Immunother Cancer21 papers
JAMA Oncol18 papers
JCO Precis Oncol17 papers

Trial-results highlights

The OAK study (NCT02008227) investigated atezolizumab. In the SP-ITT population, with follow-up up to approximately 2.87 years, the median Overall Survival (OS) was 13.3 Months for the atezolizumab arm and 9.8 Months for the docetaxel arm. For the PP-ITT population, with follow-up up to approximately 2.25 years, the median OS was 13.8 Months in the atezolizumab arm and 9.6 Months in the docetaxel arm.

Further OS results from the OAK study (NCT02008227) were observed in specific subgroups:

In the TC1/2/3 or IC1/2/3 Subgroup of PP, with follow-up up to approximately 2.25 years, median OS was 15.7 Months for atezolizumab and 10.3 Months for docetaxel.
In the TC1/2/3 Or IC1/2/3 Subgroup of SP, with follow-up up to approximately 2.87 years, median OS was 14.3 Months for atezolizumab and 10.8 Months for docetaxel.
In the TC2/3 or IC2/3 Subgroup of SP, with follow-up up to approximately 2.87 years, median OS was 16.6 Months for atezolizumab and 11.4 Months for docetaxel.
In the TC3 or IC3 Subgroup of SP, with follow-up up to approximately 2.87 years, median OS was 20.5 Months for atezolizumab and 9.7 Months for docetaxel.

Regarding the percentage of participants who died in the OAK study (NCT02008227): In the PP-ITT population, with follow-up up to approximately 2.25 years, 63.8 Percentage of Participants died in the atezolizumab arm, compared to 70.1 Percentage of Participants in the docetaxel arm. In the TC1/2/3 or IC1/2/3 Subgroup of PP, with follow-up up to approximately 2.25 years, 62.7 Percentage of Participants died in the atezolizumab arm, versus 67.1 Percentage of Participants in the docetaxel arm. All values are sourced from primary registry reporting, and individual papers should be consulted for clinical decisions.

All Atezolizumab publications (894)

2026 (28 papers)

Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial.
Zuniga RM, VanderWalde A, Schwartzberg LS, et al. · Future Oncol · 2026 · Derived
PubMed: PMID 41392942 · NCT04632992 (MyTACTIC)
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.
Yopp A, Chen M, Cheng AL, et al. · J Hepatol · 2026 · Derived
PubMed: PMID 41580093 · NCT04102098 (IMbrave050) · Carcinoma, Hepatocellular
Prospective evaluation of genomics-guided off-label treatment.
Verkerk K, Spiekman AC, Haj Mohammad SF, et al. · Nature · 2026 · Derived
PubMed: PMID 41986720 · NCT02925234 (DRUP) · Neoplasms
Randomized Parallel-Group Phase II Study (NEOTERIC) of Atezolizumab With or Without Tiragolumab After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
Tang W, Wu A, Lan P, et al. · J Clin Oncol · 2026 · Derived
PubMed: PMID 41529226 · NCT05009069 · Rectal Neoplasms
Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer.
Svalheim KG, Andresen NK, Bjerre C, et al. · Breast · 2026 · Derived
PubMed: PMID 41581361 · NCT03164993 (ALICE) · Neoplasms
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.
Socinski MA, Stahel R, Lee DH, et al. · JAMA Oncol · 2026 · Derived
PubMed: PMID 42060297 · NCT04619797 (SKYSCRAPER-06) · Carcinoma, Non-Small-Cell Lung
Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.
Sinicrope FA, Ou FS, Arnold D, et al. · N Engl J Med · 2026 · Derived
PubMed: PMID 41880612 · NCT02912559 · Colonic Neoplasms
Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Pisick E, Rothe M, Garrett-Mayer E, et al. · JCO Precis Oncol · 2026 · Derived
PubMed: PMID 42018965 · NCT02693535 (TAPUR) · Neoplasms
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).
Pascual T, Vidal M, Cejalvo JM, et al. · Nat Commun · 2026 · Derived
PubMed: PMID 41698899 · NCT03802604 (PROMETEO) · Breast Neoplasms
IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer.
Okada M, Sugawara S, Watanabe Y, et al. · Cancer Sci · 2026 · Derived
PubMed: PMID 41416818 · NCT02486718 · Carcinoma, Non-Small-Cell Lung
Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial.
Melero I, Reis B, Rusterholz C, et al. · Nat Cancer · 2026 · Derived
PubMed: PMID 42067656 · NCT04857138
Reciprocal regulation of hMENA and TGF-β signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC.
Melchionna R, Di Modugno F, Di Carlo A, et al. · J Immunother Cancer · 2026 · Derived
PubMed: PMID 41592891 · NCT02008227 (OAK)
Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.
Martynchyk A, Chong G, Khor R, et al. · Br J Haematol · 2026 · Derived
PubMed: PMID 41949430 · NCT04962126 (FLUORO) · Lymphoma, Follicular
The role of the molecular tumor board: learnings from the ROME trial.
Marchetti P, Curigliano G, Westphalen CB, et al. · NPJ Precis Oncol · 2026 · Derived
PubMed: PMID 41963505 · NCT04591431 (ROME) · Carcinoma, Non-Small-Cell Lung
Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer.
Majem M, Chewaskulyong B, Zvirbule Z, et al. · Oncol Ther · 2026 · Derived
PubMed: PMID 41296193 · NCT05171777 · Carcinoma, Non-Small-Cell Lung
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.
Lewis KL, Assouline SE, Baker R, et al. · Blood Adv · 2026 · Derived
PubMed: PMID 41643182 · NCT02500407 · Lymphoma, Non-Hodgkin
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.
Higgins KA, Hu C, Ross HJ, et al. · J Clin Oncol · 2026 · Derived
PubMed: PMID 41529214 · NCT03811002 · Lung Neoplasms
ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation.
Hayashi H, Tatsumi K, Katada H, et al. · J Immunother Cancer · 2026 · Derived
PubMed: PMID 41513409 · NCT05907980
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.
Harter P, Marmé F, Redondo A, et al. · J Clin Oncol · 2026 · Derived
PubMed: PMID 41337696 · NCT03353831 · Ovarian Neoplasms
LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial.
Hamid O, Ekström-Rydén V, Mehmi I, et al. · Nat Commun · 2026 · Derived
PubMed: PMID 41698954 · NCT04123470 · Melanoma
Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients.
Grauers Wiktorin H, Ekström-Rydén V, Ek I, et al. · Biomark Res · 2026 · Derived
PubMed: PMID 41888981 · NCT04123470 · Melanoma
A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis.
Giordano A, Graham N, Aizer AA, et al. · Breast Cancer Res Treat · 2026 · Derived
PubMed: PMID 41793510 · NCT03483012 · Breast Neoplasms
Intratumoral Expression of a Composite B Cell / CD8 T Cell Biomarker Stratifies Overall Survival by Circulating Tumor DNA Status and Benefit From Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Carcinoma.
Elias R, Aragaki AK, Hoffman-Censits JH, et al. · J Urol · 2026 · Derived
PubMed: PMID 41144872 · NCT02450331 (IMvigor010) · Carcinoma, Transitional Cell
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
Cobain EF, Rothe M, Garrett-Mayer E, et al. · JCO Precis Oncol · 2026 · Derived
PubMed: PMID 42060861 · NCT02693535 (TAPUR) · Neoplasms
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.
Chen AP, Rosenberger CL, Moore N, et al. · J Clin Oncol · 2026 · Derived
PubMed: PMID 41999612 · NCT03141684 · Sarcoma, Alveolar Soft Part
Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Carrizosa DR, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2026 · Derived
PubMed: PMID 41538762 · NCT02693535 (TAPUR) · Neoplasms
PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.
Booth A, Hillman S, Laumann K, et al. · J Thorac Oncol · 2026 · Derived
PubMed: PMID 41747891 · NCT06632327 · Lung Neoplasms
Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.
Bartlett NL, Sehn LH, Assouline S, et al. · Am J Hematol · 2026 · Derived
PubMed: PMID 41862428 · NCT02500407 · Lymphoma, Non-Hodgkin

2025 (59 papers)

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.
Block MS, Nelson GD, Chen J, et al. · J Immunother Cancer · 2025 · Trial result
PubMed: PMID 40234093 · NCT03554083
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.
Zhou C, Dong X, Chen G, et al. · Nat Med · 2025 · Derived
PubMed: PMID 40379995 · NCT02366143 (IMpower150) · Carcinoma, Non-Small-Cell Lung
Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis.
Xu XQ, Li WM, Shi LC, et al. · Oncologist · 2025 · Derived
PubMed: PMID 40891895 · NCT03434379 (IMbrave150) · Carcinoma, Hepatocellular
Cost of Neoadjuvant Immunotherapy vs Up-Front Surgery in Cutaneous Squamous Cell Carcinoma: A Post Hoc Analysis of a Nonrandomized Clinical Trial.
Wu SS, Colevas AD, Martinez Ramirez L, et al. · JAMA Otolaryngol Head Neck Surg · 2025 · Derived
PubMed: PMID 40178841 · NCT04710498
Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial.
Wick W, Lanz LM, Wick A, et al. · Nat Med · 2025 · Derived
PubMed: PMID 40913172 · NCT03158389 (N²M²) · Glioblastoma
Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitors.
Villalona-Calero MA, Tian L, Li X, et al. · JCI Insight · 2025 · Derived
PubMed: PMID 39903538 · NCT05334329 · Carcinoma, Non-Small-Cell Lung
Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc.
Takekuma M, Nishio S, Yamaguchi S, et al. · J Gynecol Oncol · 2025 · Derived
PubMed: PMID 40968753 · NCT03556839 (BEATcc) · Uterine Cervical Neoplasms
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial.
Sun JM, Chao Y, Kim SB, et al. · Lancet Oncol · 2025 · Derived
PubMed: PMID 41449151 · NCT04540211 (SKYSCRAPER-08) · Esophageal Neoplasms
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.
Soo RA, Vervita K, Früh M, et al. · Lung Cancer · 2025 · Derived
PubMed: PMID 40023017 · NCT04245085 (ABC-lung)
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
Sehn LH, Bartlett NL, Matasar MJ, et al. · Blood · 2025 · Derived
PubMed: PMID 39447094 · NCT02500407 · Lymphoma, Non-Hodgkin
Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial.
Saxena M, Anker JF, Kodysh J, et al. · Nat Cancer · 2025 · Derived
PubMed: PMID 40346292 · NCT03359239 · Urologic Neoplasms
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
Sacher AG, Miller WH, Patel MR, et al. · J Clin Oncol · 2025 · Derived
PubMed: PMID 40632992 · NCT04449874 · Carcinoma, Non-Small-Cell Lung
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - dissection of IO- efficacy in NSCLC by longitudinal tracKing - protocol of a non-randomised, open-label, single-arm, phase II study.
Roesch RM, Schnorbach J, Klotz LV, et al. · BMJ Open · 2025 · Derived
PubMed: PMID 40147985 · NCT05825625 · Carcinoma, Non-Small-Cell Lung
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).
Rauber C, Roberti MP, Vehreschild MJ, et al. · BMJ Open · 2025 · Derived
PubMed: PMID 40930564 · NCT05690048 (FLORA) · Carcinoma, Hepatocellular
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
Powles T, Kann AG, Castellano D, et al. · N Engl J Med · 2025 · Derived
PubMed: PMID 41124204 · NCT04660344 (IMvigor011)
Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot study.
Pomej K, Frick A, Scheiner B, et al. · PLoS One · 2025 · Derived
PubMed: PMID 40233040 · NCT05750030 · Carcinoma, Hepatocellular
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial.
Piscaglia F, Masi G, Martinelli E, et al. · ESMO Open · 2025 · Derived
PubMed: PMID 39874903 · NCT04487067 (AMETHISTA) · Carcinoma, Hepatocellular
Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial.
Peng Z, Zhang X, Liang H, et al. · JAMA Oncol · 2025 · Derived
PubMed: PMID 40244574 · NCT04661150 · Stomach Neoplasms
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
Paz-Ares L, Borghaei H, Liu SV, et al. · Lancet · 2025 · Derived
PubMed: PMID 40473449 · NCT05091567 (IMforte) · Small Cell Lung Carcinoma
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts.
Pal SK, Loriot Y, Necchi A, et al. · J Clin Oncol · 2025 · Derived
PubMed: PMID 39965176 · NCT03170960 · Carcinoma, Non-Small-Cell Lung
Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP.
Nijland M, Issa DE, Bult JAA, et al. · Blood Adv · 2025 · Derived
PubMed: PMID 40249860 · NCT03463057 (HO151DLBCL)
Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer.
Moore KN, Pignata S, IMagyn050 Steering Committee, et al. · Int J Gynecol Cancer · 2025 · Derived
PubMed: PMID 30630885 · NCT03038100 (IMagyn050) · Ovarian Neoplasms
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.
Mittendorf EA, Assaf ZJ, Harbeck N, et al. · Nat Med · 2025 · Derived
PubMed: PMID 40467898 · NCT03197935 (IMpassion031) · Triple Negative Breast Neoplasms
Update on Liquid Biopsy.
Mayerhoefer ME, Kienzle A, Woo S, et al. · Radiology · 2025 · Derived
PubMed: PMID 40525978 · NCT03178552 (B-FAST) · Carcinoma, Non-Small-Cell Lung
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.
Marchetti P, Curigliano G, Biffoni M, et al. · Nat Med · 2025 · Derived
PubMed: PMID 41023484 · NCT04591431 (ROME) · Carcinoma, Non-Small-Cell Lung
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor).
Marbach D, Brouer-Visser J, Brennan L, et al. · BMC Cancer · 2025 · Derived
PubMed: PMID 40102759 · NCT03292172 · Triple Negative Breast Neoplasms
Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study.
Mangat PK, Kirkwood MK, Hinshaw DC, et al. · NPJ Precis Oncol · 2025 · Derived
PubMed: PMID 40610648 · NCT02693535 (TAPUR) · Neoplasms
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial.
Macarulla T, Ren Z, Chon HJ, et al. · J Clin Oncol · 2025 · Derived
PubMed: PMID 39423355 · NCT04677504 · Biliary Tract Neoplasms
A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.
Ma Y, Yang Y, Huang Y, et al. · Nat Med · 2025 · Derived
PubMed: PMID 40082695 · NCT05434234
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Lopez J, Powles T, Braiteh F, et al. · Nat Med · 2025 · Derived
PubMed: PMID 39762422 · NCT03289962 · Carcinoma, Non-Small-Cell Lung
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.
Long GV, Nair N, Marbach D, et al. · Nat Med · 2025 · Derived
PubMed: PMID 40993242 · NCT05116202 · Melanoma
Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma.
Li J, Liao MZ, Wilkins J, et al. · Clin Transl Sci · 2025 · Derived
PubMed: PMID 40279333 · NCT02500407 · Lymphoma, Non-Hodgkin
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results.
Levy A, Morel D, Texier M, et al. · Signal Transduct Target Ther · 2025 · Derived
PubMed: PMID 40097400 · NCT02992912 (SABR-PDL1) · Colorectal Neoplasms
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).
Lee J, Ahn HK, Lee KH, et al. · BMC Cancer · 2025 · Derived
PubMed: PMID 40783751 · NCT03756298 · Triple Negative Breast Neoplasms
Selected Abstracts.
Langenfeld SJ, Raman S, Gribovskaja-Rupp I, et al. · Dis Colon Rectum · 2025 · Derived
PubMed: PMID 40953502 · NCT02912559 · Colonic Neoplasms
A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) - design and rationale.
Kydd AR, Chandran E, Simon NI, et al. · Future Oncol · 2025 · Derived
PubMed: PMID 40548513 · NCT06161532 · Carcinoma, Transitional Cell
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.
Kuemmel S, Jung KH, Andrade L, et al. · ESMO Open · 2025 · Derived
PubMed: PMID 41297162 · NCT04584112 · Triple Negative Breast Neoplasms
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21).
Im SA, Park K, Koh J, et al. · ESMO Open · 2025 · Derived
PubMed: PMID 40997746 · NCT03756298 · Triple Negative Breast Neoplasms
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.
Ignatiadis M, Bailey A, McArthur H, et al. · JAMA · 2025 · Derived
PubMed: PMID 39883436 · NCT03498716 (IMpassion030) · Triple Negative Breast Neoplasms
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.
Hutchings M, Sureda A, Bosch F, et al. · J Clin Oncol · 2025 · Derived
PubMed: PMID 41115257 · NCT03533283 · Lymphoma, Non-Hodgkin
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial.
Hsu CH, Lu Z, Gao S, et al. · Lancet Oncol · 2025 · Derived
PubMed: PMID 41449142 · NCT04540211 (SKYSCRAPER-08) · Esophageal Neoplasms
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.
Hecht JR, Park YS, Tabernero J, et al. · Lancet · 2025 · Derived
PubMed: PMID 41130252 · NCT05425940 (STELLAR-303) · Colorectal Neoplasms
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.
Harano K, Fossati R, Pardo B, et al. · J Gynecol Oncol · 2025 · Derived
PubMed: PMID 40590326 · NCT03603184 (AtTEnd) · Neoplasms
First-line atezolizumab monotherapy vs. single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation.
Han B, Peters S, Le AT, et al. · Chin Med J (Engl) · 2025 · Derived
PubMed: PMID 41424028 · NCT03191786 (IPSOS) · Carcinoma, Non-Small-Cell Lung
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
Haddad R, Fayette J, Teixeira M, et al. · JAMA · 2025 · Derived
PubMed: PMID 40079944 · NCT03452137 (IMvoke010)
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.
Gion M, Blancas I, Cortez-Castedo P, et al. · Nat Med · 2025 · Derived
PubMed: PMID 40467896 · NCT04408118 (ATRACTIB) · Breast Neoplasms
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.
Finn RS, Ryoo BY, Hsu CH, et al. · Lancet Oncol · 2025 · Derived
PubMed: PMID 39855251 · NCT04524871 (MORPHEUS-LIVER)
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
Felip E, Altorki N, Zhou C, et al. · J Clin Oncol · 2025 · Derived
PubMed: PMID 40446184 · NCT02486718 · Carcinoma, Non-Small-Cell Lung
Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial.
Fang W, Fang J, Tian P, et al. · Cancer Med · 2025 · Derived
PubMed: PMID 41388935 · NCT04426825 · Carcinoma, Non-Small-Cell Lung
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions.
Desai AV, Bagchi A, Armstrong AE, et al. · Eur J Cancer · 2025 · Derived
PubMed: PMID 40086048 · NCT04589845
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma.
Danilov AV, Kambhampati Thiruvengadam S, Linton K, et al. · Blood Adv · 2025 · Derived
PubMed: PMID 40472301 · NCT02500407 · Lymphoma, Non-Hodgkin
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.
Chong EA, Penuel E, Napier EB, et al. · Blood Adv · 2025 · Derived
PubMed: PMID 39571171 · NCT02500407 · Lymphoma, Non-Hodgkin
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor.
Bang YH, Park GH, Oh JW, et al. · J Immunother Cancer · 2025 · Derived
PubMed: PMID 41173494 · NCT03991403 · Carcinoma, Non-Small-Cell Lung
Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial.
Bandos H, Kim S, Henry NL, et al. · JNCI Cancer Spectr · 2025 · Derived
PubMed: PMID 40170372 · NCT03199885 · Breast Neoplasms
Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Al Baghdadi T, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2025 · Derived
PubMed: PMID 41100773 · NCT02693535 (TAPUR) · Neoplasms
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial.
Agarwal N, Azad AA, Carles J, et al. · Lancet Oncol · 2025 · Derived
PubMed: PMID 40523369 · NCT04446117 (CONTACT-02) · Prostatic Neoplasms
Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer.
Qin T, Wang J, Wang J, et al. · Adv Sci (Weinh) · 2025 · Background
PubMed: PMID 39887933 · NCT07172412
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.
Paulson KG, Lau SCM, Ahn MJ, et al. · Lancet Oncol · 2025 · Background
PubMed: PMID 40934933 · NCT05361395 · Lung Neoplasms
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
Kudo M, Ren Z, Guo Y, et al. · Lancet · 2025 · Background
PubMed: PMID 39798578 · NCT07157969 · Carcinoma, Hepatocellular

2024 (83 papers)

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Hieken TJ, Nelson GD, Flotte TJ, et al. · Nat Commun · 2024 · Trial result
PubMed: PMID 38365756 · NCT03554083
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
Yau T, Kaseb A, Cheng AL, et al. · Lancet Gastroenterol Hepatol · 2024 · Derived
PubMed: PMID 38364832 · NCT03755791 (COSMIC-312) · Carcinoma, Hepatocellular
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Worden FP, Pisick E, Rothe M, et al. · JCO Precis Oncol · 2024 · Derived
PubMed: PMID 39413339 · NCT02693535 (TAPUR) · Neoplasms
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.
Wermke M, Holderried TAW, Luke JJ, et al. · J Immunother Cancer · 2024 · Derived
PubMed: PMID 39038917 · NCT04639245 · Carcinoma, Non-Small-Cell Lung
Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
Wang HY, Ho CC, Lin YT, et al. · JCO Precis Oncol · 2024 · Derived
PubMed: PMID 38190582 · NCT03178552 (B-FAST) · Carcinoma, Non-Small-Cell Lung
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor YL, van de Haar J, van den Berg JG, et al. · Nat Med · 2024 · Derived
PubMed: PMID 38191613 · NCT03448835 (PANDA) · Stomach Neoplasms
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.
Verlingue L, Italiano A, Prenen H, et al. · EBioMedicine · 2024 · Derived
PubMed: PMID 39395231 · NCT03386721 · Uterine Cervical Neoplasms
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
Van den Bossche J, De Laere M, Deschepper K, et al. · PLoS One · 2024 · Derived
PubMed: PMID 39008481 · NCT05765084 (Immuno-MESODEC) · Mesothelioma, Malignant
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.
Tedeschi A, Frustaci AM, Condoluci A, et al. · Lancet Oncol · 2024 · Derived
PubMed: PMID 39270702 · NCT04082897 (MOLTO)
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial.
Sweis RF, Gajate P, Morales-Barrera R, et al. · JAMA Oncol · 2024 · Derived
PubMed: PMID 39298147 · NCT03473756 (FORT-2) · Carcinoma, Transitional Cell
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors.
Sweeney CJ, Hainsworth JD, Bose R, et al. · J Clin Oncol · 2024 · Derived
PubMed: PMID 37793085 · NCT02091141 · Neoplasms
Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.
Srkalovic G, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
PubMed: PMID 38865672 · NCT02693535 (TAPUR) · Neoplasms
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors.
Shemesh CS, Wang Y, An A, et al. · Cancer Chemother Pharmacol · 2024 · Derived
PubMed: PMID 38451273 · NCT02794571 · Neoplasm Metastasis
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies.
Shapira-Frommer R, Niu J, Perets R, et al. · Future Oncol · 2024 · Derived
PubMed: PMID 39230120 · NCT05224141 · Small Cell Lung Carcinoma
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
Schuster SJ, Huw LY, Bolen CR, et al. · Blood · 2024 · Derived
PubMed: PMID 38048694 · NCT02500407 · Lymphoma, Non-Hodgkin
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study.
Schuetze S, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
PubMed: PMID 39013131 · NCT02693535 (TAPUR) · Neoplasms
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.
Schmid P, Turner NC, Barrios CH, et al. · Clin Cancer Res · 2024 · Derived
PubMed: PMID 38060199 · NCT03800836 · Breast Neoplasms
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04).
Salani R, McCormack M, Kim YM, et al. · Int J Gynecol Cancer · 2024 · Derived
PubMed: PMID 38858106 · NCT04300647 (SKYSCRAPER-04) · Uterine Cervical Neoplasms
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.
Saeed A, Tabernero J, Parikh A, et al. · Future Oncol · 2024 · Derived
PubMed: PMID 39041200 · NCT05425940 (STELLAR-303) · Colorectal Neoplasms
Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition.
Saal J, Bald T, Eckstein M, et al. · Lung Cancer · 2024 · Derived
PubMed: PMID 38367405 · NCT02031458 (BIRCH) · Carcinoma, Non-Small-Cell Lung
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
Rudin CM, Liu SV, Soo RA, et al. · J Clin Oncol · 2024 · Derived
PubMed: PMID 37976444 · NCT04256421 (SKYSCRAPER-02) · Small Cell Lung Carcinoma
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
Ross HJ, Kozono D, Wang XF, et al. · JAMA Oncol · 2024 · Derived
PubMed: PMID 39052256 · NCT03102242 · Carcinoma, Non-Small-Cell Lung
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.
Reck M, Dziadziuszko R, Sugawara S, et al. · Lung Cancer · 2024 · Derived
PubMed: PMID 39306923 · NCT03148418 · Neoplasms
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.
Rebucci-Peixoto M, Vienot A, Adotevi O, et al. · Front Oncol · 2024 · Derived
PubMed: PMID 35928870 · NCT03946358 (VolATIL) · Uterine Cervical Neoplasms
Matching-Adjusted Indirect Comparisons of Axicabtagene Ciloleucel to Mosunetuzumab for the Treatment of Relapsed/Refractory Follicular Lymphoma.
Ray MD, Kanters S, Beygi S, et al. · Transplant Cell Ther · 2024 · Derived
PubMed: PMID 38901633 · NCT02500407 · Lymphoma, Non-Hodgkin
Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial.
Ramnaraign BH, Lee JH, Ali A, et al. · Future Oncol · 2024 · Derived
PubMed: PMID 36399037 · NCT05000294 · Breast Neoplasms
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.
Prenen H, Deva S, Keam B, et al. · Clin Cancer Res · 2024 · Derived
PubMed: PMID 38709220 · NCT03386721 · Uterine Cervical Neoplasms
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Peters S, Gadgeel SM, Mok T, et al. · Nat Med · 2024 · Derived
PubMed: PMID 38898120 · NCT03178552 (B-FAST) · Carcinoma, Non-Small-Cell Lung
Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
Perez JK, Kleber J, Rothe M, et al. · JCO Precis Oncol · 2024 · Derived
PubMed: PMID 38564684 · NCT02693535 (TAPUR) · Neoplasms
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).
Park S, Kim TM, Han JY, et al. · J Clin Oncol · 2024 · Derived
PubMed: PMID 37861993 · NCT03991403 · Carcinoma, Non-Small-Cell Lung
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, et al. · Lancet · 2024 · Derived
PubMed: PMID 38048793 · NCT03556839 (BEATcc) · Uterine Cervical Neoplasms
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC.
Negrao MV, Papadimitrakopoulou VA, Price AC, et al. · JTO Clin Res Rep · 2024 · Derived
PubMed: PMID 36925644 · NCT03438318 · Carcinoma, Non-Small-Cell Lung
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
Necchi A, Ramlau R, Falcón González A, et al. · JNCI Cancer Spectr · 2024 · Derived
PubMed: PMID 38627238 · NCT04045613 (FIDES-02) · Carcinoma, Transitional Cell
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
Neal J, Pavlakis N, Kim SW, et al. · J Clin Oncol · 2024 · Derived
PubMed: PMID 38552197 · NCT04471428 (CONTACT-01) · Carcinoma, Non-Small-Cell Lung
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
Mutch D, Voulgari A, Chen XM, et al. · Cancer · 2024 · Derived
PubMed: PMID 38288862 · NCT03695380 · Ovarian Neoplasms
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.
Musher BL, Rowinsky EK, Smaglo BG, et al. · Lancet Oncol · 2024 · Derived
PubMed: PMID 38547893 · NCT02705196 · Neoplasms
Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data.
Mhatre SK, Machado RJM, Ton TGN, et al. · Clin Pharmacol Ther · 2024 · Derived
PubMed: PMID 37696652 · NCT02008227 (OAK)
Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.
Mang A, Zou W, Rolny V, et al. · Tumour Biol · 2024 · Derived
PubMed: PMID 37545290 · NCT02366143 (IMpower150) · Carcinoma, Non-Small-Cell Lung
Preclinical Evaluation of Off-The-Shelf PD-L1+ Human Natural Killer Cells Secreting IL15 to Treat Non-Small Cell Lung Cancer.
Lu T, Ma R, Mansour AG, et al. · Cancer Immunol Res · 2024 · Derived
PubMed: PMID 38572955 · NCT05334329 · Carcinoma, Non-Small-Cell Lung
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
Lorenzen S, Götze TO, Thuss-Patience P, et al. · J Clin Oncol · 2024 · Derived
PubMed: PMID 37963317 · NCT03421288 (DANTE) · Stomach Neoplasms
Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021).
Li D, Loriot Y, Burgoyne AM, et al. · EClinicalMedicine · 2024 · Derived
PubMed: PMID 38204489 · NCT03170960 · Carcinoma, Non-Small-Cell Lung
Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a cost-effectiveness analysis in the USA.
Li B, Rong D, Lin H, et al. · BMJ Open · 2024 · Derived
PubMed: PMID 39532375 · NCT02409342
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Levy A, Morel D, Texier M, et al. · Mol Cancer · 2024 · Derived
PubMed: PMID 38519913 · NCT02992912 (SABR-PDL1) · Colorectal Neoplasms
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
Lehmann BD, Abramson VG, Dees EC, et al. · JAMA Oncol · 2024 · Derived
PubMed: PMID 38095878 · NCT03206203 · Breast Neoplasms
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
Kristeleit R, Leary A, Oaknin A, et al. · Br J Cancer · 2024 · Derived
PubMed: PMID 38971950 · NCT03101280 · Genital Neoplasms, Female
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.
Krämer A, Bochtler T, Pauli C, et al. · Lancet · 2024 · Derived
PubMed: PMID 39096924 · NCT03498521 (CUPISCO) · Neoplasms, Unknown Primary
Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
Kim SY, Kim JH, Kim TY, et al. · BMC Cancer · 2024 · Derived
PubMed: PMID 38724991 · NCT05525858 (KOSMOSII) · Neoplasm Metastasis
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
Jenkins KA, Park M, Pederzoli-Ribeil M, et al. · J Immunother Cancer · 2024 · Derived
PubMed: PMID 38164757 · NCT04896697
Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose-Positron Emission Tomography.
Jemaa S, Ounadjela S, Wang X, et al. · J Clin Oncol · 2024 · Derived
PubMed: PMID 38843483 · NCT02500407 · Lymphoma, Non-Hodgkin
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Guan X, Hu R, Choi Y, et al. · Nature · 2024 · Derived
PubMed: PMID 38418879 · NCT03563716 · Carcinoma, Non-Small-Cell Lung
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Grande E, Arranz JÁ, De Santis M, et al. · Lancet Oncol · 2024 · Derived
PubMed: PMID 38101433 · NCT02807636 (IMvigor130) · Carcinoma, Transitional Cell
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
González-Martín A, Rubio MJ, Heitz F, et al. · J Clin Oncol · 2024 · Derived
PubMed: PMID 39292975 · NCT03598270 (ANITA) · Ovarian Neoplasms
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
Geurts BS, Zeverijn LJ, Leek LVM, et al. · Clin Cancer Res · 2024 · Derived
PubMed: PMID 38630551 · NCT02925234 (DRUP) · Neoplasms
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
Garralda E, Oh DY, Italiano A, et al. · J Clin Pharmacol · 2024 · Derived
PubMed: PMID 38105505 · NCT02794571 · Neoplasm Metastasis
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
Galsky MD, Guan X, Rishipathak D, et al. · Cell Rep Med · 2024 · Derived
PubMed: PMID 38280376 · NCT02807636 (IMvigor130) · Carcinoma, Transitional Cell
Targeting pancreatic cancer metabolic dependencies through glutamine antagonism.
Encarnación-Rosado J, Sohn ASW, Biancur DE, et al. · Nat Cancer · 2024 · Derived
PubMed: PMID 37814010 · NCT04471415
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Desai J, Alonso G, Kim SH, et al. · Nat Med · 2024 · Derived
PubMed: PMID 38052910 · NCT04449874 · Carcinoma, Non-Small-Cell Lung
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
Colombo N, Biagioli E, Harano K, et al. · Lancet Oncol · 2024 · Derived
PubMed: PMID 39102832 · NCT03603184 (AtTEnd) · Neoplasms
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Cannon TL, Rothe M, Mangat PK, et al. · J Clin Oncol · 2024 · Derived
PubMed: PMID 38748939 · NCT02693535 (TAPUR) · Neoplasms
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Calfa CJ, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
PubMed: PMID 38354330 · NCT02693535 (TAPUR) · Neoplasms
Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.
Cabanillas ME, Dadu R, Ferrarotto R, et al. · JAMA Oncol · 2024 · Derived
PubMed: PMID 39446377 · NCT03181100 · Thyroid Neoplasms
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
Budde LE, Assouline S, Sehn LH, et al. · J Clin Oncol · 2024 · Derived
PubMed: PMID 38547425 · NCT02500407 · Lymphoma, Non-Hodgkin
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
Bria E, Morgillo F, Garassino MC, et al. · Oncologist · 2024 · Derived
PubMed: PMID 38377176 · NCT04028050 (MAURIS) · Small Cell Lung Carcinoma
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
Bosch F, Kuruvilla J, Vassilakopoulos TP, et al. · Clin Lymphoma Myeloma Leuk · 2024 · Derived
PubMed: PMID 37981564 · NCT02500407 · Lymphoma, Non-Hodgkin
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
Bogani G, Monk BJ, Powell MA, et al. · Ann Oncol · 2024 · Derived
PubMed: PMID 38431043 · NCT03603184 (AtTEnd) · Neoplasms
Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab.
Bernabé R, Liu SV, Sánchez-Gastaldo A, et al. · Oncol Ther · 2024 · Derived
PubMed: PMID 38280181 · NCT02763579 (IMpower133) · Small Cell Lung Carcinoma
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Bender B, Li CC, Marchand M, et al. · Clin Transl Sci · 2024 · Derived
PubMed: PMID 38808543 · NCT02500407 · Lymphoma, Non-Hodgkin
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
Bamias A, Davis ID, Galsky MD, et al. · Lancet Oncol · 2024 · Derived
PubMed: PMID 38101431 · NCT02807636 (IMvigor130) · Carcinoma, Transitional Cell
IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma.
Badhrinarayanan S, Cotter C, Zhu H, et al. · Future Oncol · 2024 · Derived
PubMed: PMID 38861301 · NCT05904886 (SKYSCRAPER-14) · Carcinoma, Hepatocellular
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.
Antoniotti C, Rossini D, Pietrantonio F, et al. · J Clin Oncol · 2024 · Derived
PubMed: PMID 38865678 · NCT03721653 (AtezoTRIBE) · Colorectal Neoplasms
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).
Amari L, Tomasini P, Dantony E, et al. · Lung Cancer · 2024 · Derived
PubMed: PMID 38830303 · NCT04042558 (GFPC 06-2018) · Carcinoma, Non-Small-Cell Lung
Differences between low and high grade fetal adenocarcinoma of the lung: a clinicopathological and molecular study.
Zhang J, Sun J, Liang XL, et al. · J Thorac Dis · 2024 · Background
PubMed: PMID 28840008 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
Weykamp F, König L, Seidensaal K, et al. · Front Oncol · 2024 · Background
PubMed: PMID 32676455 · NCT06416436 · Neoplasm Metastasis
The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond.
Onderdonk BE, Chmura SJ · Front Oncol · 2024 · Background
PubMed: PMID 31428580 · NCT06416436 · Neoplasm Metastasis
Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
Luo L, He Y, Zhu G, et al. · J Hepatocell Carcinoma · 2024 · Background
PubMed: PMID 36578526 · NCT05717738 (CCGLC-008) · Carcinoma, Hepatocellular
Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.
Liu Q, Zhang J, Guo C, et al. · Cell · 2024 · Background
PubMed: PMID 38181741 · NCT07172412
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial.
Kuboki Y, Fakih M, Strickler J, et al. · Nat Med · 2024 · Background
PubMed: PMID 38177853 · NCT04185883
Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
Iyengar P, All S, Berry MF, et al. · Pract Radiat Oncol · 2024 · Background
PubMed: PMID 37294262 · NCT06416436 · Neoplasm Metastasis
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.
Daniel D, Kuchava V, Bondarenko I, et al. · Int J Cancer · 2024 · Background
PubMed: PMID 33348420 · NCT03041311 · Small Cell Lung Carcinoma
Patient selection for thoracic radiotherapy in extensive-stage small-cell lung cancer.
Corkum MT, Rodrigues GB · Lung Cancer Manag · 2024 · Background
PubMed: PMID 30643570 · NCT06416436 · Neoplasm Metastasis
Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma.
Chiang CL, Lee FAS, Chan KSK, et al. · Liver Cancer · 2024 · Background
PubMed: PMID 38756147 · NCT07293468 (BIIRTH) · Carcinoma, Hepatocellular
Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma.
Chiang CL, Chan KSK, Chiu KWH, et al. · JAMA Oncol · 2024 · Background
PubMed: PMID 39325464 · NCT07293468 (BIIRTH) · Carcinoma, Hepatocellular
Organ-specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study.
Cheon J, Jung S, Kim JS, et al. · Liver Int · 2024 · Background
PubMed: PMID 38618972 · NCT04862949 · Carcinoma, Hepatocellular

2023 (80 papers)

Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
Spaas M, Sundahl N, Kruse V, et al. · JAMA Oncol · 2023 · Trial result
PubMed: PMID 37410476 · NCT03511391 (CHEERS) · Carcinoma, Non-Small-Cell Lung
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.
Røssevold AH, Andresen NK, Bjerre CA, et al. · Nat Med · 2023 · Trial result
PubMed: PMID 36482103 · NCT03164993 (ALICE) · Neoplasms
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
Zhou C, Srivastava MK, Xu H, et al. · J Immunother Cancer · 2023 · Derived
PubMed: PMID 37903590 · NCT02486718 · Carcinoma, Non-Small-Cell Lung
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Zeverijn LJ, Looze EJ, Thavaneswaran S, et al. · Int J Cancer · 2023 · Derived
PubMed: PMID 37424386 · NCT02925234 (DRUP) · Neoplasms
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.
Yuan Y, Yost SE, Cui Y, et al. · Oncologist · 2023 · Derived
PubMed: PMID 37023705 · NCT03853707 · Triple Negative Breast Neoplasms
Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.
Younes A, Burke JM, Cheson BD, et al. · Blood Adv · 2023 · Derived
PubMed: PMID 36287231 · NCT02596971 · Lymphoma, Follicular
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
Yang ES, Halabi S, Rothe M, et al. · JCO Precis Oncol · 2023 · Derived
PubMed: PMID 36753688 · NCT02693535 (TAPUR) · Neoplasms
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Yam C, Mittendorf EA, Garber HR, et al. · Breast Cancer Res Treat · 2023 · Derived
PubMed: PMID 37061619 · NCT02530489 · Triple Negative Breast Neoplasms
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.
Wong S, Hamidi H, Costa LJ, et al. · Front Immunol · 2023 · Derived
PubMed: PMID 37559718 · NCT02431208 · Multiple Myeloma
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.
Voorwerk L, Isaeva OI, Horlings HM, et al. · Nat Cancer · 2023 · Derived
PubMed: PMID 37038006 · NCT03147040 (GELATO) · Breast Neoplasms
Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition.
van den Ende T, Ezdoglian A, Baas LM, et al. · Oncoimmunology · 2023 · Derived
PubMed: PMID 37470057 · NCT03087864 (PERFECT) · Esophageal Neoplasms
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Tsimberidou AM, Guenther K, Andersson BS, et al. · Cancer Immunol Res · 2023 · Derived
PubMed: PMID 37172100 · NCT02876510 (ACTolog) · Carcinoma, Non-Small-Cell Lung
Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
Topp MS, Eradat H, Florschütz A, et al. · J Cancer Res Clin Oncol · 2023 · Derived
PubMed: PMID 35182224 · NCT02729896 · Lymphoma
Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer.
Taraborrelli L, Şenbabaoğlu Y, Wang L, et al. · Nat Commun · 2023 · Derived
PubMed: PMID 37741832 · NCT02788279 · Colorectal Neoplasms
Principles of Surgical Management of Peritoneal Mesothelioma.
Steadman JA, Grotz TE · J Natl Compr Canc Netw · 2023 · Derived
PubMed: PMID 37673112 · NCT05001880
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.
Socinski MA, Jotte RM, Cappuzzo F, et al. · JAMA Oncol · 2023 · Derived
PubMed: PMID 36795388 · NCT02657434 · Carcinoma, Non-Small-Cell Lung
Multiple Real-World Data Sources in a Bayesian Framework to Inform Long-Term Survival Estimates of Mosunetuzumab in Patients with Follicular Lymphoma.
Sanchez Alvarez J, Jaber M, Blanchet Zumofen MH, et al. · Oncol Ther · 2023 · Derived
PubMed: PMID 37851321 · NCT02500407 · Lymphoma, Non-Hodgkin
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Sacher A, LoRusso P, Patel MR, et al. · N Engl J Med · 2023 · Derived
PubMed: PMID 37611121 · NCT04449874 · Carcinoma, Non-Small-Cell Lung
Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial.
Saal J, Bald T, Eckstein M, et al. · JNCI Cancer Spectr · 2023 · Derived
PubMed: PMID 37004206 · NCT02008227 (OAK)
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
Roussot N, Fumet JD, Limagne E, et al. · BMC Cancer · 2023 · Derived
PubMed: PMID 37946136 · NCT05259319 (IMMUNOs-SBRT) · Carcinoma, Non-Small-Cell Lung
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Rohatgi N, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
PubMed: PMID 38039429 · NCT02693535 (TAPUR) · Neoplasms
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes.
Rahim MK, Okholm TLH, Jones KB, et al. · Cell · 2023 · Derived
PubMed: PMID 36931243 · NCT03708224 · Neoplasms
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, et al. · Lancet · 2023 · Derived
PubMed: PMID 37871608 · NCT04102098 (IMbrave050) · Carcinoma, Hepatocellular
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.
Provencio M, Ortega AL, Coves-Sarto J, et al. · JAMA Oncol · 2023 · Derived
PubMed: PMID 36520426 · NCT03836066 (TELMA) · Carcinoma, Non-Small-Cell Lung
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.
Powles T, Young A, Nimeiri H, et al. · Front Oncol · 2023 · Derived
PubMed: PMID 37601688 · NCT02450331 (IMvigor010) · Carcinoma, Transitional Cell
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Pignata S, Bookman M, Sehouli J, et al. · Gynecol Oncol · 2023 · Derived
PubMed: PMID 37625235 · NCT03038100 (IMagyn050) · Ovarian Neoplasms
Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19).
Petrausch U, Spahn M, Schneider M, et al. · BMJ Open · 2023 · Derived
PubMed: PMID 37286312 · NCT04630730 · Urinary Bladder Neoplasms
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Pal SK, Albiges L, Tomczak P, et al. · Lancet · 2023 · Derived
PubMed: PMID 37290461 · NCT04338269 (CONTACT-03) · Carcinoma, Renal Cell
Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade.
Nazerai L, Willis SC, Yankilevich P, et al. · Oncoimmunology · 2023 · Derived
PubMed: PMID 36545256 · NCT05276284 (TEMPLE) · Neoplasm Metastasis
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
Nadal E, Rodríguez-Abreu D, Simó M, et al. · J Clin Oncol · 2023 · Derived
PubMed: PMID 37603816 · NCT03526900 (ATEZO-BRAIN) · Carcinoma, Non-Small-Cell Lung
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab.
Nabbi A, Danesh A, Espin-Garcia O, et al. · Nat Cancer · 2023 · Derived
PubMed: PMID 37038005 · NCT02541604
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Meric-Bernstam F, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
PubMed: PMID 38096472 · NCT02693535 (TAPUR) · Neoplasms
The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial.
Mangat PK, Garrett-Mayer E, Perez JK, et al. · Clin Trials · 2023 · Derived
PubMed: PMID 37489819 · NCT02693535 (TAPUR) · Neoplasms
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.
Luke JJ, Piha-Paul SA, Medina T, et al. · Clin Cancer Res · 2023 · Derived
PubMed: PMID 37227176 · NCT04167137 · Neoplasm Metastasis
Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer.
Lu S, Fang J, Wang Z, et al. · Cancer Med · 2023 · Derived
PubMed: PMID 36052772 · NCT02657434 · Carcinoma, Non-Small-Cell Lung
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
Liu SV, Mok TSK, Nabet BY, et al. · Lung Cancer · 2023 · Derived
PubMed: PMID 37931445 · NCT02763579 (IMpower133) · Small Cell Lung Carcinoma
Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma.
Li SN, Wan X, Peng LB, et al. · BMC Health Serv Res · 2023 · Derived
PubMed: PMID 36653848 · NCT02908672 · Melanoma
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lee SM, Schulz C, Prabhash K, et al. · Lancet · 2023 · Derived
PubMed: PMID 37423228 · NCT03191786 (IPSOS) · Carcinoma, Non-Small-Cell Lung
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
Landen CN, Molinero L, Hamidi H, et al. · Clin Cancer Res · 2023 · Derived
PubMed: PMID 36595569 · NCT03038100 (IMagyn050) · Ovarian Neoplasms
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Kurtz JE, Pujade-Lauraine E, Oaknin A, et al. · J Clin Oncol · 2023 · Derived
PubMed: PMID 37643382 · NCT02891824 (ATALANTE) · Ovarian Neoplasms
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
Kringelbach T, Højgaard M, Rohrberg K, et al. · BMC Cancer · 2023 · Derived
PubMed: PMID 36814246 · NCT04341181 (ProTarget) · Neoplasms
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
Ko AH, Kim KP, Siveke JT, et al. · Oncologist · 2023 · Derived
PubMed: PMID 36940261 · NCT03281369 · Esophageal Neoplasms
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
Kim TW, Bedard PL, LoRusso P, et al. · JAMA Oncol · 2023 · Derived
PubMed: PMID 37768658 · NCT02794571 · Neoplasm Metastasis
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery.
Jackson-Spence F, Toms C, O'Mahony LF, et al. · Future Oncol · 2023 · Derived
PubMed: PMID 37082935 · NCT04660344 (IMvigor011)
A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
Inman BA, Hahn NM, Stratton K, et al. · Eur Urol Oncol · 2023 · Derived
PubMed: PMID 36803840 · NCT02792192 · Urinary Bladder Neoplasms
Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA).
Iivanainen S, Baird AM, Balas B, et al. · BMJ Open · 2023 · Derived
PubMed: PMID 37076159 · NCT05694013 (ORIGAMA) · Neoplasms
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
Grande E, Bamias A, Galsky MD, et al. · Eur Urol Open Sci · 2023 · Derived
PubMed: PMID 37954037 · NCT02807636 (IMvigor130) · Carcinoma, Transitional Cell
Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C, McCullagh L, O'Donnell H, et al. · Cochrane Database Syst Rev · 2023 · Derived
PubMed: PMID 36648215 · NCT02303951 (NEO-VC) · Melanoma
Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.
Gijtenbeek RG, de Jong K, Venmans BJ, et al. · Cochrane Database Syst Rev · 2023 · Derived
PubMed: PMID 37419867 · NCT03191786 (IPSOS) · Carcinoma, Non-Small-Cell Lung
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Geurts BS, Battaglia TW, van Berge Henegouwen JM, et al. · BMC Cancer · 2023 · Derived
PubMed: PMID 36870947 · NCT02925234 (DRUP) · Neoplasms
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
Gentzler RD, Villaruz LC, Rhee JC, et al. · Oncologist · 2023 · Derived
PubMed: PMID 37555284 · NCT04631029 · Brain Neoplasms
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
Ganti AK, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
PubMed: PMID 37315265 · NCT02693535 (TAPUR) · Neoplasms
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Gaitskell K, Rogozińska E, Platt S, et al. · Cochrane Database Syst Rev · 2023 · Derived
PubMed: PMID 37185961 · NCT02659384 · Ovarian Neoplasms
An LC-MS/MS method for simultaneous determination of LB-100 and its active metabolite, endothall, in human plasma.
Feng Y, Massarelli E, Forman E, et al. · Bioanalysis · 2023 · Derived
PubMed: PMID 37584370 · NCT04560972
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.
Felip E, Altorki N, Zhou C, et al. · Ann Oncol · 2023 · Derived
PubMed: PMID 37467930 · NCT02486718 · Carcinoma, Non-Small-Cell Lung
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
Duvivier HL, Rothe M, Mangat PK, et al. · J Clin Oncol · 2023 · Derived
PubMed: PMID 37561967 · NCT02693535 (TAPUR) · Neoplasms
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
Dummer R, Queirolo P, Gerard Duhard P, et al. · Lancet Oncol · 2023 · Derived
PubMed: PMID 37459873 · NCT03625141 · Melanoma
Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.
Ducreux M, Tabernero J, Grothey A, et al. · Eur J Cancer · 2023 · Derived
PubMed: PMID 36921494 · NCT02291289 (MODUL) · Colorectal Neoplasms
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
Drakaki A, Powles T, Bamias A, et al. · Clin Cancer Res · 2023 · Derived
PubMed: PMID 37651261 · NCT03869190 · Carcinoma, Transitional Cell
Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial.
de Vries HM, Rafael TS, Gil-Jimenez A, et al. · J Clin Oncol · 2023 · Derived
PubMed: PMID 37487169 · NCT03686332 (PERICLES) · Penile Neoplasms
Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial.
Crabb S, Wickens R, Jane-Bibby S, et al. · BMC Cancer · 2023 · Derived
PubMed: PMID 37726695 · NCT05038657 (AURORA) · Carcinoma, Squamous Cell
Atezolizumab for Advanced Alveolar Soft Part Sarcoma.
Chen AP, Sharon E, O'Sullivan-Coyne G, et al. · N Engl J Med · 2023 · Derived
PubMed: PMID 37672694 · NCT03141684 · Sarcoma, Alveolar Soft Part
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Caligiuri M, Williams GL, Castro J, et al. · Target Oncol · 2023 · Derived
PubMed: PMID 36826464 · NCT03568656 · Carcinoma, Non-Small-Cell Lung
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.
Bylicki O, Tomasini P, Radj G, et al. · Eur J Cancer · 2023 · Derived
PubMed: PMID 36801605 · NCT04042558 (GFPC 06-2018) · Carcinoma, Non-Small-Cell Lung
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.
Burotto M, Zvirbule Z, Mochalova A, et al. · Ann Oncol · 2023 · Derived
PubMed: PMID 37268157 · NCT03735121 · Carcinoma, Non-Small-Cell Lung
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
Black PC, Tangen CM, Singh P, et al. · Eur Urol · 2023 · Derived
PubMed: PMID 37596191 · NCT02844816
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bartlett NL, Assouline S, Giri P, et al. · Blood Adv · 2023 · Derived
PubMed: PMID 37067952 · NCT02500407 · Lymphoma, Non-Hodgkin
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.
Bamias A, Merseburger A, Loriot Y, et al. · J Immunother Cancer · 2023 · Derived
PubMed: PMID 36627145 · NCT02928406 · Urologic Neoplasms
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Ascierto PA, Stroyakovskiy D, Gogas H, et al. · Lancet Oncol · 2023 · Derived
PubMed: PMID 36460017 · NCT02908672 · Melanoma
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
Aldin A, Besiroglu B, Adams A, et al. · Cochrane Database Syst Rev · 2023 · Derived
PubMed: PMID 37146227 · NCT01984242 (IMmotion150) · Carcinoma, Renal Cell
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.
Ahn ER, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
PubMed: PMID 37027810 · NCT02693535 (TAPUR) · Neoplasms
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A, Jacquin M, Rebucci-Peixoto M, et al. · BMC Cancer · 2023 · Background
PubMed: PMID 37516867 · NCT05528952 (TERTIO) · Carcinoma, Hepatocellular
Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.
Tan W, Yang M, Yang H, et al. · Cancer Manag Res · 2023 · Background
PubMed: PMID 30349367 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma.
Saliby RM, El Zarif T, Bakouny Z, et al. · Cancer Immunol Res · 2023 · Background
PubMed: PMID 37279009 · NCT02724878 · Kidney Neoplasms
Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors.
Panda A, Betigeri A, Subramanian K, et al. · JCO Precis Oncol · 2023 · Background
PubMed: PMID 29951597 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance.
Oh J, Barve M, Senzer N, et al. · Gynecol Oncol Rep · 2023 · Background
PubMed: PMID 33364285 · NCT03073525 · Ovarian Neoplasms
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer.
Keup C, Storbeck M, Hauch S, et al. · Cancers (Basel) · 2023 · Background
PubMed: PMID 30781720 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases.
Hecht JR, Raman SS, Chan A, et al. · ESMO Open · 2023 · Background
PubMed: PMID 36863095 · NCT03256344 · Triple Negative Breast Neoplasms
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019.
Ditsch N, Untch M, Thill M, et al. · Breast Care (Basel) · 2023 · Background
PubMed: PMID 31558897 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial.
Chiang CL, Chiu KWH, Chan KSK, et al. · Lancet Gastroenterol Hepatol · 2023 · Background
PubMed: PMID 36529152 · NCT07293468 (BIIRTH) · Carcinoma, Hepatocellular

2022 (104 papers)

Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
Rocconi RP, Stevens EE, Bottsford-Miller JN, et al. · Cancer Gene Ther · 2022 · Trial result
PubMed: PMID 33753870 · NCT03073525 · Ovarian Neoplasms
New therapies for advanced, recurrent, and metastatic endometrial cancers.
Makker V, Green AK, Wenham RM, et al. · Gynecol Oncol Res Pract · 2022 · Trial result
PubMed: PMID 29214032 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Surgeon Assessment of the Technical Impact of Neoadjuvant Systemic Therapy on Operable Stage III Melanoma.
Hieken TJ, Price DL, Piltin MA, et al. · Ann Surg Oncol · 2022 · Trial result
PubMed: PMID 34825282 · NCT03554083
Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma.
Younes A, Burke JM, Diefenbach C, et al. · Blood Adv · 2022 · Derived
PubMed: PMID 35359000 · NCT02596971 · Lymphoma, Follicular
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.
Yarchoan M, Cope L, Ruggieri AN, et al. · J Clin Invest · 2022 · Derived
PubMed: PMID 34907910 · NCT03201458 · Cholangiocarcinoma
Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
Yang Y, Psutka SP, Parikh AB, et al. · Cancer Med · 2022 · Derived
PubMed: PMID 35304832 · NCT04338269 (CONTACT-03) · Carcinoma, Renal Cell
Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.
Xing P, Wang M, Zhao J, et al. · Thorac Cancer · 2022 · Derived
PubMed: PMID 34409776 · NCT03689855 (RamAtezo-1) · Carcinoma, Non-Small-Cell Lung
Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
Wang H, Ma H, Sové RJ, et al. · J Immunother Cancer · 2022 · Derived
PubMed: PMID 33579739 · NCT02425891 · Triple Negative Breast Neoplasms
Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
van der Heijden MS, Loriot Y, Durán I, et al. · Eur Urol · 2022 · Derived
PubMed: PMID 33902955 · NCT02302807 · Urinary Bladder Neoplasms
Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, et al. · Cancer Chemother Pharmacol · 2022 · Derived
PubMed: PMID 35598186 · NCT02925234 (DRUP) · Neoplasms
Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data.
Ton TGN, Pal N, Trinh H, et al. · Clin Cancer Res · 2022 · Derived
PubMed: PMID 35511917 · NCT02657434 · Carcinoma, Non-Small-Cell Lung
The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
Thompson NA, Stewart GD, Welsh SJ, et al. · BMC Cancer · 2022 · Derived
PubMed: PMID 35073853 · NCT04107168 · Lung Neoplasms
Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers.
Tabernero J, Andre F, Blay JY, et al. · ESMO Open · 2022 · Derived
PubMed: PMID 35305400 · NCT02458638 · Neoplasms
Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI).
Szabados B, Ponz-Sarvisé M, Machado R, et al. · Clin Cancer Res · 2022 · Derived
PubMed: PMID 35877091 · NCT02951767 · Urinary Bladder Neoplasms
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma.
Schjesvold F, Paiva B, Ribrag V, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
PubMed: PMID 36450626 · NCT03312530 · Multiple Myeloma
Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy.
Sandhu S, Atkinson V, Cao MG, et al. · Eur J Cancer · 2022 · Derived
PubMed: PMID 36455412 · NCT03178851 · Melanoma
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
Salem R, Li D, Sommer N, et al. · Cancer Med · 2022 · Derived
PubMed: PMID 34189869 · NCT03434379 (IMbrave150) · Carcinoma, Hepatocellular
Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.
Robert C, Lewis KD, Gutzmer R, et al. · Ann Oncol · 2022 · Derived
PubMed: PMID 35131452 · NCT02908672 · Melanoma
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.
Remon J, Girard N, Novello S, et al. · Clin Lung Cancer · 2022 · Derived
PubMed: PMID 34393061 · NCT04321330 · Thymoma
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.
Powles T, Yuen KC, Gillessen S, et al. · Nat Med · 2022 · Derived
PubMed: PMID 35013615 · NCT03016312 (IMbassador250) · Prostatic Neoplasms, Castration-Resistant
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
Petrylak DP, Loriot Y, Shaffer DR, et al. · Clin Cancer Res · 2022 · Derived
PubMed: PMID 33568344 · NCT01375842 · Neoplasms
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S, Dziadziuszko R, Morabito A, et al. · Nat Med · 2022 · Derived
PubMed: PMID 35995953 · NCT03178552 (B-FAST) · Carcinoma, Non-Small-Cell Lung
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.
Perez-Gracia JL, Loriot Y, Rosenberg JE, et al. · Eur Urol · 2022 · Derived
PubMed: PMID 29273410 · NCT02108652 · Urinary Bladder Neoplasms
Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.
Palomba ML, Till BG, Park SI, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
PubMed: PMID 35031227 · NCT02220842 · Lymphoma
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.
Palomba ML, Cartron G, Popplewell L, et al. · Clin Lymphoma Myeloma Leuk · 2022 · Derived
PubMed: PMID 35151584 · NCT02220842 · Lymphoma
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Pal SK, Uzzo R, Karam JA, et al. · Lancet · 2022 · Derived
PubMed: PMID 36099926 · NCT03024996 (IMmotion010) · Carcinoma, Renal Cell
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
Nogami N, Barlesi F, Socinski MA, et al. · J Thorac Oncol · 2022 · Derived
PubMed: PMID 34626838 · NCT02366143 (IMpower150) · Carcinoma, Non-Small-Cell Lung
Development and Validation of a Simplified Prognostic Score in SCLC.
Negre E, Coffy A, Langlais A, et al. · JTO Clin Res Rep · 2022 · Derived
PubMed: PMID 34589918 · NCT03059667 · Small Cell Lung Carcinoma
Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm.
Narita Y, Yoshimoto T, Namai T, et al. · JCO Clin Cancer Inform · 2022 · Derived
PubMed: PMID 35649212 · NCT02091141 · Neoplasms
Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
Nakauma-González JA, Rijnders M, van Riet J, et al. · Eur Urol · 2022 · Derived
PubMed: PMID 35086719 · NCT02925234 (DRUP) · Neoplasms
ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.
Mulgaonkar A, Elias R, Woolford L, et al. · Clin Cancer Res · 2022 · Derived
PubMed: PMID 36074149 · NCT04006522 · Carcinoma, Renal Cell
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
Motzer RJ, Powles T, Atkins MB, et al. · JAMA Oncol · 2022 · Derived
PubMed: PMID 34940781 · NCT02420821 (IMmotion151) · Carcinoma, Renal Cell
Top advances in lung cancer, 2021.
Mohindra NA, Patel JD · Cancer · 2022 · Derived
PubMed: PMID 35947027 · NCT02486718 · Carcinoma, Non-Small-Cell Lung
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB, Ou FS, Zemla TJ, et al. · JAMA Netw Open · 2022 · Derived
PubMed: PMID 35179586 · NCT02873195 · Colorectal Neoplasms
The target antigen determines the mechanism of acquired resistance to T cell-based therapies.
Martínez-Sabadell A, Morancho B, Rius Ruiz I, et al. · Cell Rep · 2022 · Derived
PubMed: PMID 36261015 · NCT02650713
Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study.
Mao L, Fang M, Chen Y, et al. · Clin Cancer Res · 2022 · Derived
PubMed: PMID 36044526 · NCT04091217 · Melanoma
Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
Li Y, Liang X, Li H, et al. · Cancer · 2022 · Derived
PubMed: PMID 36111952 · NCT03434379 (IMbrave150) · Carcinoma, Hepatocellular
Prognostic Value of NUSAP1 and Its Correlation with Immune Infiltrates in Human Breast Cancer.
Li M, Yang B · Crit Rev Eukaryot Gene Expr · 2022 · Derived
PubMed: PMID 35695609 · NCT02425891 · Triple Negative Breast Neoplasms
Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial.
Komatsu SI, Kayukawa Y, Miyazaki Y, et al. · Sci Rep · 2022 · Derived
PubMed: PMID 35853994 · NCT05022927 · Carcinoma, Hepatocellular
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Kim ES, Velcheti V, Mekhail T, et al. · Nat Med · 2022 · Derived
PubMed: PMID 35422531 · NCT02848651 (B-F1RST) · Carcinoma, Non-Small-Cell Lung
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Kelley RK, Rimassa L, Cheng AL, et al. · Lancet Oncol · 2022 · Derived
PubMed: PMID 35798016 · NCT03755791 (COSMIC-312) · Carcinoma, Hepatocellular
Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma.
Kaseb AO, Guan Y, Gok Yavuz B, et al. · J Hepatocell Carcinoma · 2022 · Derived
PubMed: PMID 36254201 · NCT03434379 (IMbrave150) · Carcinoma, Hepatocellular
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.
Hussein M, Maglakelidze M, Richards DA, et al. · Cancer Manag Res · 2022 · Derived
PubMed: PMID 34408488 · NCT03041311 · Small Cell Lung Carcinoma
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
Hurvitz SA, Bachelot T, Bianchini G, et al. · Future Oncol · 2022 · Derived
PubMed: PMID 36382554 · NCT04873362 (Astefania) · Breast Neoplasms
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
Huober J, Barrios CH, Niikura N, et al. · J Clin Oncol · 2022 · Derived
PubMed: PMID 35763704 · NCT03726879 (IMpassion050) · Breast Neoplasms
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.
Holm JS, Funt SA, Borch A, et al. · Nat Commun · 2022 · Derived
PubMed: PMID 35410325 · NCT02108652 · Urinary Bladder Neoplasms
Creating and Implementing a Principal Investigator Tool Kit for Enhancing Accrual to Late Phase Clinical Trials: Development and Usability Study.
Higgins KA, Thomas A, Soto N, et al. · JMIR Cancer · 2022 · Derived
PubMed: PMID 36006678 · NCT03811002 · Lung Neoplasms
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.
Helland Å, Russnes HG, Fagereng GL, et al. · J Transl Med · 2022 · Derived
PubMed: PMID 35568909 · NCT04817956 (IMPRESS-N) · Neoplasm Metastasis
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial.
Heilig CE, Horak P, Kreutzfeldt S, et al. · ESMO Open · 2022 · Derived
PubMed: PMID 34808524 · NCT04551521 · Neoplasm Metastasis
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.
Halperin DM, Liu S, Dasari A, et al. · JAMA Oncol · 2022 · Derived
PubMed: PMID 35389428 · NCT03074513 · Mesothelioma, Malignant
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.
Hack SP, Verret W, Mulla S, et al. · Ther Adv Med Oncol · 2022 · Derived
PubMed: PMID 34377158 · NCT04677504 · Biliary Tract Neoplasms
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
Gupta R, Meric-Bernstam F, Rothe M, et al. · JCO Precis Oncol · 2022 · Derived
PubMed: PMID 36315917 · NCT02693535 (TAPUR) · Neoplasms
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
Gonzalez Martin A, Sanchez Lorenzo L, Colombo N, et al. · Int J Gynecol Cancer · 2022 · Derived
PubMed: PMID 33318079 · NCT03598270 (ANITA) · Ovarian Neoplasms
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C, Cassier P, Zamarin D, et al. · J Immunother Cancer · 2022 · Derived
PubMed: PMID 35577503 · NCT02323191
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.
Gerds AT, Scott BL, Greenberg P, et al. · Blood Adv · 2022 · Derived
PubMed: PMID 34932793 · NCT02508870 · Myelodysplastic Syndromes
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Gadgeel S, Hirsch FR, Kerr K, et al. · Clin Lung Cancer · 2022 · Derived
PubMed: PMID 34226144 · NCT02008227 (OAK)
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Funt SA, Lattanzi M, Whiting K, et al. · J Clin Oncol · 2022 · Derived
PubMed: PMID 35089812 · NCT02989584 · Carcinoma, Transitional Cell
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
Friedman CF, Hainsworth JD, Kurzrock R, et al. · Cancer Discov · 2022 · Derived
PubMed: PMID 34876409 · NCT02091141 · Neoplasms
A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
Fong L, Morris MJ, Sartor O, et al. · Clin Cancer Res · 2022 · Derived
PubMed: PMID 34108181 · NCT02814669
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
Ferrarotto R, Anderson I, Medgyasszay B, et al. · Cancer Med · 2022 · Derived
PubMed: PMID 34405547 · NCT03041311 · Small Cell Lung Carcinoma
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
Fennell DA, King A, Mohammed S, et al. · Lancet Oncol · 2022 · Derived
PubMed: PMID 35157829 · NCT03654833 (MiST) · Mesothelioma, Malignant
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Felip E, Burotto M, Zvirbule Z, et al. · Clin Pharmacol Drug Dev · 2022 · Derived
PubMed: PMID 33788415 · NCT03735121 · Carcinoma, Non-Small-Cell Lung
Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.
Eickhoff N, Bergman AM, Zwart W, et al. · Endocrinology · 2022 · Derived
PubMed: PMID 36125208 · NCT03568656 · Carcinoma, Non-Small-Cell Lung
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
Dummer R, Queirolo P, Abajo Guijarro AM, et al. · Lancet Oncol · 2022 · Derived
PubMed: PMID 35940183 · NCT03625141 · Melanoma
Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T.
Dorff T, Hirasawa Y, Acoba J, et al. · J Immunother Cancer · 2022 · Derived
PubMed: PMID 34376554 · NCT03024216
Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer.
Dong Y, Zhu Y, Zhuo M, et al. · Cancers (Basel) · 2022 · Derived
PubMed: PMID 36428744 · NCT01903993 · Carcinoma, Non-Small-Cell Lung
First-line atezolizumab monotherapy in patients with advanced BRAFV600 wild-type melanoma.
de Azevedo SJ, de Melo AC, Roberts L, et al. · Pigment Cell Melanoma Res · 2022 · Derived
PubMed: PMID 33476492 · NCT03178851 · Melanoma
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Cortellini A, Ricciuti B, Borghaei H, et al. · Cancer · 2022 · Derived
PubMed: PMID 35727053 · NCT02008227 (OAK)
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Cho BC, Abreu DR, Hussein M, et al. · Lancet Oncol · 2022 · Derived
PubMed: PMID 35576957 · NCT03563716 · Carcinoma, Non-Small-Cell Lung
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Cheng AL, Qin S, Ikeda M, et al. · J Hepatol · 2022 · Derived
PubMed: PMID 34902530 · NCT03434379 (IMbrave150) · Carcinoma, Hepatocellular
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.
Chawla SP, Van Tine BA, Pollack SM, et al. · J Clin Oncol · 2022 · Derived
PubMed: PMID 34260265 · NCT02609984 · Sarcoma
The current management and biomarkers of immunotherapy in advanced gastric cancer.
Chang X, Ge X, Zhang Y, et al. · Medicine (Baltimore) · 2022 · Derived
PubMed: PMID 35623069 · NCT03421288 (DANTE) · Stomach Neoplasms
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
Chaft JE, Oezkan F, Kris MG, et al. · Nat Med · 2022 · Derived
PubMed: PMID 36097216 · NCT02927301 · Carcinoma, Non-Small-Cell Lung
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, et al. · Lancet Oncol · 2022 · Derived
PubMed: PMID 35803286 · NCT02500407 · Lymphoma, Non-Hodgkin
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
Budde LE, Assouline S, Sehn LH, et al. · J Clin Oncol · 2022 · Derived
PubMed: PMID 34914545 · NCT02500407 · Lymphoma, Non-Hodgkin
Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial.
Bozorgmehr F, Christopoulos P, Chung I, et al. · BMC Cancer · 2022 · Derived
PubMed: PMID 36153496 · NCT04462276 (TREASURE)
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.
Ben Khaled N, Seidensticker M, Ricke J, et al. · Future Oncol · 2022 · Derived
PubMed: PMID 35081747 · NCT04224636 (DEMAND)
Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies.
Barteselli G, Goodman GR, Patel Y, et al. · Drug Saf · 2022 · Derived
PubMed: PMID 36310331 · NCT03178851 · Melanoma
Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni A, Azevedo S, Rubio-Viqueira B, et al. · J Immunother Cancer · 2022 · Derived
PubMed: PMID 36450379 · NCT03285763 (TAIL) · Carcinoma, Non-Small-Cell Lung
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C, Rossini D, Pietrantonio F, et al. · Lancet Oncol · 2022 · Derived
PubMed: PMID 35636444 · NCT03721653 (AtezoTRIBE) · Colorectal Neoplasms
Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.
Agostinetto E, Eiger D, Punie K, et al. · Curr Oncol Rep · 2022 · Derived
PubMed: PMID 33763756 · NCT04408118 (ATRACTIB) · Breast Neoplasms
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Agarwal N, McGregor B, Maughan BL, et al. · Lancet Oncol · 2022 · Derived
PubMed: PMID 35690072 · NCT03170960 · Carcinoma, Non-Small-Cell Lung
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.
Agarwal N, Azad A, Carles J, et al. · Future Oncol · 2022 · Derived
PubMed: PMID 35034502 · NCT04446117 (CONTACT-02) · Prostatic Neoplasms
Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity.
Yang C, Jin J, Yang Y, et al. · Immunity · 2022 · Background
PubMed: PMID 35700739 · NCT06416436 · Neoplasm Metastasis
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
Weiss J, Goldschmidt J, Andric Z, et al. · Clin Lung Cancer · 2022 · Background
PubMed: PMID 33895103 · NCT03041311 · Small Cell Lung Carcinoma
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer.
Vernieri C, Fucà G, Ligorio F, et al. · Cancer Discov · 2022 · Background
PubMed: PMID 34789537 · NCT05703997 (FASTIMMUNE) · Small Cell Lung Carcinoma
Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy.
Tamminga M, de Wit S, Schuuring E, et al. · Transl Lung Cancer Res · 2022 · Background
PubMed: PMID 32010564 · NCT06416436 · Neoplasm Metastasis
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study.
Simonelli M, Garralda E, Eskens F, et al. · ESMO Open · 2022 · Background
PubMed: PMID 35987165 · NCT03637764 · Neoplasms
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Rocconi RP, Monk BJ, Walter A, et al. · Gynecol Oncol · 2022 · Background
PubMed: PMID 33715892 · NCT03073525 · Ovarian Neoplasms
Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.
Oweida A, Lennon S, Calame D, et al. · Oncoimmunology · 2022 · Background
PubMed: PMID 29123967 · NCT06416436 · Neoplasm Metastasis
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Lu LC, Hsu C, Shao YY, et al. · Liver Cancer · 2022 · Background
PubMed: PMID 31799205 · NCT04862949 · Carcinoma, Hepatocellular
Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States.
Liu P, Xie SH, Hu S, et al. · Oncotarget · 2022 · Background
PubMed: PMID 28978103 · NCT06789757 ((HCC)) · Carcinoma, Hepatocellular
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial.
Ligorio F, Fucà G, Provenzano L, et al. · Eur J Cancer · 2022 · Background
PubMed: PMID 35810555 · NCT05703997 (FASTIMMUNE) · Small Cell Lung Carcinoma
Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer.
Li L, Liu T, Liu Q, et al. · Front Pharmacol · 2022 · Background
PubMed: PMID 36147357 · NCT06663098 (CARRY-ON) · Small Cell Lung Carcinoma
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C, Feuerhake F, Garke M, et al. · Breast Cancer Res · 2022 · Background
PubMed: PMID 36056374 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Hugo W, Zaretsky JM, Sun L, et al. · Cell · 2022 · Background
PubMed: PMID 28129544 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.
Hata A, Katakami N, Nanjo S, et al. · Oncotarget · 2022 · Background
PubMed: PMID 29371947 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Comprehensive assessment of circulating immune cell populations in response to stereotactic body radiation therapy in patients with liver cancer.
Gustafson MP, Bornschlegl S, Park SS, et al. · Adv Radiat Oncol · 2022 · Background
PubMed: PMID 29204520 · NCT06416436 · Neoplasm Metastasis
Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study.
de la Torre-Aláez M, Matilla A, Varela M, et al. · J Immunother Cancer · 2022 · Background
PubMed: PMID 36450386 · NCT07293468 (BIIRTH) · Carcinoma, Hepatocellular
Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.
Chmura S, Winter KA, Robinson C, et al. · JAMA Oncol · 2022 · Background
PubMed: PMID 33885704 · NCT06416436 · Neoplasm Metastasis
Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer.
Cheng Y, Wang T, Lv X, et al. · Cancer Manag Res · 2022 · Background
PubMed: PMID 32256114 · NCT06416436 · Neoplasm Metastasis
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.
Bestvina CM, Pointer KB, Karrison T, et al. · J Thorac Oncol · 2022 · Background
PubMed: PMID 34500113 · NCT06416436 · Neoplasm Metastasis
External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline.
Apisarnthanarax S, Barry A, Cao M, et al. · Pract Radiat Oncol · 2022 · Background
PubMed: PMID 34688956 · NCT07293468 (BIIRTH) · Carcinoma, Hepatocellular
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade.
Ajona D, Ortiz-Espinosa S, Lozano T, et al. · Nat Cancer · 2022 · Background
PubMed: PMID 35121837 · NCT05703997 (FASTIMMUNE) · Small Cell Lung Carcinoma

2021 (77 papers)

PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
Zeng R, Liu F, Fang C, et al. · Front Immunol · 2021 · Derived
PubMed: PMID 34777341 · NCT03041311 · Small Cell Lung Carcinoma
Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial.
Yuk HD, Jeong CW, Kwak C, et al. · BMJ Open · 2021 · Derived
PubMed: PMID 33060077 · NCT03577132 · Carcinoma, Transitional Cell
Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
Wen F, Zheng H, Zhang P, et al. · Liver Int · 2021 · Derived
PubMed: PMID 33556230 · NCT03434379 (IMbrave150) · Carcinoma, Hepatocellular
Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.
Wang S, Huang HY, Wu D, et al. · BMJ Open · 2021 · Derived
PubMed: PMID 34083331 · NCT04423185
CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
Uprety D · Clin Lung Cancer · 2021 · Derived
PubMed: PMID 33358660 · NCT03762018 (BEAT-meso)
Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial.
Spaas M, Sundahl N, Hulstaert E, et al. · BMC Cancer · 2021 · Derived
PubMed: PMID 33962592 · NCT03511391 (CHEERS) · Carcinoma, Non-Small-Cell Lung
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.
Socinski MA, Nishio M, Jotte RM, et al. · J Thorac Oncol · 2021 · Derived
PubMed: PMID 34311108 · NCT02366143 (IMpower150) · Carcinoma, Non-Small-Cell Lung
Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.
Shemesh CS, Chan P, Legrand FA, et al. · Pharmacol Res Perspect · 2021 · Derived
PubMed: PMID 33241650 · NCT01375842 · Neoplasms
Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer.
Romero Román A, Campo-Cañaveral de la Cruz JL, Macía I, et al. · Eur J Cardiothorac Surg · 2021 · Derived
PubMed: PMID 33661301 · NCT03456063
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
Reck M, Wehler T, Orlandi F, et al. · J Clin Oncol · 2021 · Derived
PubMed: PMID 32459597 · NCT02366143 (IMpower150) · Carcinoma, Non-Small-Cell Lung
Atezolizumab in the treatment of metastatic triple-negative breast cancer.
Pérez-García J, Soberino J, Racca F, et al. · Expert Opin Biol Ther · 2021 · Derived
PubMed: PMID 32450725 · NCT03281954 · Triple Negative Breast Neoplasms
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer.
Pascual T, Cejalvo JM, Oliveira M, et al. · Future Oncol · 2021 · Derived
PubMed: PMID 32633563 · NCT03802604 (PROMETEO) · Breast Neoplasms
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
Pal SK, McGregor B, Suárez C, et al. · J Clin Oncol · 2021 · Derived
PubMed: PMID 34491815 · NCT03170960 · Carcinoma, Non-Small-Cell Lung
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.
Oh DY, Kwek SS, Raju SS, et al. · Cell · 2021 · Derived
PubMed: PMID 32497499 · NCT02451423 · Carcinoma, Transitional Cell
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Moore KN, Bookman M, Sehouli J, et al. · J Clin Oncol · 2021 · Derived
PubMed: PMID 33891472 · NCT03038100 (IMagyn050) · Ovarian Neoplasms
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D, Gligorov J, André F, et al. · Ann Oncol · 2021 · Derived
PubMed: PMID 34219000 · NCT03125902 (IMpassion131) · Triple Negative Breast Neoplasms
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
Merseburger AS, Castellano D, Powles T, et al. · J Urol · 2021 · Derived
PubMed: PMID 33835866 · NCT02928406 · Urologic Neoplasms
Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials.
Marconi L, Sun M, Beisland C, et al. · Clin Genitourin Cancer · 2021 · Derived
PubMed: PMID 33526329 · NCT03024996 (IMmotion010) · Carcinoma, Renal Cell
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.
Mansfield AS, Każarnowicz A, Karaseva N, et al. · Ann Oncol · 2021 · Derived
PubMed: PMID 31959349 · NCT02763579 (IMpower133) · Small Cell Lung Carcinoma
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma.
Loriot Y, Sternberg CN, Castellano D, et al. · Eur J Cancer · 2021 · Derived
PubMed: PMID 32905959 · NCT02928406 · Urologic Neoplasms
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
Liu SV, Reck M, Mansfield AS, et al. · J Clin Oncol · 2021 · Derived
PubMed: PMID 33439693 · NCT02763579 (IMpower133) · Small Cell Lung Carcinoma
Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol.
le Guevelou J, Debaigt C, Saada-Bouzid E, et al. · BMJ Open · 2021 · Derived
PubMed: PMID 32967883 · NCT03548428 (Stereosarc) · Sarcoma
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.
Kyte JA, Røssevold A, Falk RS, et al. · J Transl Med · 2021 · Derived
PubMed: PMID 32576225 · NCT03164993 (ALICE) · Neoplasms
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
Kelley RK, W Oliver J, Hazra S, et al. · Future Oncol · 2021 · Derived
PubMed: PMID 32491932 · NCT03755791 (COSMIC-312) · Carcinoma, Hepatocellular
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
Javle M, Borad MJ, Azad NS, et al. · Lancet Oncol · 2021 · Derived
PubMed: PMID 34339623 · NCT02091141 · Neoplasms
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
Harter P, Pautier P, Van Nieuwenhuysen E, et al. · Int J Gynecol Cancer · 2021 · Derived
PubMed: PMID 32606097 · NCT03353831 · Ovarian Neoplasms
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
Hack SP, Spahn J, Chen M, et al. · Future Oncol · 2021 · Derived
PubMed: PMID 32352320 · NCT04102098 (IMbrave050) · Carcinoma, Hepatocellular
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
Gandara D, Reck M, Moro-Sibilot D, et al. · J Immunother Cancer · 2021 · Derived
PubMed: PMID 33737340 · NCT02008227 (OAK)
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR, Finn RS, Qin S, et al. · Lancet Oncol · 2021 · Derived
PubMed: PMID 34051880 · NCT03434379 (IMbrave150) · Carcinoma, Hepatocellular
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.
Friedman CF, Snyder Charen A, Zhou Q, et al. · J Immunother Cancer · 2021 · Derived
PubMed: PMID 33004542 · NCT02921269 · Uterine Cervical Neoplasms
Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes.
Friebel E, Kapolou K, Unger S, et al. · Cell · 2021 · Derived
PubMed: PMID 32470397 · NCT02451423 · Carcinoma, Transitional Cell
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Fisher JG, Tait D, Garrett-Mayer E, et al. · Target Oncol · 2021 · Derived
PubMed: PMID 33090333 · NCT02693535 (TAPUR) · Neoplasms
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.
Fennell DA, King A, Mohammed S, et al. · Lancet Respir Med · 2021 · Derived
PubMed: PMID 33515503 · NCT03654833 (MiST) · Mesothelioma, Malignant
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E, Altorki N, Zhou C, et al. · Lancet · 2021 · Derived
PubMed: PMID 34555333 · NCT02486718 · Carcinoma, Non-Small-Cell Lung
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M, Oeser A, Besiroglu B, et al. · Cochrane Database Syst Rev · 2021 · Derived
PubMed: PMID 34515338 · NCT02926833 (ZUMA-6) · Lymphoma, Large B-Cell, Diffuse
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
Chiang AC, Sequist LVD, Gilbert J, et al. · Clin Lung Cancer · 2021 · Derived
PubMed: PMID 32586767 · NCT01375842 · Neoplasms
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
Chalabi M, Cardona A, Nagarkar DR, et al. · Ann Oncol · 2021 · Derived
PubMed: PMID 32115349 · NCT01903993 · Carcinoma, Non-Small-Cell Lung
Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice.
Cathomas R, Schardt J, Pless M, et al. · Swiss Med Wkly · 2021 · Derived
PubMed: PMID 32399958 · NCT02928406 · Urologic Neoplasms
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Bellmunt J, Hussain M, Gschwend JE, et al. · Lancet Oncol · 2021 · Derived
PubMed: PMID 33721560 · NCT02450331 (IMvigor010) · Carcinoma, Transitional Cell
Emerging systemic antitarget treatment for differentiated thyroid carcinoma.
Basté N, Mora M, Grau JJ, et al. · Curr Opin Oncol · 2021 · Derived
PubMed: PMID 33720068 · NCT03181100 · Thyroid Neoplasms
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.
Bar N, Costa F, Das R, et al. · JCI Insight · 2021 · Derived
PubMed: PMID 32427579 · NCT02784483 · Smoldering Multiple Myeloma
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.
Bamias A, Merseburger AS, Loriot Y, et al. · ESMO Open · 2021 · Derived
PubMed: PMID 33984672 · NCT02928406 · Urologic Neoplasms
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma.
Atkins MB, Rini BI, Motzer RJ, et al. · Clin Cancer Res · 2021 · Derived
PubMed: PMID 32127394 · NCT02420821 (IMmotion151) · Carcinoma, Renal Cell
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni A, Azevedo S, Rubio-Viqueira B, et al. · J Immunother Cancer · 2021 · Derived
PubMed: PMID 33737339 · NCT03285763 (TAIL) · Carcinoma, Non-Small-Cell Lung
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C, Borelli B, Rossini D, et al. · BMC Cancer · 2021 · Derived
PubMed: PMID 32698790 · NCT03721653 (AtezoTRIBE) · Colorectal Neoplasms
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Alva AS, Mangat PK, Garrett-Mayer E, et al. · J Clin Oncol · 2021 · Derived
PubMed: PMID 33844595 · NCT02693535 (TAPUR) · Neoplasms
Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Al Baghdadi T, Garrett-Mayer E, Halabi S, et al. · Target Oncol · 2021 · Derived
PubMed: PMID 33068284 · NCT02693535 (TAPUR) · Neoplasms
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
Adams S, Diéras V, Barrios CH, et al. · Ann Oncol · 2021 · Derived
PubMed: PMID 32178964 · NCT02425891 · Triple Negative Breast Neoplasms
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy.
Abraham I, Onyekwere U, Deniz B, et al. · J Med Econ · 2021 · Derived
PubMed: PMID 34873975 · NCT03041311 · Small Cell Lung Carcinoma
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.
Yu J, Green MD, Li S, et al. · Nat Med · 2021 · Background
PubMed: PMID 33398162 · NCT06416436 · Neoplasm Metastasis
PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers.
Ying L, Yan F, Meng Q, et al. · Oncoimmunology · 2021 · Background
PubMed: PMID 29872566 · NCT06416436 · Neoplasm Metastasis
T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer.
Wu L, Zhu J, Rudqvist NP, et al. · Front Immunol · 2021 · Background
PubMed: PMID 34733273 · NCT06416436 · Neoplasm Metastasis
XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
Wang J, Sun T, Meng Z, et al. · Cancer Lett · 2021 · Background
PubMed: PMID 33493586 · NCT07172412
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H, Ferlay J, Siegel RL, et al. · CA Cancer J Clin · 2021 · Background
PubMed: PMID 33538338 · NCT05197504 (HCC) · Carcinoma, Hepatocellular
Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells.
Sun R, Sundahl N, Hecht M, et al. · J Immunother Cancer · 2021 · Background
PubMed: PMID 33188037 · NCT06416436 · Neoplasm Metastasis
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review.
Spagnolo F, Boutros A, Cecchi F, et al. · BMC Cancer · 2021 · Background
PubMed: PMID 33865350 · NCT06663098 (CARRY-ON) · Small Cell Lung Carcinoma
Epidemiology and surveillance for hepatocellular carcinoma: New trends.
Singal AG, Lampertico P, Nahon P, et al. · J Hepatol · 2021 · Background
PubMed: PMID 31954490 · NCT06789757 ((HCC)) · Carcinoma, Hepatocellular
Immunotherapy as a Downstaging Therapy for Liver Transplantation.
Schwacha-Eipper B, Minciuna I, Banz V, et al. · Hepatology · 2021 · Background
PubMed: PMID 32171041 · NCT05185505 · Carcinoma, Hepatocellular
ESMO 2018 presidential symposium-IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer.
Schmid P · ESMO Open · 2021 · Background
PubMed: PMID 30425847 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Small-cell lung cancer.
Rudin CM, Brambilla E, Faivre-Finn C, et al. · Nat Rev Dis Primers · 2021 · Background
PubMed: PMID 33446664 · NCT05703997 (FASTIMMUNE) · Small Cell Lung Carcinoma
Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS).
Rokni MB, Pointer KB, George J, et al. · J Appl Clin Med Phys · 2021 · Background
PubMed: PMID 33626240 · NCT06416436 · Neoplasm Metastasis
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rocconi RP, Grosen EA, Ghamande SA, et al. · Lancet Oncol · 2021 · Background
PubMed: PMID 33271095 · NCT03073525 · Ovarian Neoplasms
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Phillips R, Shi WY, Deek M, et al. · JAMA Oncol · 2021 · Background
PubMed: PMID 32215577 · NCT06416436 · Neoplasm Metastasis
Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges.
Nimmagadda S · Cancers (Basel) · 2021 · Background
PubMed: PMID 33137949 · NCT06416436 · Neoplasm Metastasis
Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
Mitchell KG, Farooqi A, Ludmir EB, et al. · Clin Lung Cancer · 2021 · Background
PubMed: PMID 31447303 · NCT06416436 · Neoplasm Metastasis
Stereotactic Body Radiotherapy in Contralateral Kidney Oligometastasis From Renal Cell Carcinoma in a Nephrectomized Patient.
Marzo AD, Casale M, Trippa F, et al. · Ochsner J · 2021 · Background
PubMed: PMID 34566513 · NCT06416436 · Neoplasm Metastasis
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
Luke JJ, Onderdonk BE, Bhave SR, et al. · Clin Cancer Res · 2021 · Background
PubMed: PMID 33028595 · NCT06416436 · Neoplasm Metastasis
mRECIST for HCC: Performance and novel refinements.
Llovet JM, Lencioni R · J Hepatol · 2021 · Background
PubMed: PMID 31954493 · NCT05185505 · Carcinoma, Hepatocellular
A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab.
Korpics MC, Polley MY, Bhave SR, et al. · Int J Radiat Oncol Biol Phys · 2021 · Background
PubMed: PMID 32569799 · NCT06416436 · Neoplasm Metastasis
Hepatocellular carcinoma: old friends and new tricks.
Kim E, Viatour P · Exp Mol Med · 2021 · Background
PubMed: PMID 33268834 · NCT06789757 ((HCC)) · Carcinoma, Hepatocellular
Targeting metastatic cancer.
Ganesh K, Massagué J · Nat Med · 2021 · Background
PubMed: PMID 33442008 · NCT06416436 · Neoplasm Metastasis
Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.
Frost N, Zhamurashvili T, von Laffert M, et al. · Clin Lung Cancer · 2021 · Background
PubMed: PMID 32620471 · NCT05689671 (ANTELOPE)
Atezolizumab: A Review in Extensive-Stage SCLC.
Frampton JE · Drugs · 2021 · Background
PubMed: PMID 32990939 · NCT06663098 (CARRY-ON) · Small Cell Lung Carcinoma
Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination.
Dosset M, Vauchy C, Beziaud L, et al. · Oncoimmunology · 2021 · Background
PubMed: PMID 23802085 · NCT03946358 (VolATIL) · Uterine Cervical Neoplasms
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.
Dingemans AC, Früh M, Ardizzoni A, et al. · Ann Oncol · 2021 · Background
PubMed: PMID 33864941 · NCT06663098 (CARRY-ON) · Small Cell Lung Carcinoma
Immune checkpoint inhibitors: use them early, combined and instead of TACE?
De Toni EN · Gut · 2021 · Background
PubMed: PMID 31611301 · NCT04224636 (DEMAND)
A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer.
Akanda ZZ, Neeson PJ, John T, et al. · Transl Lung Cancer Res · 2021 · Background
PubMed: PMID 34295676 · NCT06416436 · Neoplasm Metastasis

2020 (56 papers)

Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
McGregor BA, McKay RR, Braun DA, et al. · J Clin Oncol · 2020 · Trial result
PubMed: PMID 31721643 · NCT02724878 · Kidney Neoplasms
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H, McCleod M, Hussein M, et al. · Lancet Oncol · 2020 · Derived
PubMed: PMID 31122901 · NCT02367781 (IMpower130) · Carcinoma
Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC‡ 04-2017).
Vergnenegre A, Monnet I, Bizieux A, et al. · Future Oncol · 2020 · Derived
PubMed: PMID 31894704 · NCT03801304 (VinMetAtezo) · Carcinoma, Non-Small-Cell Lung
Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.
Vander Velde N, Guerin A, Ionescu-Ittu R, et al. · Eur Urol Oncol · 2020 · Derived
PubMed: PMID 30929841 · NCT02951767 · Urinary Bladder Neoplasms
Cutaneous Toxicity After Chemoradiotherapy and PD-L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye.
van den Ende T, Menting SP, Ambarus CA, et al. · Oncologist · 2020 · Derived
PubMed: PMID 30902915 · NCT03087864 (PERFECT) · Esophageal Neoplasms
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg CN, Loriot Y, James N, et al. · Eur Urol · 2020 · Derived
PubMed: PMID 30910346 · NCT02928406 · Urologic Neoplasms
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
Shemesh CS, Chanu P, Jamsen K, et al. · J Immunother Cancer · 2020 · Derived
PubMed: PMID 31753029 · NCT02541604
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P, Rugo HS, Adams S, et al. · Lancet Oncol · 2020 · Derived
PubMed: PMID 31786121 · NCT02425891 · Triple Negative Breast Neoplasms
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Reck M, Mok TSK, Nishio M, et al. · Lancet Respir Med · 2020 · Derived
PubMed: PMID 30922878 · NCT02366143 (IMpower150) · Carcinoma, Non-Small-Cell Lung
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
Pal SK, McDermott DF, Atkins MB, et al. · BJU Int · 2020 · Derived
PubMed: PMID 32233107 · NCT01984242 (IMmotion150) · Carcinoma, Renal Cell
Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).
Nishio M, Sugawara S, Atagi S, et al. · Clin Lung Cancer · 2020 · Derived
PubMed: PMID 31466854 · NCT02763579 (IMpower133) · Small Cell Lung Carcinoma
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
Morrissey KM, Marchand M, Patel H, et al. · Cancer Chemother Pharmacol · 2020 · Derived
PubMed: PMID 31542806 · NCT01375842 · Neoplasms
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L, Li Y, Chang CW, et al. · J Immunother Cancer · 2020 · Derived
PubMed: PMID 31647026 · NCT01375842 · Neoplasms
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA, Zhang H, Barrios CH, et al. · Lancet · 2020 · Derived
PubMed: PMID 32966830 · NCT03197935 (IMpassion031) · Triple Negative Breast Neoplasms
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. · Lancet Oncol · 2020 · Derived
PubMed: PMID 30857956 · NCT02091141 · Neoplasms
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer.
Mayadev J, Zamarin D, Deng W, et al. · Int J Gynecol Cancer · 2020 · Derived
PubMed: PMID 31871115 · NCT03738228 · Uterine Cervical Neoplasms
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS, Ryoo BY, Hsu CH, et al. · Lancet Oncol · 2020 · Derived
PubMed: PMID 32502443 · NCT02715531
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Jung KH, LoRusso P, Burris H, et al. · Clin Cancer Res · 2020 · Derived
PubMed: PMID 30770348 · NCT02471846
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Herbst RS, Giaccone G, de Marinis F, et al. · N Engl J Med · 2020 · Derived
PubMed: PMID 32997907 · NCT02409342
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
Hellmann MD, Kim TW, Lee CB, et al. · Ann Oncol · 2020 · Derived
PubMed: PMID 30918950 · NCT01988896
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab.
Hamid O, Molinero L, Bolen CR, et al. · Clin Cancer Res · 2020 · Derived
PubMed: PMID 31358540 · NCT01375842 · Neoplasms
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
Gutzmer R, Stroyakovskiy D, Gogas H, et al. · Lancet · 2020 · Derived
PubMed: PMID 32534646 · NCT02908672 · Melanoma
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
Grünewald S, Politz O, Bender S, et al. · Int J Cancer · 2020 · Derived
PubMed: PMID 30807645 · NCT03473756 (FORT-2) · Carcinoma, Transitional Cell
A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF, Farinas-Madrid L, Oaknin A, et al. · Int J Gynecol Cancer · 2020 · Derived
PubMed: PMID 31645423 · NCT03556839 (BEATcc) · Uterine Cervical Neoplasms
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.
Geoerger B, Zwaan CM, Marshall LV, et al. · Lancet Oncol · 2020 · Derived
PubMed: PMID 31780255 · NCT02541604
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Galsky MD, Arija JÁA, Bamias A, et al. · Lancet · 2020 · Derived
PubMed: PMID 32416780 · NCT02807636 (IMvigor130) · Carcinoma, Transitional Cell
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, et al. · N Engl J Med · 2020 · Derived
PubMed: PMID 32402160 · NCT03434379 (IMbrave150) · Carcinoma, Hepatocellular
Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M, Jhunjhunwala S, Kowanetz M, et al. · J Immunother Cancer · 2020 · Derived
PubMed: PMID 31511069 · NCT01903993 · Carcinoma, Non-Small-Cell Lung
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C, Kim TW, Bendell J, et al. · Lancet Oncol · 2020 · Derived
PubMed: PMID 31003911 · NCT02788279 · Colorectal Neoplasms
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Emens LA, Esteva FJ, Beresford M, et al. · Lancet Oncol · 2020 · Derived
PubMed: PMID 33002436 · NCT02924883 (KATE2) · Breast Neoplasms
Platinum-containing regimens for triple-negative metastatic breast cancer.
Egger SJ, Chan MMK, Luo Q, et al. · Cochrane Database Syst Rev · 2020 · Derived
PubMed: PMID 33084020 · NCT01898117 (Triple-B) · Breast Neoplasms
Metastasis Stemming from Circulating Tumor Cell Clusters.
Yu M · Trends Cell Biol · 2020 · Background
PubMed: PMID 30799250 · NCT06416436 · Neoplasm Metastasis
Emerging therapies for small cell lung cancer.
Yang S, Zhang Z, Wang Q, et al. · J Hematol Oncol · 2020 · Background
PubMed: PMID 31046803 · NCT06663098 (CARRY-ON) · Small Cell Lung Carcinoma
An assessment of prognostic immunity markers in breast cancer.
Yang B, Chou J, Tao Y, et al. · NPJ Breast Cancer · 2020 · Background
PubMed: PMID 30393759 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule.
Witek MA, Aufforth RD, Wang H, et al. · NPJ Precis Oncol · 2020 · Background
PubMed: PMID 29657983 · NCT06416436 · Neoplasm Metastasis
The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis-From Conception to Treatment.
Weichselbaum RR · J Clin Oncol · 2020 · Background
PubMed: PMID 30260759 · NCT06416436 · Neoplasm Metastasis
A guide to cancer immunotherapy: from T cell basic science to clinical practice.
Waldman AD, Fritz JM, Lenardo MJ, et al. · Nat Rev Immunol · 2020 · Background
PubMed: PMID 32433532 · NCT06416436 · Neoplasm Metastasis
Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy.
Riegler LL, Jones GP, Lee DW, et al. · Ther Clin Risk Manag · 2020 · Background
PubMed: PMID 30880998 · NCT06416436 · Neoplasm Metastasis
Update in global trends and aetiology of hepatocellular carcinoma.
Rawla P, Sunkara T, Muralidharan P, et al. · Contemp Oncol (Pozn) · 2020 · Background
PubMed: PMID 30455585 · NCT06789757 ((HCC)) · Carcinoma, Hepatocellular
A Case of Solitary Lung Metastasis of Breast Cancer Successfully Treated with Stereotactic Body Radiotherapy after Chemotherapy.
Oura S, Mori M, Makimoto S, et al. · Case Rep Oncol · 2020 · Background
PubMed: PMID 32355496 · NCT06416436 · Neoplasm Metastasis
Liver transplantation for hepatocellular carcinoma: pushing the boundaries.
O'Rourke JM, Shetty S, Shah T, et al. · Transl Gastroenterol Hepatol · 2020 · Background
PubMed: PMID 30854488 · NCT05185505 · Carcinoma, Hepatocellular
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.
Merad M, Martin JC · Nat Rev Immunol · 2020 · Background
PubMed: PMID 32376901 · NCT06416436 · Neoplasm Metastasis
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.
Mazzaferro V, Citterio D, Bhoori S, et al. · Lancet Oncol · 2020 · Background
PubMed: PMID 32615109 · NCT05713994 (CCGLC-001) · Carcinoma, Hepatocellular
Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy.
Matsushita M, Kawaguchi M · J Oncol · 2020 · Background
PubMed: PMID 30498512 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Loibl S, Untch M, Burchardi N, et al. · Ann Oncol · 2020 · Background
PubMed: PMID 31095287 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Lee DW, Santomasso BD, Locke FL, et al. · Biol Blood Marrow Transplant · 2020 · Background
PubMed: PMID 30592986 · NCT06416436 · Neoplasm Metastasis
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.
La Rosée P, Horne A, Hines M, et al. · Blood · 2020 · Background
PubMed: PMID 30992265 · NCT06416436 · Neoplasm Metastasis
Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature.
Kim C, Rajan A, DeBrito PA, et al. · Transl Lung Cancer Res · 2020 · Background
PubMed: PMID 28149767 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
Gorgen A, Rosales R, Sadler E, et al. · Transplantation · 2020 · Background
PubMed: PMID 30801510 · NCT05185505 · Carcinoma, Hepatocellular
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Gluz O, Kolberg-Liedtke C, Prat A, et al. · Int J Cancer · 2020 · Background
PubMed: PMID 31162838 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Finn RS, Ryoo BY, Merle P, et al. · J Clin Oncol · 2020 · Background
PubMed: PMID 31790344 · NCT04862949 · Carcinoma, Hepatocellular
Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies.
Dixon JM, Cameron DA, Arthur LM, et al. · Adv Ther · 2020 · Background
PubMed: PMID 30859501 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma.
Berggren KL, Restrepo Cruz S, Hixon MD, et al. · Oncogene · 2020 · Background
PubMed: PMID 31417185 · NCT06416436 · Neoplasm Metastasis
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Baize N, Monnet I, Greillier L, et al. · Lancet Oncol · 2020 · Background
PubMed: PMID 32888454 · NCT06663098 (CARRY-ON) · Small Cell Lung Carcinoma
Cytokine Release Syndrome Resulting From Anti-Programmed Death-1 Antibody: Raising Awareness Among Community Oncologists.
Adashek ML, Feldman M · J Oncol Pract · 2020 · Background
PubMed: PMID 31310573 · NCT05776875 · Carcinoma, Hepatocellular
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Adams S, Schmid P, Rugo HS, et al. · Ann Oncol · 2020 · Background
PubMed: PMID 30475950 · NCT04862949 · Carcinoma, Hepatocellular

2019 (61 papers)

Potential plasma biomarkers of bladder cancer identified by proteomic analysis: A pilot study.
Lemańska-Perek A, Lis-Kuberka J, Lepczyński A, et al. · Adv Clin Exp Med · 2019 · Trial result
PubMed: PMID 29963784 · NCT04186013 · Urinary Bladder Neoplasms
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.
Kim ST, Cristescu R, Bass AJ, et al. · Nat Med · 2019 · Trial result
PubMed: PMID 30013197 · NCT04059887 (BUDDY) · Carcinoma, Non-Small-Cell Lung
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
Goldberg SB, Narayan A, Kole AJ, et al. · Clin Cancer Res · 2019 · Trial result
PubMed: PMID 29330207 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
Gandara DR, Paul SM, Kowanetz M, et al. · Nat Med · 2019 · Trial result
PubMed: PMID 30082870 · NCT04059887 (BUDDY) · Carcinoma, Non-Small-Cell Lung
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.
Chiappinelli KB, Strissel PL, Desrichard A, et al. · Cell · 2019 · Trial result
PubMed: PMID 28388418 · NCT04186013 · Urinary Bladder Neoplasms
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Bray F, Ferlay J, Soerjomataram I, et al. · CA Cancer J Clin · 2019 · Trial result
PubMed: PMID 30207593 · NCT05097911
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Teo MY, Seier K, Ostrovnaya I, et al. · J Clin Oncol · 2019 · Derived
PubMed: PMID 29489427 · NCT02108652 · Urinary Bladder Neoplasms
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
Sullivan RJ, Hamid O, Gonzalez R, et al. · Nat Med · 2019 · Derived
PubMed: PMID 31171876 · NCT01656642 · Melanoma
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Rini BI, Powles T, Atkins MB, et al. · Lancet · 2019 · Derived
PubMed: PMID 31079938 · NCT02420821 (IMmotion151) · Carcinoma, Renal Cell
A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer.
Rassy EE, Bakouny Z, Aoun F, et al. · Immunotherapy · 2019 · Derived
PubMed: PMID 29562804 · NCT02302807 · Urinary Bladder Neoplasms
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
Petrylak DP, Powles T, Bellmunt J, et al. · JAMA Oncol · 2019 · Derived
PubMed: PMID 29423515 · NCT01375842 · Neoplasms
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
Liu SV, Camidge DR, Gettinger SN, et al. · Eur J Cancer · 2019 · Derived
PubMed: PMID 30053670 · NCT01633970 · Neoplasms
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
Liu JF, Gordon M, Veneris J, et al. · Gynecol Oncol · 2019 · Derived
PubMed: PMID 31204078 · NCT01375842 · Neoplasms
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, et al. · N Engl J Med · 2019 · Derived
PubMed: PMID 30280641 · NCT02763579 (IMpower133) · Small Cell Lung Carcinoma
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
Horn L, Gettinger SN, Gordon MS, et al. · Eur J Cancer · 2019 · Derived
PubMed: PMID 30077125 · NCT01375842 · Neoplasms
Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study.
Hida T, Kaji R, Satouchi M, et al. · Clin Lung Cancer · 2019 · Derived
PubMed: PMID 29525239 · NCT02008227 (OAK)
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
Hainsworth JD, Meric-Bernstam F, Swanton C, et al. · J Clin Oncol · 2019 · Derived
PubMed: PMID 29320312 · NCT02091141 · Neoplasms
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
Gadgeel SM, Lukas RV, Goldschmidt J, et al. · Lung Cancer · 2019 · Derived
PubMed: PMID 30642441 · NCT02008227 (OAK)
Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection.
Fritsche J, Rakitsch B, Hoffgaard F, et al. · Proteomics · 2019 · Derived
PubMed: PMID 29505699 · NCT02876510 (ACTolog) · Carcinoma, Non-Small-Cell Lung
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Emens LA, Cruz C, Eder JP, et al. · JAMA Oncol · 2019 · Derived
PubMed: PMID 30242306 · NCT01375842 · Neoplasms
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial.
Colevas AD, Bahleda R, Braiteh F, et al. · Ann Oncol · 2019 · Derived
PubMed: PMID 30219915 · NCT01375842 · Neoplasms
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.
Bordoni R, Ciardiello F, von Pawel J, et al. · Clin Lung Cancer · 2019 · Derived
PubMed: PMID 30017645 · NCT02008227 (OAK)
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Adams S, Diamond JR, Hamilton E, et al. · JAMA Oncol · 2019 · Derived
PubMed: PMID 30347025 · NCT01633970 · Neoplasms
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Zhu AX, Finn RS, Edeline J, et al. · Lancet Oncol · 2019 · Background
PubMed: PMID 29875066 · NCT05173298 (HCC) · Carcinoma, Hepatocellular
Immunogenic neoantigens derived from gene fusions stimulate T cell responses.
Yang W, Lee KW, Srivastava RM, et al. · Nat Med · 2019 · Background
PubMed: PMID 31011208 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Prognostic value of PD-L1 expression in combination with CD8+ TILs density in patients with surgically resected non-small cell lung cancer.
Yang H, Shi J, Lin D, et al. · Cancer Med · 2019 · Background
PubMed: PMID 29168339 · NCT05185505 · Carcinoma, Hepatocellular
Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer.
Yang CJ, Chan DY, Shah SA, et al. · Ann Surg · 2019 · Background
PubMed: PMID 28475559 · NCT04696939 · Small Cell Lung Carcinoma
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
Westin SN, Sill MW, Coleman RL, et al. · Gynecol Oncol · 2019 · Background
PubMed: PMID 31623857 · NCT04486352 (EndoMAP) · Endometrial Neoplasms
Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.
Versteven M, Van den Bergh JMJ, Marcq E, et al. · Front Immunol · 2019 · Background
PubMed: PMID 29599770 · NCT05765084 (Immuno-MESODEC) · Mesothelioma, Malignant
A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches.
Versteven M, Van den Bergh JMJ, Broos K, et al. · Oncotarget · 2019 · Background
PubMed: PMID 29963238 · NCT05765084 (Immuno-MESODEC) · Mesothelioma, Malignant
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R, Limkin EJ, Vakalopoulou M, et al. · Lancet Oncol · 2019 · Background
PubMed: PMID 30120041 · NCT06416436 · Neoplasm Metastasis
Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes.
Solovyov A, Vabret N, Arora KS, et al. · Cell Rep · 2019 · Background
PubMed: PMID 29642008 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Molecular Tests for the Choice of Cancer Therapy.
Sokolenko AP, Imyanitov EN · Curr Pharm Des · 2019 · Background
PubMed: PMID 28721808 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Intron retention is a source of neoepitopes in cancer.
Smart AC, Margolis CA, Pimentel H, et al. · Nat Biotechnol · 2019 · Background
PubMed: PMID 30114007 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Cancer statistics, 2018.
Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2019 · Background
PubMed: PMID 29313949 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Shen J, Ju Z, Zhao W, et al. · Nat Med · 2019 · Background
PubMed: PMID 29736026 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Circulating Tumor Cells: Come Together, Right Now, Over Metastasis.
Rodrigues P, Vanharanta S · Cancer Discov · 2019 · Background
PubMed: PMID 30626605 · NCT06416436 · Neoplasm Metastasis
MAVIS: merging, annotation, validation, and illustration of structural variants.
Reisle C, Mungall KL, Choo C, et al. · Bioinformatics · 2019 · Background
PubMed: PMID 30016509 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.
Raja R, Kuziora M, Brohawn PZ, et al. · Clin Cancer Res · 2019 · Background
PubMed: PMID 30093454 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, et al. · Lancet · 2019 · Background
PubMed: PMID 31590988 · NCT06663098 (CARRY-ON) · Small Cell Lung Carcinoma
Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer.
Pao W, Ooi CH, Birzele F, et al. · Cancer Discov · 2019 · Background
PubMed: PMID 29545369 · NCT04862949 · Carcinoma, Hepatocellular
Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma.
Panda A, de Cubas AA, Stein M, et al. · JCI Insight · 2019 · Background
PubMed: PMID 30135306 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
Palma DA, Olson R, Harrow S, et al. · Lancet · 2019 · Background
PubMed: PMID 30982687 · NCT06416436 · Neoplasm Metastasis
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Oweida A, Hararah MK, Phan A, et al. · Clin Cancer Res · 2019 · Background
PubMed: PMID 30042205 · NCT06416436 · Neoplasm Metastasis
Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT.
Ogawa Y, Shibamoto Y, Hashizume C, et al. · Radiat Oncol · 2019 · Background
PubMed: PMID 30055636 · NCT06416436 · Neoplasm Metastasis
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
Nuciforo P, Pascual T, Cortés J, et al. · Ann Oncol · 2019 · Background
PubMed: PMID 29045543 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity.
Nioche C, Orlhac F, Boughdad S, et al. · Cancer Res · 2019 · Background
PubMed: PMID 29959149 · NCT06416436 · Neoplasm Metastasis
Measurement of circulating tumor cells in squamous cell carcinoma of the head and neck and patient outcomes.
Morgan TM, Wang X, Qian X, et al. · Clin Transl Oncol · 2019 · Background
PubMed: PMID 30084036 · NCT06416436 · Neoplasm Metastasis
Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
Mego M, Karaba M, Minarik G, et al. · Anticancer Res · 2019 · Background
PubMed: PMID 30952723 · NCT06416436 · Neoplasm Metastasis
Recent advances in triple negative breast cancer: the immunotherapy era.
Marra A, Viale G, Curigliano G, et al. · BMC Med · 2019 · Background
PubMed: PMID 31068190 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).
Marabelle A, Andtbacka R, Harrington K, et al. · Ann Oncol · 2019 · Background
PubMed: PMID 30295695 · NCT04167137 · Neoplasm Metastasis
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
Luke JJ, Lemons JM, Karrison TG, et al. · J Clin Oncol · 2019 · Background
PubMed: PMID 29437535 · NCT06416436 · Neoplasm Metastasis
Molecular therapies and precision medicine for hepatocellular carcinoma.
Llovet JM, Montal R, Sia D, et al. · Nat Rev Clin Oncol · 2019 · Background
PubMed: PMID 30061739 · NCT05197504 (HCC) · Carcinoma, Hepatocellular
The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer.
Ko EC, Raben D, Formenti SC, et al. · Clin Cancer Res · 2019 · Background
PubMed: PMID 29945993 · NCT06416436 · Neoplasm Metastasis
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S, François E, André T, et al. · Lancet Oncol · 2019 · Background
PubMed: PMID 30042063 · NCT03946358 (VolATIL) · Uterine Cervical Neoplasms
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
Gluz O, Nitz U, Liedtke C, et al. · J Natl Cancer Inst · 2019 · Background
PubMed: PMID 29228315 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer.
Foulds GA, Vadakekolathu J, Abdel-Fatah TMA, et al. · Front Immunol · 2019 · Background
PubMed: PMID 30254632 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
European Association for the Study of the Liver · J Hepatol · 2019 · Background
PubMed: PMID 29628281 · NCT04862949 · Carcinoma, Hepatocellular
Correction: A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.
Cancer Discov · 2019 · Background
PubMed: PMID 30385525 · NCT04486352 (EndoMAP) · Endometrial Neoplasms
Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.
Chan AWH, Zhong J, Berhane S, et al. · J Hepatol · 2019 · Background
PubMed: PMID 30236834 · NCT04954339 (DYNAMIC) · Carcinoma, Hepatocellular
Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1).
Armato SG, Nowak AK · J Thorac Oncol · 2019 · Background
PubMed: PMID 29753121 · NCT03762018 (BEAT-meso)

2018 (32 papers)

Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G, Marone G, Mercurio V, et al. · Curr Med Chem · 2018 · Trial result
PubMed: PMID 28403786 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.
Totzeck M, Mincu RI, Rassaf T, et al. · J Am Heart Assoc · 2018 · Trial result
PubMed: PMID 28862931 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies.
Rückert M, Deloch L, Fietkau R, et al. · Strahlenther Onkol · 2018 · Trial result
PubMed: PMID 29500551 · NCT04186013 · Urinary Bladder Neoplasms
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Matson V, Fessler J, Bao R, et al. · Science · 2018 · Trial result
PubMed: PMID 29302014 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S, Xia W, Yamaguchi H, et al. · Clin Cancer Res · 2018 · Trial result
PubMed: PMID 28167507 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
Gopalakrishnan V, Spencer CN, Nezi L, et al. · Science · 2018 · Trial result
PubMed: PMID 29097493 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M, Böhle A, Burger M, et al. · Eur Urol · 2018 · Trial result
PubMed: PMID 27324428 · NCT04186013 · Urinary Bladder Neoplasms
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA, Jotte RM, Cappuzzo F, et al. · N Engl J Med · 2018 · Derived
PubMed: PMID 29863955 · NCT02366143 (IMpower150) · Carcinoma, Non-Small-Cell Lung
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Schmid P, Adams S, Rugo HS, et al. · N Engl J Med · 2018 · Derived
PubMed: PMID 30345906 · NCT02425891 · Triple Negative Breast Neoplasms
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A, Barlesi F, Waterkamp D, et al. · Lancet · 2018 · Derived
PubMed: PMID 27979383 · NCT02008227 (OAK)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Powles T, Durán I, van der Heijden MS, et al. · Lancet · 2018 · Derived
PubMed: PMID 29268948 · NCT02302807 · Urinary Bladder Neoplasms
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.
Necchi A, Joseph RW, Loriot Y, et al. · Ann Oncol · 2018 · Derived
PubMed: PMID 28950298 · NCT02108652 · Urinary Bladder Neoplasms
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
Lukas RV, Rodon J, Becker K, et al. · J Neurooncol · 2018 · Derived
PubMed: PMID 30073642 · NCT01375842 · Neoplasms
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
Wallin JJ, Bendell JC, Funke R, et al. · Nat Commun · 2018 · Background
PubMed: PMID 27571927 · NCT03762018 (BEAT-meso)
Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.
Van den Bergh JMJ, Smits ELJM, Berneman ZN, et al. · Cancer Immunol Res · 2018 · Background
PubMed: PMID 28637876 · NCT05765084 (Immuno-MESODEC) · Mesothelioma, Malignant
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
Tumeh PC, Hellmann MD, Hamid O, et al. · Cancer Immunol Res · 2018 · Background
PubMed: PMID 28411193 · NCT04862949 · Carcinoma, Hepatocellular
Cancer immunotherapy using checkpoint blockade.
Ribas A, Wolchok JD · Science · 2018 · Background
PubMed: PMID 29567705 · NCT06416436 · Neoplasm Metastasis
Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.
Pereira C, Gimenez-Xavier P, Pros E, et al. · Clin Cancer Res · 2018 · Background
PubMed: PMID 28302866 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.
Ock CY, Hwang JE, Keam B, et al. · Nat Commun · 2018 · Background
PubMed: PMID 29051489 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
Miao D, Margolis CA, Gao W, et al. · Science · 2018 · Background
PubMed: PMID 29301960 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M, Finn RS, Qin S, et al. · Lancet · 2018 · Background
PubMed: PMID 29433850 · NCT05173298 (HCC) · Carcinoma, Hepatocellular
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014.
Jung KW, Won YJ, Oh CM, et al. · Cancer Res Treat · 2018 · Background
PubMed: PMID 28279062 · NCT04862949 · Carcinoma, Hepatocellular
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Jiang L, Su X, Zhang T, et al. · Oncotarget · 2018 · Background
PubMed: PMID 28460468 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.
Hendry S, Salgado R, Gevaert T, et al. · Adv Anat Pathol · 2018 · Background
PubMed: PMID 28777142 · NCT06416436 · Neoplasm Metastasis
AASLD guidelines for the treatment of hepatocellular carcinoma.
Heimbach JK, Kulik LM, Finn RS, et al. · Hepatology · 2018 · Background
PubMed: PMID 28130846 · NCT04954339 (DYNAMIC) · Carcinoma, Hepatocellular
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics.
Hegde PS, Wallin JJ, Mancao C, et al. · Semin Cancer Biol · 2018 · Background
PubMed: PMID 29229461 · NCT04862949 · Carcinoma, Hepatocellular
Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
Gockley AA, Kolin DL, Awtrey CS, et al. · Gynecol Oncol · 2018 · Background
PubMed: PMID 29937315 · NCT04486352 (EndoMAP) · Endometrial Neoplasms
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Garcia-Diaz A, Shin DS, Moreno BH, et al. · Cell Rep · 2018 · Background
PubMed: PMID 28494868 · NCT06416436 · Neoplasm Metastasis
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Gainor JF, Shaw AT, Sequist LV, et al. · Clin Cancer Res · 2018 · Background
PubMed: PMID 27225694 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Hepatocellular carcinoma.
Forner A, Reig M, Bruix J, et al. · Lancet · 2018 · Background
PubMed: PMID 29307467 · NCT04862949 · Carcinoma, Hepatocellular
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB, Sangro B, Yau T, et al. · Lancet · 2018 · Background
PubMed: PMID 28434648 · NCT04862949 · Carcinoma, Hepatocellular
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
Balachandran VP, Łuksza M, Zhao JN, et al. · Nature · 2018 · Background
PubMed: PMID 29132146 · NCT04273061 (CAPTIV-8) · Breast Neoplasms

2017 (46 papers)

A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer.
Xiong Y, Li J, Ma S, et al. · PLoS One · 2017 · Trial result
PubMed: PMID 28192481 · NCT04186013 · Urinary Bladder Neoplasms
Biomarkers for Immunotherapy: Current Developments and Challenges.
Spencer KR, Wang J, Silk AW, et al. · Am Soc Clin Oncol Educ Book · 2017 · Trial result
PubMed: PMID 27249758 · NCT04186013 · Urinary Bladder Neoplasms
Cancer Statistics, 2017.
Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2017 · Trial result
PubMed: PMID 28055103 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
Ott PA, Bang YJ, Berton-Rigaud D, et al. · J Clin Oncol · 2017 · Trial result
PubMed: PMID 28489510 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Nagueh SF, Smiseth OA, Appleton CP, et al. · J Am Soc Echocardiogr · 2017 · Trial result
PubMed: PMID 27037982 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
McMeekin DS, Tritchler DL, Cohn DE, et al. · J Clin Oncol · 2017 · Trial result
PubMed: PMID 27325856 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.
Mak KS, Smith AB, Eidelman A, et al. · Int J Radiat Oncol Biol Phys · 2017 · Trial result
PubMed: PMID 27727064 · NCT04186013 · Urinary Bladder Neoplasms
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Lee JM, Cimino-Mathews A, Peer CJ, et al. · J Clin Oncol · 2017 · Trial result
PubMed: PMID 28471727 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours.
Humphrey PA, Moch H, Cubilla AL, et al. · Eur Urol · 2017 · Trial result
PubMed: PMID 26996659 · NCT04186013 · Urinary Bladder Neoplasms
Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
Huddart RA, Birtle A, Maynard L, et al. · BJU Int · 2017 · Trial result
PubMed: PMID 28453896 · NCT04186013 · Urinary Bladder Neoplasms
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
Cosgrove CM, Cohn DE, Hampel H, et al. · Gynecol Oncol · 2017 · Trial result
PubMed: PMID 28709704 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH, Freeman GJ, Dranoff G, et al. · Annu Rev Immunol · 2017 · Trial result
PubMed: PMID 26927206 · NCT04186013 · Urinary Bladder Neoplasms
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Snyder A, Nathanson T, Funt SA, et al. · PLoS Med · 2017 · Derived
PubMed: PMID 28552987 · NCT02108652 · Urinary Bladder Neoplasms
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Balar AV, Galsky MD, Rosenberg JE, et al. · Lancet · 2017 · Derived
PubMed: PMID 27939400 · NCT02108652 · Urinary Bladder Neoplasms
Surgery Versus Optimal Medical Management for N1 Small Cell Lung Cancer.
Yang CJ, Chan DY, Speicher PJ, et al. · Ann Thorac Surg · 2017 · Background
PubMed: PMID 28385378 · NCT04696939 · Small Cell Lung Carcinoma
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
Wasan HS, Gibbs P, Sharma NK, et al. · Lancet Oncol · 2017 · Background
PubMed: PMID 28781171 · NCT04659382 (SIRTCI) · Colorectal Neoplasms
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP, Niedzwiecki D, Lenz HJ, et al. · JAMA · 2017 · Background
PubMed: PMID 28632865 · NCT04659382 (SIRTCI) · Colorectal Neoplasms
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
van Hazel GA, Heinemann V, Sharma NK, et al. · J Clin Oncol · 2017 · Background
PubMed: PMID 26903575 · NCT04659382 (SIRTCI) · Colorectal Neoplasms
Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI).
Tseng YH, Hung HY, Sung YC, et al. · J Chemother · 2017 · Background
PubMed: PMID 25976428 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.
Tiseo M, Boni L, Ambrosio F, et al. · J Clin Oncol · 2017 · Background
PubMed: PMID 28135143 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC, Howitt BE, Shukla SA, et al. · Oncotarget · 2017 · Background
PubMed: PMID 26871470 · NCT04486352 (EndoMAP) · Endometrial Neoplasms
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Seymour L, Bogaerts J, Perrone A, et al. · Lancet Oncol · 2017 · Background
PubMed: PMID 28271869 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group.
Schwartz LH, Seymour L, Litière S, et al. · Eur J Cancer · 2017 · Background
PubMed: PMID 27237360 · NCT04486352 (EndoMAP) · Endometrial Neoplasms
The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study.
Sapisochin G, Goldaracena N, Laurence JM, et al. · Hepatology · 2017 · Background
PubMed: PMID 27178646 · NCT05185505 · Carcinoma, Hepatocellular
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.
Sapisochin G, Bruix J · Nat Rev Gastroenterol Hepatol · 2017 · Background
PubMed: PMID 28053342 · NCT05185505 · Carcinoma, Hepatocellular
Clinicopathologic and genetic features of primary bronchopulmonary mucoepidermoid carcinoma: the MD Anderson Cancer Center experience and comprehensive review of the literature.
Salem A, Bell D, Sepesi B, et al. · Virchows Arch · 2017 · Background
PubMed: PMID 28343305 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
Ruers T, Van Coevorden F, Punt CJ, et al. · J Natl Cancer Inst · 2017 · Background
PubMed: PMID 28376151 · NCT06416436 · Neoplasm Metastasis
Severe cytokine release syndrome in a patient receiving PD-1-directed therapy.
Rotz SJ, Leino D, Szabo S, et al. · Pediatr Blood Cancer · 2017 · Background
PubMed: PMID 28544595 · NCT06416436 · Neoplasm Metastasis
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Peters S, Gettinger S, Johnson ML, et al. · J Clin Oncol · 2017 · Background
PubMed: PMID 28609226 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
Ott PA, Elez E, Hiret S, et al. · J Clin Oncol · 2017 · Background
PubMed: PMID 28813164 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
LoRusso PM · J Clin Oncol · 2017 · Background
PubMed: PMID 27621407 · NCT04486352 (EndoMAP) · Endometrial Neoplasms
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Llombart-Cussac A, Cortés J, Paré L, et al. · Lancet Oncol · 2017 · Background
PubMed: PMID 28238593 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.
Gounant V, Brosseau S, Naltet C, et al. · Lung Cancer · 2017 · Background
PubMed: PMID 27565934 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.
Ghisoli M, Barve M, Mennel R, et al. · Mol Ther · 2017 · Background
PubMed: PMID 27109631 · NCT03073525 · Ovarian Neoplasms
Emerging from their burrow: Hedgehog pathway inhibitors for cancer.
Gan GN, Jimeno A · Expert Opin Investig Drugs · 2017 · Background
PubMed: PMID 27459882 · NCT06416436 · Neoplasm Metastasis
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C, Snee M, Ashcroft L, et al. · Lancet Oncol · 2017 · Background
PubMed: PMID 28642008 · NCT04696939 · Small Cell Lung Carcinoma
Tumor regulation of the tissue environment in the liver.
Eggert T, Greten TF · Pharmacol Ther · 2017 · Background
PubMed: PMID 28167218 · NCT04862949 · Carcinoma, Hepatocellular
Germline and Somatic DICER1 Mutations in a Well-Differentiated Fetal Adenocarcinoma of the Lung.
de Kock L, Bah I, Wu Y, et al. · J Thorac Oncol · 2017 · Background
PubMed: PMID 26886166 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Immunotherapy and patients treated for cancer with microsatellite instability.
Colle R, Cohen R, Cochereau D, et al. · Bull Cancer · 2017 · Background
PubMed: PMID 27979364 · NCT04486352 (EndoMAP) · Endometrial Neoplasms
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
Cheson BD, Ansell S, Schwartz L, et al. · Blood · 2017 · Background
PubMed: PMID 27574190 · NCT04167137 · Neoplasm Metastasis
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Champiat S, Dercle L, Ammari S, et al. · Clin Cancer Res · 2017 · Background
PubMed: PMID 27827313 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Ayers M, Lunceford J, Nebozhyn M, et al. · J Clin Invest · 2017 · Background
PubMed: PMID 28650338 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Antonia SJ, López-Martin JA, Bendell J, et al. · Lancet Oncol · 2017 · Background
PubMed: PMID 27269741 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.
Anguille S, Van de Velde AL, Smits EL, et al. · Blood · 2017 · Background
PubMed: PMID 28830889 · NCT05765084 (Immuno-MESODEC) · Mesothelioma, Malignant
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.
Alme AK, Karir BS, Faltas BM, et al. · Urol Oncol · 2017 · Background
PubMed: PMID 26923782 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
EGFR TKI combination with immunotherapy in non-small cell lung cancer.
Ahn MJ, Sun JM, Lee SH, et al. · Expert Opin Drug Saf · 2017 · Background
PubMed: PMID 28271729 · NCT03647956 · Carcinoma, Non-Small-Cell Lung

2016 (44 papers)

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.
Sharabi AB, Lim M, DeWeese TL, et al. · Lancet Oncol · 2016 · Trial result
PubMed: PMID 26433823 · NCT04186013 · Urinary Bladder Neoplasms
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE, Hoffman-Censits J, Powles T, et al. · Lancet · 2016 · Trial result
PubMed: PMID 26952546 · NCT04186013 · Urinary Bladder Neoplasms
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.
Phillips T, Simmons P, Inzunza HD, et al. · Appl Immunohistochem Mol Morphol · 2016 · Trial result
PubMed: PMID 26317305 · NCT04186013 · Urinary Bladder Neoplasms
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.
Pham CD, Flores C, Yang C, et al. · Clin Cancer Res · 2016 · Trial result
PubMed: PMID 26405194 · NCT04186013 · Urinary Bladder Neoplasms
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Patel SP, Kurzrock R · Mol Cancer Ther · 2016 · Trial result
PubMed: PMID 25695955 · NCT04186013 · Urinary Bladder Neoplasms
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Higuchi T, Flies DB, Marjon NA, et al. · Cancer Immunol Res · 2016 · Trial result
PubMed: PMID 26138335 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
Heinzerling L, Ott PA, Hodi FS, et al. · J Immunother Cancer · 2016 · Trial result
PubMed: PMID 27532025 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
Goodfellow PJ, Billingsley CC, Lankes HA, et al. · J Clin Oncol · 2016 · Trial result
PubMed: PMID 26552419 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Second-Line Therapy for Endometrial Cancer: The Need for Better Options.
Fleming GF · J Clin Oncol · 2016 · Trial result
PubMed: PMID 26195695 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L, Spira A, Ballinger M, et al. · Lancet · 2016 · Trial result
PubMed: PMID 26970723 · NCT04186013 · Urinary Bladder Neoplasms
Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy.
Ahmed KA, Stallworth DG, Kim Y, et al. · Ann Oncol · 2016 · Trial result
PubMed: PMID 26712903 · NCT04186013 · Urinary Bladder Neoplasms
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
McDermott DF, Sosman JA, Sznol M, et al. · J Clin Oncol · 2016 · Derived
PubMed: PMID 26755520 · NCT01375842 · Neoplasms
A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS, Lee SI, Park SH, et al. · Clin Genitourin Cancer · 2016 · Derived
PubMed: PMID 26454620 · NCT02302807 · Urinary Bladder Neoplasms
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, et al. · Lancet · 2016 · Background
PubMed: PMID 26719230 · NCT03762018 (BEAT-meso)
Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment.
Yang CJ, Tsai MJ, Hung JY, et al. · Onco Targets Ther · 2016 · Background
PubMed: PMID 27051298 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Human Tumor Antigens and Cancer Immunotherapy.
Vigneron N · Biomed Res Int · 2016 · Background
PubMed: PMID 26161423 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
Untch M, Jackisch C, Schneeweiss A, et al. · Lancet Oncol · 2016 · Background
PubMed: PMID 26869049 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Unraveling the molecular pathways of DNA-methylation inhibitors: human endogenous retroviruses induce the innate immune response in tumors.
Strick R, Strissel PL, Baylin SB, et al. · Oncoimmunology · 2016 · Background
PubMed: PMID 27467919 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
A cancer treatment based on synergy between anti-angiogenic and immune cell therapies.
Soto-Ortiz L, Finley SD · J Theor Biol · 2016 · Background
PubMed: PMID 26826488 · NCT03762018 (BEAT-meso)
Cancer statistics, 2016.
Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2016 · Background
PubMed: PMID 26742998 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.
Sanford RA, Song J, Gutierrez-Barrera AM, et al. · Cancer · 2016 · Background
PubMed: PMID 26280679 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions.
Saliou A, Bidard FC, Lantz O, et al. · Expert Rev Mol Diagn · 2016 · Background
PubMed: PMID 26568208 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Histopathologic and Cytogenetic Features of Pulmonary Adenoid Cystic Carcinoma.
Roden AC, Greipp PT, Knutson DL, et al. · J Thorac Oncol · 2016 · Background
PubMed: PMID 26309189 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Single versus multiple session stereotactic body radiotherapy for spinal metastasis: the risk-benefit ratio.
Redmond KJ, Sahgal A, Foote M, et al. · Future Oncol · 2016 · Background
PubMed: PMID 26369361 · NCT06416436 · Neoplasm Metastasis
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. · N Engl J Med · 2016 · Background
PubMed: PMID 27718847 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Immunotherapy for small-cell lung cancer: emerging evidence.
Reck M, Heigener D, Reinmuth N, et al. · Future Oncol · 2016 · Background
PubMed: PMID 26882955 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Ravelli A, Minoia F, Davì S, et al. · Arthritis Rheumatol · 2016 · Background
PubMed: PMID 26314788 · NCT05776875 · Carcinoma, Hepatocellular
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Ravelli A, Minoia F, Davì S, et al. · Ann Rheum Dis · 2016 · Background
PubMed: PMID 26865703 · NCT06416436 · Neoplasm Metastasis
Reply to the letter to the editor 'Flaws in the trial design of IFCT-0802' by Gyawali et al.
Pujol JL, Morin F, Zalcman G, et al. · Ann Oncol · 2016 · Background
PubMed: PMID 26254441 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
Peng W, Chen JQ, Liu C, et al. · Cancer Discov · 2016 · Background
PubMed: PMID 26645196 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets.
Nielsen M, Andreatta M · Genome Med · 2016 · Background
PubMed: PMID 27029192 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M, Sasano H, Tamaki K, et al. · Breast Cancer Res · 2016 · Background
PubMed: PMID 26341640 · NCT06416436 · Neoplasm Metastasis
Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
Lee HJ, Lee JJ, Song IH, et al. · Breast Cancer Res Treat · 2016 · Background
PubMed: PMID 26006068 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.
Laskin J, Jones S, Aparicio S, et al. · Cold Spring Harb Mol Case Stud · 2016 · Background
PubMed: PMID 27148575 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Treatment of hemophagocytic lymphohistiocytosis in adults.
La Rosée P · Hematology Am Soc Hematol Educ Program · 2016 · Background
PubMed: PMID 26637720 · NCT06416436 · Neoplasm Metastasis
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
Johnson DB, Balko JM, Compton ML, et al. · N Engl J Med · 2016 · Background
PubMed: PMID 27806233 · NCT03102242 · Carcinoma, Non-Small-Cell Lung
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Hugo W, Zaretsky JM, Sun L, et al. · Cell · 2016 · Background
PubMed: PMID 26997480 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Herbst RS, Baas P, Kim DW, et al. · Lancet · 2016 · Background
PubMed: PMID 26712084 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Pulmonary lymphoepithelioma-like carcinoma: a Surveillance, Epidemiology, and End Results database analysis.
He J, Shen J, Pan H, et al. · J Thorac Dis · 2016 · Background
PubMed: PMID 26793355 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Gruenberger T, Bridgewater J, Chau I, et al. · Ann Oncol · 2016 · Background
PubMed: PMID 25538173 · NCT04659382 (SIRTCI) · Colorectal Neoplasms
Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.
Ghisoli M, Barve M, Schneider R, et al. · Mol Ther · 2016 · Background
PubMed: PMID 25917459 · NCT03073525 · Ovarian Neoplasms
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N, Fang W, Zhan J, et al. · J Thorac Oncol · 2016 · Background
PubMed: PMID 25658629 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Profiling tissue-resident T cell repertoires by RNA sequencing.
Brown SD, Raeburn LA, Holt RA, et al. · Genome Med · 2016 · Background
PubMed: PMID 26620832 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
The evolving role of radiotherapy in treatment of oligometastatic NSCLC.
Bergsma DP, Salama JK, Singh DP, et al. · Expert Rev Anticancer Ther · 2016 · Background
PubMed: PMID 26536370 · NCT06416436 · Neoplasm Metastasis

2015 (40 papers)

Radiotherapy in muscle-invasive bladder cancer: the latest research progress and clinical application.
Zhang S, Yu YH, Zhang Y, et al. · Am J Cancer Res · 2015 · Trial result
PubMed: PMID 25973322 · NCT04186013 · Urinary Bladder Neoplasms
Global cancer statistics, 2012.
Torre LA, Bray F, Siegel RL, et al. · CA Cancer J Clin · 2015 · Trial result
PubMed: PMID 25651787 · NCT04186013 · Urinary Bladder Neoplasms
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.
Sistigu A, Yamazaki T, Vacchelli E, et al. · Nat Med · 2015 · Trial result
PubMed: PMID 25344738 · NCT04186013 · Urinary Bladder Neoplasms
Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C, Long GV, Brady B, et al. · N Engl J Med · 2015 · Trial result
PubMed: PMID 25399552 · NCT04186013 · Urinary Bladder Neoplasms
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Rizvi NA, Hellmann MD, Snyder A, et al. · Science · 2015 · Trial result
PubMed: PMID 25765070 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Powles T, Eder JP, Fine GD, et al. · Nature · 2015 · Trial result
PubMed: PMID 25428503 · NCT04186013 · Urinary Bladder Neoplasms
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data.
Ott PA, Hodi FS, Buchbinder EI, et al. · Front Oncol · 2015 · Trial result
PubMed: PMID 26442214 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Radiation in combination with immune-checkpoint inhibitors.
Mayor S · Lancet Oncol · 2015 · Trial result
PubMed: PMID 25773169 · NCT04186013 · Urinary Bladder Neoplasms
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Liu JF, Barry WT, Birrer M, et al. · Lancet Oncol · 2015 · Trial result
PubMed: PMID 25218906 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Le DT, Uram JN, Wang H, et al. · N Engl J Med · 2015 · Trial result
PubMed: PMID 26028255 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Lang RM, Badano LP, Mor-Avi V, et al. · J Am Soc Echocardiogr · 2015 · Trial result
PubMed: PMID 25559473 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Herbst RS, Soria JC, Kowanetz M, et al. · Nature · 2015 · Trial result
PubMed: PMID 25428504 · NCT04186013 · Urinary Bladder Neoplasms
Prognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy.
Avci N, Deligonul A, Tolunay S, et al. · J BUON · 2015 · Trial result
PubMed: PMID 26416041 · NCT04186013 · Urinary Bladder Neoplasms
A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC).
Arcangeli G, Arcangeli S, Strigari L, et al. · Crit Rev Oncol Hematol · 2015 · Trial result
PubMed: PMID 25541350 · NCT04186013 · Urinary Bladder Neoplasms
Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.
Xue G, Zippelius A, Wicki A, et al. · J Natl Cancer Inst · 2015 · Background
PubMed: PMID 26071042 · NCT04486352 (EndoMAP) · Endometrial Neoplasms
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
Voron T, Colussi O, Marcheteau E, et al. · J Exp Med · 2015 · Background
PubMed: PMID 25601652 · NCT04862949 · Carcinoma, Hepatocellular
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Van Allen EM, Miao D, Schilling B, et al. · Science · 2015 · Background
PubMed: PMID 26359337 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Tumeh PC, Harview CL, Yearley JH, et al. · Nature · 2015 · Background
PubMed: PMID 25428505 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.
Tiseo M, Boni L, Ambrosio F, et al. · Clin Lung Cancer · 2015 · Background
PubMed: PMID 25450879 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
OptiType: precision HLA typing from next-generation sequencing data.
Szolek A, Schubert B, Mohr C, et al. · Bioinformatics · 2015 · Background
PubMed: PMID 25143287 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Sikov WM, Berry DA, Perou CM, et al. · J Clin Oncol · 2015 · Background
PubMed: PMID 25092775 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
The future of immune checkpoint therapy.
Sharma P, Allison JP · Science · 2015 · Background
PubMed: PMID 25838373 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
How I treat hemophagocytic lymphohistiocytosis in the adult patient.
Schram AM, Berliner N · Blood · 2015 · Background
PubMed: PMID 25758828 · NCT05776875 · Carcinoma, Hepatocellular
Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline.
Rodrigues G, Videtic GM, Sur R, et al. · Pract Radiat Oncol · 2015 · Background
PubMed: PMID 25740118 · NCT06416436 · Neoplasm Metastasis
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA, Mazières J, Planchard D, et al. · Lancet Oncol · 2015 · Background
PubMed: PMID 25704439 · NCT03102242 · Carcinoma, Non-Small-Cell Lung
Immunologic checkpoint blockade in lung cancer.
Reck M, Paz-Ares L · Semin Oncol · 2015 · Background
PubMed: PMID 25965358 · NCT03102242 · Carcinoma, Non-Small-Cell Lung
The Distinctive Features of a Feasibility Study: Objectives and Guiding Questions.
Orsmond GI, Cohn ES · OTJR (Thorofare N J) · 2015 · Background
PubMed: PMID 26594739 · NCT05185505 · Carcinoma, Hepatocellular
Robust enumeration of cell subsets from tissue expression profiles.
Newman AM, Liu CL, Green MR, et al. · Nat Methods · 2015 · Background
PubMed: PMID 25822800 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Melero I, Berman DM, Aznar MA, et al. · Nat Rev Cancer · 2015 · Background
PubMed: PMID 26205340 · NCT03762018 (BEAT-meso)
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
Lyman GH, Bohlke K, Khorana AA, et al. · J Clin Oncol · 2015 · Background
PubMed: PMID 25605844 · NCT05185505 · Carcinoma, Hepatocellular
Role of radiation therapy in palliative care of the patient with cancer.
Lutz ST, Jones J, Chow E, et al. · J Clin Oncol · 2015 · Background
PubMed: PMID 25113773 · NCT06416436 · Neoplasm Metastasis
Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma.
Ji J, Eggert T, Budhu A, et al. · Hepatology · 2015 · Background
PubMed: PMID 25833323 · NCT04862949 · Carcinoma, Hepatocellular
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Jänne PA, Yang JC, Kim DW, et al. · N Engl J Med · 2015 · Background
PubMed: PMID 25923549 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V, von Weikersthal LF, Decker T, et al. · Lancet Oncol · 2015 · Background
PubMed: PMID 25088940 · NCT04659382 (SIRTCI) · Colorectal Neoplasms
Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers.
Gan GN, Eagles J, Keysar SB, et al. · Cancer Res · 2015 · Background
PubMed: PMID 25297633 · NCT06416436 · Neoplasm Metastasis
Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy.
Gaipl US, Multhoff G, Scheithauer H, et al. · Immunotherapy · 2015 · Background
PubMed: PMID 24896628 · NCT06416436 · Neoplasm Metastasis
Current clinical trials testing combinations of immunotherapy and radiation.
Crittenden M, Kohrt H, Levy R, et al. · Semin Radiat Oncol · 2015 · Background
PubMed: PMID 25481267 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J, Reckamp KL, Baas P, et al. · N Engl J Med · 2015 · Background
PubMed: PMID 26028407 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Borghaei H, Paz-Ares L, Horn L, et al. · N Engl J Med · 2015 · Background
PubMed: PMID 26412456 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
MiXCR: software for comprehensive adaptive immunity profiling.
Bolotin DA, Poslavsky S, Mitrophanov I, et al. · Nat Methods · 2015 · Background
PubMed: PMID 25924071 · NCT04273061 (CAPTIV-8) · Breast Neoplasms

2014 (30 papers)

Immune interferon: a pleiotropic lymphokine with multiple effects.
Trinchieri G, Perussia B · Immunol Today · 2014 · Trial result
PubMed: PMID 25289500 · NCT04186013 · Urinary Bladder Neoplasms
Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.
Thavendiranathan P, Poulin F, Lim KD, et al. · J Am Coll Cardiol · 2014 · Trial result
PubMed: PMID 24703918 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Powell MA, Sill MW, Goodfellow PJ, et al. · Gynecol Oncol · 2014 · Trial result
PubMed: PMID 25019571 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Evaluation and management of patients with heart disease and cancer: cardio-oncology.
Herrmann J, Lerman A, Sandhu NP, et al. · Mayo Clin Proc · 2014 · Trial result
PubMed: PMID 25192616 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base.
Gray PJ, Lin CC, Jemal A, et al. · Int J Radiat Oncol Biol Phys · 2014 · Trial result
PubMed: PMID 24661658 · NCT04186013 · Urinary Bladder Neoplasms
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
Castonguay V, Lheureux S, Welch S, et al. · Gynecol Oncol · 2014 · Trial result
PubMed: PMID 24882554 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Past, present, and future of hormonal therapy in recurrent endometrial cancer.
Carlson MJ, Thiel KW, Leslie KK, et al. · Int J Womens Health · 2014 · Trial result
PubMed: PMID 24833920 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
Ackerman A, Klein O, McDermott DF, et al. · Cancer · 2014 · Derived
PubMed: PMID 24577748 · NCT01656642 · Melanoma
Which threshold for ER positivity? a retrospective study based on 9639 patients.
Yi M, Huo L, Koenig KB, et al. · Ann Oncol · 2014 · Background
PubMed: PMID 24562447 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Derivation of HLA types from shotgun sequence datasets.
Warren RL, Choe G, Freeman DJ, et al. · Genome Med · 2014 · Background
PubMed: PMID 23228053 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
Shi Y, Au JS, Thongprasert S, et al. · J Thorac Oncol · 2014 · Background
PubMed: PMID 24419411 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Sequist LV, Yang JC, Yamamoto N, et al. · J Clin Oncol · 2014 · Background
PubMed: PMID 23816960 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology.
Rossi G, Mengoli MC, Cavazza A, et al. · Virchows Arch · 2014 · Background
PubMed: PMID 24221342 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
Park MM, Ebel JJ, Zhao W, et al. · Breast J · 2014 · Background
PubMed: PMID 24261318 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.
Nishino M, Giobbie-Hurder A, Gargano M, et al. · Clin Cancer Res · 2014 · Background
PubMed: PMID 23743568 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver.
Nemunaitis J, Barve M, Orr D, et al. · Oncology · 2014 · Background
PubMed: PMID 24968881 · NCT03073525 · Ovarian Neoplasms
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.
Motz GT, Santoro SP, Wang LP, et al. · Nat Med · 2014 · Background
PubMed: PMID 24793239 · NCT04862949 · Carcinoma, Hepatocellular
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
Miyasaka A, Oda K, Ikeda Y, et al. · BMC Cancer · 2014 · Background
PubMed: PMID 24625059 · NCT04486352 (EndoMAP) · Endometrial Neoplasms
Immune responses following stereotactic body radiotherapy for stage I primary lung cancer.
Maehata Y, Onishi H, Kuriyama K, et al. · Biomed Res Int · 2014 · Background
PubMed: PMID 24324972 · NCT06416436 · Neoplasm Metastasis
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F, Cremolini C, Masi G, et al. · N Engl J Med · 2014 · Background
PubMed: PMID 25337750 · NCT04659382 (SIRTCI) · Colorectal Neoplasms
Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?
El-Serag HB, Kanwal F · Hepatology · 2014 · Background
PubMed: PMID 24839253 · NCT06789757 ((HCC)) · Carcinoma, Hepatocellular
Immunologically augmented cancer treatment using modern radiotherapy.
Durante M, Reppingen N, Held KD, et al. · Trends Mol Med · 2014 · Background
PubMed: PMID 23831337 · NCT06416436 · Neoplasm Metastasis
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Cortazar P, Zhang L, Untch M, et al. · Lancet · 2014 · Background
PubMed: PMID 24529560 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.
Choi W, Czerniak B, Ochoa A, et al. · Nat Rev Urol · 2014 · Background
PubMed: PMID 24960601 · NCT03577132 · Carcinoma, Transitional Cell
Comprehensive molecular characterization of urothelial bladder carcinoma.
Cancer Genome Atlas Research Network · Nature · 2014 · Background
PubMed: PMID 24476821 · NCT03577132 · Carcinoma, Transitional Cell
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.
Brown SD, Warren RL, Gibb EA, et al. · Genome Res · 2014 · Background
PubMed: PMID 24782321 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
MiTCR: software for T-cell receptor sequencing data analysis.
Bolotin DA, Shugay M, Mamedov IZ, et al. · Nat Methods · 2014 · Background
PubMed: PMID 23892897 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials.
Ardizzoni A, Tiseo M, Boni L, et al. · Eur J Cancer · 2014 · Background
PubMed: PMID 24981975 · NCT06663098 (CARRY-ON) · Small Cell Lung Carcinoma
Clinical use of dendritic cells for cancer therapy.
Anguille S, Smits EL, Lion E, et al. · Lancet Oncol · 2014 · Background
PubMed: PMID 24872109 · NCT05765084 (Immuno-MESODEC) · Mesothelioma, Malignant
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Akbay EA, Koyama S, Carretero J, et al. · Cancer Discov · 2014 · Background
PubMed: PMID 24078774 · NCT03647956 · Carcinoma, Non-Small-Cell Lung

2013 (21 papers)

Immunogenic cell death in cancer therapy.
Kroemer G, Galluzzi L, Kepp O, et al. · Annu Rev Immunol · 2013 · Trial result
PubMed: PMID 23157435 · NCT04186013 · Urinary Bladder Neoplasms
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Coleman RL, Sill MW, Lankes HA, et al. · Gynecol Oncol · 2013 · Trial result
PubMed: PMID 22922531 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Integrated genomic characterization of endometrial carcinoma.
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. · Nature · 2013 · Trial result
PubMed: PMID 23636398 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.
Zitvogel L, Galluzzi L, Smyth MJ, et al. · Immunity · 2013 · Background
PubMed: PMID 23890065 · NCT06663098 (CARRY-ON) · Small Cell Lung Carcinoma
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Yu HA, Arcila ME, Rekhtman N, et al. · Clin Cancer Res · 2013 · Background
PubMed: PMID 23470965 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions.
Wu Y, Kuang DM, Pan WD, et al. · Hepatology · 2013 · Background
PubMed: PMID 23225218 · NCT04862949 · Carcinoma, Hepatocellular
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
Slovin SF, Higano CS, Hamid O, et al. · Ann Oncol · 2013 · Background
PubMed: PMID 23535954 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs.
Saunders CT, Wong WS, Swamy S, et al. · Bioinformatics · 2013 · Background
PubMed: PMID 22581179 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Peters S, Adjei AA, Gridelli C, et al. · Ann Oncol · 2013 · Background
PubMed: PMID 22997455 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.
Nowak AK · Ann Cardiothorac Surg · 2013 · Background
PubMed: PMID 23977545 · NCT03762018 (BEAT-meso)
Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
Li H, Wu K, Tao K, et al. · Hepatology · 2013 · Background
PubMed: PMID 22505239 · NCT04862949 · Carcinoma, Hepatocellular
Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
Ji Y, Wang SJ · J Clin Oncol · 2013 · Background
PubMed: PMID 23569307 · NCT04167137 · Neoplasm Metastasis
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
Houssami N, Macaskill P, von Minckwitz G, et al. · Eur J Cancer · 2013 · Background
PubMed: PMID 22766518 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. · Eur J Cancer · 2013 · Background
PubMed: PMID 23485231 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.
Dosset M, Godet Y, Vauchy C, et al. · Clin Cancer Res · 2013 · Background
PubMed: PMID 23032748 · NCT03946358 (VolATIL) · Uterine Cervical Neoplasms
Effect of ASCO/CAP guidelines for determining ER status on molecular subtype.
Deyarmin B, Kane JL, Valente AL, et al. · Ann Surg Oncol · 2013 · Background
PubMed: PMID 22875649 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.
Cibulskis K, Lawrence MS, Carter SL, et al. · Nat Biotechnol · 2013 · Background
PubMed: PMID 23396013 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
Chen DS, Irving BA, Hodi FS, et al. · Clin Cancer Res · 2013 · Background
PubMed: PMID 23087408 · NCT06416436 · Neoplasm Metastasis
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
Ceresoli GL, Zucali PA, Mencoboni M, et al. · Br J Cancer · 2013 · Background
PubMed: PMID 23860535 · NCT03762018 (BEAT-meso)
Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo.
Benteyn D, Anguille S, Van Lint S, et al. · Mol Ther Nucleic Acids · 2013 · Background
PubMed: PMID 24253259 · NCT05765084 (Immuno-MESODEC) · Mesothelioma, Malignant
Clinicopathologic features and long-term outcomes of NUT midline carcinoma.
Bauer DE, Mitchell CM, Strait KM, et al. · Clin Cancer Res · 2013 · Background
PubMed: PMID 22896655 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung

2012 (18 papers)

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Topalian SL, Hodi FS, Brahmer JR, et al. · N Engl J Med · 2012 · Trial result
PubMed: PMID 22658127 · NCT04186013 · Urinary Bladder Neoplasms
A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence.
Naselli A, Introini C, Timossi L, et al. · Eur Urol · 2012 · Trial result
PubMed: PMID 22280855 · NCT04186013 · Urinary Bladder Neoplasms
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
James ND, Hussain SA, Hall E, et al. · N Engl J Med · 2012 · Trial result
PubMed: PMID 22512481 · NCT04186013 · Urinary Bladder Neoplasms
Narrow-band imaging cystoscopy in non-muscle-invasive bladder cancer: a prospective comparison to the standard approach.
Geavlete B, Jecu M, Multescu R, et al. · Ther Adv Urol · 2012 · Trial result
PubMed: PMID 23024703 · NCT04186013 · Urinary Bladder Neoplasms
Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA, Spiegel DY, Shipley WU, et al. · Eur Urol · 2012 · Trial result
PubMed: PMID 22101114 · NCT04186013 · Urinary Bladder Neoplasms
Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans.
Caskey M, Lefebvre F, Filali-Mouhim A, et al. · J Exp Med · 2012 · Trial result
PubMed: PMID 22065672 · NCT03721679
Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.
Van Driessche A, Berneman ZN, Van Tendeloo VF, et al. · Oncologist · 2012 · Background
PubMed: PMID 22291091 · NCT05765084 (Immuno-MESODEC) · Mesothelioma, Malignant
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.
Senzer N, Barve M, Kuhn J, et al. · Mol Ther · 2012 · Background
PubMed: PMID 22186789 · NCT03073525 · Ovarian Neoplasms
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.
Ready NE, Dudek AZ, Pang HH, et al. · J Clin Oncol · 2012 · Background
PubMed: PMID 21969504 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers.
Raghav KP, Hernandez-Aya LF, Lei X, et al. · Cancer · 2012 · Background
PubMed: PMID 21837669 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
The blockade of immune checkpoints in cancer immunotherapy.
Pardoll DM · Nat Rev Cancer · 2012 · Background
PubMed: PMID 22437870 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.
Iwamoto T, Booser D, Valero V, et al. · J Clin Oncol · 2012 · Background
PubMed: PMID 22291085 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.
Godet Y, Fabre E, Dosset M, et al. · Clin Cancer Res · 2012 · Background
PubMed: PMID 22407833 · NCT03946358 (VolATIL) · Uterine Cervical Neoplasms
Hepatocellular carcinoma.
Forner A, Llovet JM, Bruix J, et al. · Lancet · 2012 · Background
PubMed: PMID 22353262 · NCT04954339 (DYNAMIC) · Carcinoma, Hepatocellular
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Dowsett M, Smith I, Robertson J, et al. · J Natl Cancer Inst Monogr · 2012 · Background
PubMed: PMID 22043057 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Radiation as an immunological adjuvant: current evidence on dose and fractionation.
Demaria S, Formenti SC · Front Oncol · 2012 · Background
PubMed: PMID 23112958 · NCT06416436 · Neoplasm Metastasis
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Brahmer JR, Tykodi SS, Chow LQ, et al. · N Engl J Med · 2012 · Background
PubMed: PMID 22658128 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases.
Bae SH, Kim MS, Cho CK, et al. · J Surg Oncol · 2012 · Background
PubMed: PMID 22297789 · NCT06416436 · Neoplasm Metastasis

2011 (12 papers)

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.
Choueiri TK, Mayer EL, Je Y, et al. · J Clin Oncol · 2011 · Trial result
PubMed: PMID 21205755 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Aghajanian C, Sill MW, Darcy KM, et al. · J Clin Oncol · 2011 · Trial result
PubMed: PMID 21537039 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Zhou C, Wu YL, Chen G, et al. · Lancet Oncol · 2011 · Background
PubMed: PMID 21783417 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Type I interferon-dependent CD86(high) marginal zone precursor B cells are potent T cell costimulators in mice.
Wang JH, Wu Q, Yang P, et al. · Arthritis Rheum · 2011 · Background
PubMed: PMID 21225691 · NCT06416436 · Neoplasm Metastasis
Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Spigel DR, Townley PM, Waterhouse DM, et al. · J Clin Oncol · 2011 · Background
PubMed: PMID 21502556 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Dynamic control of endogenous retroviruses during development.
Rowe HM, Trono D · Virology · 2011 · Background
PubMed: PMID 21251689 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Quoix E, Zalcman G, Oster JP, et al. · Lancet · 2011 · Background
PubMed: PMID 21831418 · NCT03977194 (ELDERLY)
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.
Jones SJ, Laskin J, Li YY, et al. · Genome Biol · 2011 · Background
PubMed: PMID 20696054 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Global cancer statistics.
Jemal A, Bray F, Center MM, et al. · CA Cancer J Clin · 2011 · Background
PubMed: PMID 21296855 · NCT05185505 · Carcinoma, Hepatocellular
Hallmarks of cancer: the next generation.
Hanahan D, Weinberg RA · Cell · 2011 · Background
PubMed: PMID 21376230 · NCT06416436 · Neoplasm Metastasis
Hepatocellular carcinoma.
El-Serag HB · N Engl J Med · 2011 · Background
PubMed: PMID 21992124 · NCT04954339 (DYNAMIC) · Carcinoma, Hepatocellular
Screening for hepatocellular carcinoma.
Amit S, Jorge A M · Gastroenterol Hepatol (N Y) · 2011 · Background
PubMed: PMID 21904498 · NCT06789757 ((HCC)) · Carcinoma, Hepatocellular

2010 (21 papers)

Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
Stenzl A, Burger M, Fradet Y, et al. · J Urol · 2010 · Trial result
PubMed: PMID 20850152 · NCT04186013 · Urinary Bladder Neoplasms
Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.
Rudski LG, Lai WW, Afilalo J, et al. · J Am Soc Echocardiogr · 2010 · Trial result
PubMed: PMID 20620859 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
Brody JD, Ai WZ, Czerwinski DK, et al. · J Clin Oncol · 2010 · Trial result
PubMed: PMID 20697067 · NCT03721679
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Wolchok JD, Hoos A, O'Day S, et al. · Clin Cancer Res · 2010 · Background
PubMed: PMID 19934295 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. · Proc Natl Acad Sci U S A · 2010 · Background
PubMed: PMID 20631300 · NCT05765084 (Immuno-MESODEC) · Mesothelioma, Malignant
Stereotactic body radiation therapy for inoperable early stage lung cancer.
Timmerman R, Paulus R, Galvin J, et al. · JAMA · 2010 · Background
PubMed: PMID 20233825 · NCT06416436 · Neoplasm Metastasis
Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Spigel DR, Greco FA, Zubkus JD, et al. · J Thorac Oncol · 2010 · Background
PubMed: PMID 19875975 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Dendritic cell-based cancer gene therapy.
Smits EL, Anguille S, Cools N, et al. · Hum Gene Ther · 2010 · Background
PubMed: PMID 19656053 · NCT05765084 (Immuno-MESODEC) · Mesothelioma, Malignant
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
Shrimali RK, Yu Z, Theoret MR, et al. · Cancer Res · 2010 · Background
PubMed: PMID 20631075 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Review article: pulmonary sarcomatoid carcinomas: a practical overview.
Pelosi G, Sonzogni A, De Pas T, et al. · Int J Surg Pathol · 2010 · Background
PubMed: PMID 19124452 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
The changing pattern of epidemiology in hepatocellular carcinoma.
Nordenstedt H, White DL, El-Serag HB, et al. · Dig Liver Dis · 2010 · Background
PubMed: PMID 20547305 · NCT05185505 · Carcinoma, Hepatocellular
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M, Inoue A, Kobayashi K, et al. · N Engl J Med · 2010 · Background
PubMed: PMID 20573926 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Lencioni R, Llovet JM · Semin Liver Dis · 2010 · Background
PubMed: PMID 20175033 · NCT05776875 · Carcinoma, Hepatocellular
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Kantoff PW, Higano CS, Shore ND, et al. · N Engl J Med · 2010 · Background
PubMed: PMID 20818862 · NCT06416436 · Neoplasm Metastasis
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.
Hoshida Y, Toffanin S, Lachenmayer A, et al. · Semin Liver Dis · 2010 · Background
PubMed: PMID 20175032 · NCT05173298 (HCC) · Carcinoma, Hepatocellular
Improved survival with ipilimumab in patients with metastatic melanoma.
Hodi FS, O'Day SJ, McDermott DF, et al. · N Engl J Med · 2010 · Background
PubMed: PMID 20525992 · NCT06416436 · Neoplasm Metastasis
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
Hino R, Kabashima K, Kato Y, et al. · Cancer · 2010 · Background
PubMed: PMID 20143437 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Triple-negative breast cancer--current status and future directions.
Gluz O, Liedtke C, Gottschalk N, et al. · Ann Oncol · 2010 · Background
PubMed: PMID 19901010 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
The PD-1 pathway in tolerance and autoimmunity.
Francisco LM, Sage PT, Sharpe AH, et al. · Immunol Rev · 2010 · Background
PubMed: PMID 20636820 · NCT06416436 · Neoplasm Metastasis
Review article: the management of hepatocellular carcinoma.
Cabrera R, Nelson DR · Aliment Pharmacol Ther · 2010 · Background
PubMed: PMID 19925500 · NCT06789757 ((HCC)) · Carcinoma, Hepatocellular
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.
Azzoli CG, Baker S, Temin S, et al. · J Clin Oncol · 2010 · Background
PubMed: PMID 19917871 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung

2009 (10 papers)

The present and future burden of urinary bladder cancer in the world.
Ploeg M, Aben KK, Kiemeney LA, et al. · World J Urol · 2009 · Trial result
PubMed: PMID 19219610 · NCT04186013 · Urinary Bladder Neoplasms
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA, Therasse P, Bogaerts J, et al. · Eur J Cancer · 2009 · Trial result
PubMed: PMID 19097774 · NCT04186013 · Urinary Bladder Neoplasms
Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.
Bhattacharya S, Fyfe G, Gray RJ, et al. · J Clin Oncol · 2009 · Trial result
PubMed: PMID 19826121 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.
Bellmunt J, Théodore C, Demkov T, et al. · J Clin Oncol · 2009 · Trial result
PubMed: PMID 19687335 · NCT04186013 · Urinary Bladder Neoplasms
Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.
Rusthoven KE, Kavanagh BD, Cardenes H, et al. · J Clin Oncol · 2009 · Background
PubMed: PMID 19255321 · NCT06416436 · Neoplasm Metastasis
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.
Reck M, Crinò L · Lung Cancer · 2009 · Background
PubMed: PMID 18579254 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Mok TS, Wu YL, Thongprasert S, et al. · N Engl J Med · 2009 · Background
PubMed: PMID 19692680 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
Horn L, Dahlberg SE, Sandler AB, et al. · J Clin Oncol · 2009 · Background
PubMed: PMID 19826110 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Retroelements and their impact on genome evolution and functioning.
Gogvadze E, Buzdin A · Cell Mol Life Sci · 2009 · Background
PubMed: PMID 19649766 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing.
Freeman JD, Warren RL, Webb JR, et al. · Genome Res · 2009 · Background
PubMed: PMID 19541912 · NCT04273061 (CAPTIV-8) · Breast Neoplasms

2008 (7 papers)

T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.
Boorjian SA, Sheinin Y, Crispen PL, et al. · Clin Cancer Res · 2008 · Trial result
PubMed: PMID 18676751 · NCT04186013 · Urinary Bladder Neoplasms
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV, Parikh P, von Pawel J, et al. · J Clin Oncol · 2008 · Background
PubMed: PMID 18506025 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Saltz LB, Clarke S, Díaz-Rubio E, et al. · J Clin Oncol · 2008 · Background
PubMed: PMID 18421054 · NCT04659382 (SIRTCI) · Colorectal Neoplasms
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Liedtke C, Mazouni C, Hess KR, et al. · J Clin Oncol · 2008 · Background
PubMed: PMID 18250347 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
PD-1 and its ligands in tolerance and immunity.
Keir ME, Butte MJ, Freeman GJ, et al. · Annu Rev Immunol · 2008 · Background
PubMed: PMID 18173375 · NCT05185505 · Carcinoma, Hepatocellular
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
Hoechst B, Ormandy LA, Ballmaier M, et al. · Gastroenterology · 2008 · Background
PubMed: PMID 18485901 · NCT04862949 · Carcinoma, Hepatocellular
Advances in the systemic therapy of malignant pleural mesothelioma.
Fennell DA, Gaudino G, O'Byrne KJ, et al. · Nat Clin Pract Oncol · 2008 · Background
PubMed: PMID 18227828 · NCT03762018 (BEAT-meso)

2007 (17 papers)

Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?
Murta-Nascimento C, Silverman DT, Kogevinas M, et al. · Cancer Epidemiol Biomarkers Prev · 2007 · Trial result
PubMed: PMID 17684133 · NCT04186013 · Urinary Bladder Neoplasms
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Inman BA, Sebo TJ, Frigola X, et al. · Cancer · 2007 · Trial result
PubMed: PMID 17340590 · NCT04186013 · Urinary Bladder Neoplasms
Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma.
Uka K, Aikata H, Takaki S, et al. · World J Gastroenterol · 2007 · Background
PubMed: PMID 17230611 · NCT04862949 · Carcinoma, Hepatocellular
Malignant pleural mesothelioma: current concepts in treatment.
Tsiouris A, Walesby RK · Nat Clin Pract Oncol · 2007 · Background
PubMed: PMID 17534390 · NCT03762018 (BEAT-meso)
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.
Thompson RH, Dong H, Lohse CM, et al. · Clin Cancer Res · 2007 · Background
PubMed: PMID 17363529 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy.
Palena C, Polev DE, Tsang KY, et al. · Clin Cancer Res · 2007 · Background
PubMed: PMID 17438107 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
PD-1 and PD-1 ligands: from discovery to clinical application.
Okazaki T, Honjo T · Int Immunol · 2007 · Background
PubMed: PMID 17606980 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF.
Huang Y, Chen X, Dikov MM, et al. · Blood · 2007 · Background
PubMed: PMID 17376891 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Hamanishi J, Mandai M, Iwasaki M, et al. · Proc Natl Acad Sci U S A · 2007 · Background
PubMed: PMID 17360651 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
Gao Q, Qiu SJ, Fan J, et al. · J Clin Oncol · 2007 · Background
PubMed: PMID 17577038 · NCT04862949 · Carcinoma, Hepatocellular
Triple-negative breast cancer: clinical features and patterns of recurrence.
Dent R, Trudeau M, Pritchard KI, et al. · Clin Cancer Res · 2007 · Background
PubMed: PMID 17671126 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Butte MJ, Keir ME, Phamduy TB, et al. · Immunity · 2007 · Background
PubMed: PMID 17629517 · NCT06416436 · Neoplasm Metastasis
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
Boyault S, Rickman DS, de Reyniès A, et al. · Hepatology · 2007 · Background
PubMed: PMID 17187432 · NCT05173298 (HCC) · Carcinoma, Hepatocellular
Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery.
Bouzin C, Feron O · Drug Resist Updat · 2007 · Background
PubMed: PMID 17452119 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion.
Blank C, Mackensen A · Cancer Immunol Immunother · 2007 · Background
PubMed: PMID 17195077 · NCT05185505 · Carcinoma, Hepatocellular
Cross-presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-specific CD8+ T cell tolerance.
Berg M, Wingender G, Djandji D, et al. · Eur J Immunol · 2007 · Background
PubMed: PMID 17039564 · NCT04862949 · Carcinoma, Hepatocellular
Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
Bauer KR, Brown M, Cress RD, et al. · Cancer · 2007 · Background
PubMed: PMID 17387718 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms

2006 (3 papers)

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
Thompson RH, Kuntz SM, Leibovich BC, et al. · Cancer Res · 2006 · Background
PubMed: PMID 16585157 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Sandler A, Gray R, Perry MC, et al. · N Engl J Med · 2006 · Background
PubMed: PMID 17167137 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung
Myoepithelial carcinoma of the lung.
Masuya D, Haba R, Huang CL, et al. · Eur J Cardiothorac Surg · 2006 · Background
PubMed: PMID 16188445 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung

2005 (7 papers)

Global cancer statistics, 2002.
Parkin DM, Bray F, Ferlay J, et al. · CA Cancer J Clin · 2005 · Trial result
PubMed: PMID 15761078 · NCT05097911
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
von der Maase H, Sengelov L, Roberts JT, et al. · J Clin Oncol · 2005 · Background
PubMed: PMID 16034041 · NCT03577132 · Carcinoma, Transitional Cell
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.
Pawlik TM, Scoggins CR, Zorzi D, et al. · Ann Surg · 2005 · Background
PubMed: PMID 15849507 · NCT06416436 · Neoplasm Metastasis
Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.
Hartsell WF, Scott CB, Bruner DW, et al. · J Natl Cancer Inst · 2005 · Background
PubMed: PMID 15928300 · NCT06416436 · Neoplasm Metastasis
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Dowsett M, Smith IE, Ebbs SR, et al. · Clin Cancer Res · 2005 · Background
PubMed: PMID 15701892 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.
Demaria S, Kawashima N, Yang AM, et al. · Clin Cancer Res · 2005 · Background
PubMed: PMID 15701862 · NCT06416436 · Neoplasm Metastasis
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
Blank C, Gajewski TF, Mackensen A, et al. · Cancer Immunol Immunother · 2005 · Background
PubMed: PMID 15599732 · NCT06416436 · Neoplasm Metastasis

2004 (7 papers)

Structural and functional analysis of the costimulatory receptor programmed death-1.
Zhang X, Schwartz JC, Guo X, et al. · Immunity · 2004 · Trial result
PubMed: PMID 15030777 · NCT04186013 · Urinary Bladder Neoplasms
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
Fleming GF, Brunetto VL, Cella D, et al. · J Clin Oncol · 2004 · Trial result
PubMed: PMID 15169803 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation.
Bosio CM, Aman MJ, Grogan C, et al. · J Infect Dis · 2004 · Trial result
PubMed: PMID 14639532 · NCT03721679
The SWI/SNF complex--chromatin and cancer.
Roberts CW, Orkin SH · Nat Rev Cancer · 2004 · Background
PubMed: PMID 14964309 · NCT04273061 (CAPTIV-8) · Breast Neoplasms
A sense of danger from radiation.
McBride WH, Chiang CS, Olson JL, et al. · Radiat Res · 2004 · Background
PubMed: PMID 15222781 · NCT06416436 · Neoplasm Metastasis
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ, Bell DW, Sordella R, et al. · N Engl J Med · 2004 · Background
PubMed: PMID 15118073 · NCT03647956 · Carcinoma, Non-Small-Cell Lung
Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer.
Brattström D, Bergqvist M, Hesselius P, et al. · Lung Cancer · 2004 · Background
PubMed: PMID 14698537 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma

2003 (6 papers)

Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy.
Madersbacher S, Hochreiter W, Burkhard F, et al. · J Clin Oncol · 2003 · Trial result
PubMed: PMID 12586807 · NCT04186013 · Urinary Bladder Neoplasms
Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.
Lincoln S, Blessing JA, Lee RB, et al. · Gynecol Oncol · 2003 · Trial result
PubMed: PMID 12648575 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
Hagan MP, Winter KA, Kaufman DS, et al. · Int J Radiat Oncol Biol Phys · 2003 · Trial result
PubMed: PMID 14529770 · NCT04186013 · Urinary Bladder Neoplasms
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA, Dorfman DM, Ma FR, et al. · J Immunol · 2003 · Trial result
PubMed: PMID 12538684 · NCT04186013 · Urinary Bladder Neoplasms
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. · J Clin Oncol · 2003 · Background
PubMed: PMID 12860938 · NCT03762018 (BEAT-meso)
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
Grossman HB, Natale RB, Tangen CM, et al. · N Engl J Med · 2003 · Background
PubMed: PMID 12944571 · NCT03577132 · Carcinoma, Transitional Cell

2002 (3 papers)

Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.
Rödel C, Grabenbauer GG, Kühn R, et al. · J Clin Oncol · 2002 · Trial result
PubMed: PMID 12118019 · NCT04186013 · Urinary Bladder Neoplasms
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Dong H, Strome SE, Salomao DR, et al. · Nat Med · 2002 · Trial result
PubMed: PMID 12091876 · NCT04186013 · Urinary Bladder Neoplasms
Prognostic role of angiogenesis in non-small cell lung cancer.
Giatromanolaki A · Anticancer Res · 2002 · Background
PubMed: PMID 11908693 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma

2001 (4 papers)

PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Latchman Y, Wood CR, Chernova T, et al. · Nat Immunol · 2001 · Trial result
PubMed: PMID 11224527 · NCT04186013 · Urinary Bladder Neoplasms
Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells.
Van Tendeloo VF, Ponsaerts P, Lardon F, et al. · Blood · 2001 · Background
PubMed: PMID 11418462 · NCT05765084 (Immuno-MESODEC) · Mesothelioma, Malignant
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
Sørlie T, Perou CM, Tibshirani R, et al. · Proc Natl Acad Sci U S A · 2001 · Background
PubMed: PMID 11553815 · NCT04770272 (neoMono) · Triple Negative Breast Neoplasms
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.
Jain RK · Nat Med · 2001 · Background
PubMed: PMID 11533692 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma

1999 (2 papers)

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.
Fong Y, Fortner J, Sun RL, et al. · Ann Surg · 1999 · Background
PubMed: PMID 10493478 · NCT06416436 · Neoplasm Metastasis
8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party.
Radiother Oncol · 1999 · Background
PubMed: PMID 10577696 · NCT06416436 · Neoplasm Metastasis

1997 (1 paper)

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
Souhami RL, Spiro SG, Rudd RM, et al. · J Natl Cancer Inst · 1997 · Background
PubMed: PMID 9106647 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma

1996 (4 papers)

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.
Gabrilovich DI, Chen HL, Girgis KR, et al. · Nat Med · 1996 · Trial result
PubMed: PMID 8837607 · NCT03694262 (EndoBARR) · Endometrial Neoplasms
Profluorescent protease substrates: intramolecular dimers described by the exciton model.
Packard BZ, Toptygin DD, Komoriya A, et al. · Proc Natl Acad Sci U S A · 1996 · Background
PubMed: PMID 8876189 · NCT06416436 · Neoplasm Metastasis
Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie.
Nordlinger B, Guiguet M, Vaillant JC, et al. · Cancer · 1996 · Background
PubMed: PMID 8608500 · NCT06416436 · Neoplasm Metastasis
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.
Mazzaferro V, Regalia E, Doci R, et al. · N Engl J Med · 1996 · Background
PubMed: PMID 8594428 · NCT05185505 · Carcinoma, Hepatocellular

1995 (2 papers)

Oligometastases.
Hellman S, Weichselbaum RR · J Clin Oncol · 1995 · Background
PubMed: PMID 7799047 · NCT06416436 · Neoplasm Metastasis
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.
BMJ · 1995 · Background
PubMed: PMID 7580546 · NCT03976518 (CHANCE) · Carcinoma, Non-Small-Cell Lung

1992 (3 papers)

Cellular events accompanying regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma.
Ozzello L, Habif DV, De Rosa CM, et al. · Cancer Res · 1992 · Trial result
PubMed: PMID 1355007 · NCT04186013 · Urinary Bladder Neoplasms
The inhibitory effects of interferon gamma on the growth of bladder cancer cells.
Hawkyard SJ, Jackson AM, James K, et al. · J Urol · 1992 · Trial result
PubMed: PMID 1569695 · NCT04186013 · Urinary Bladder Neoplasms
Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
Roth BJ, Johnson DH, Einhorn LH, et al. · J Clin Oncol · 1992 · Background
PubMed: PMID 1310103 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma

1990 (1 paper)

Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography.
Novick D, Engelmann H, Wallach D, et al. · J Chromatogr · 1990 · Trial result
PubMed: PMID 2144854 · NCT04186013 · Urinary Bladder Neoplasms

1986 (1 paper)

Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence.
Hughes KS, Simon R, Songhorabodi S, et al. · Surgery · 1986 · Background
PubMed: PMID 3526605 · NCT06416436 · Neoplasm Metastasis

1985 (1 paper)

VP-16 and cisplatin as first-line therapy for small-cell lung cancer.
Evans WK, Shepherd FA, Feld R, et al. · J Clin Oncol · 1985 · Background
PubMed: PMID 2997406 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma

1983 (1 paper)

Recombinant interferon-gamma increases HLA-DR synthesis and expression.
Basham TY, Merigan TC · J Immunol · 1983 · Trial result
PubMed: PMID 6403609 · NCT04186013 · Urinary Bladder Neoplasms

1980 (1 paper)

A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.
Goldie JH, Coldman AJ · Cancer Treat Rep · 1980 · Background
PubMed: PMID 526911 · NCT04730999 (CeLEBrATE) · Small Cell Lung Carcinoma

1976 (1 paper)

[Extraction of peripherally located bronchial foreign bodies using a x-ray picture amplifier with a television loop].
Rous J, Rems J, Cermák Z, et al. · Cesk Otolaryngol · 1976 · Background
PubMed: PMID 1204078 · NCT04486352 (EndoMAP) · Endometrial Neoplasms

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Fri, 08 May 2026 19:09:26 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).